_unit_id,_created_at,_id,_started_at,_tainted,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,exp_decision,relation,sent_id,orig_sentence,term1,term2
788862735,9/15/2015 22:58:42,1739068993,9/15/2015 22:58:13,false,fusioncash,1,31742806,USA,OH,Kent,66.61.82.242,103,25,,,109,37,ASTHMA,THEOPHYLLINE,ASTHMA,103,25-88,THEOPHYLLINE allopurinol,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862735,9/15/2015 23:54:44,1739086026,9/15/2015 23:54:23,false,clixsense,1,31304413,CAN,BC,Kelowna,66.183.36.177,103,25,,,109,37,ASTHMA,THEOPHYLLINE,ASTHMA,103,25,THEOPHYLLINE,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862735,9/15/2015 23:55:06,1739086113,9/15/2015 23:54:34,false,elite,1,33238902,NLD,06,Budel,77.248.148.5,103,25,,,109,37,ASTHMA,THEOPHYLLINE,administration of allopurinol in ASTHMA patients,85-88-100-103-110-70,25-38,THEOPHYLLINE ingestion,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862735,9/16/2015 00:14:59,1739091084,9/16/2015 00:14:31,false,clixsense,1,26531841,CAN,ON,Toronto,64.231.8.24,103,25,,,109,37,ASTHMA,THEOPHYLLINE,ASTHMA,103,25,THEOPHYLLINE,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862735,9/16/2015 00:29:59,1739094296,9/16/2015 00:29:40,false,instagc,1,31771119,USA,NY,Victor,72.230.179.20,103,25,,,109,37,ASTHMA,THEOPHYLLINE,ASTHMA,103,25,THEOPHYLLINE,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862735,9/16/2015 00:45:43,1739098192,9/16/2015 00:44:08,false,neodev,1,32114597,USA,"","",73.151.173.249,103,25,,,109,37,ASTHMA,THEOPHYLLINE,Excretory theophylline allopurinol ASTHMA rats existence metabolic pathways of theophylline.,0-25-88-103-126-143-162-172-184-181,0-25-70-88-103-110-126-131-143-156-162-172-184-181,Excretory THEOPHYLLINE administration allopurinol asthma patients rats suggest existence three metabolic pathways of theophylline.,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862735,9/16/2015 01:16:58,1739113043,9/16/2015 01:15:58,false,clixsense,1,20587495,CAN,NB,Saint John,142.162.106.74,103,25,,,109,37,ASTHMA,THEOPHYLLINE,Excretory theophylline in ASTHMA metabolic pathways theophylline.,0-25-100-103-162-184-172,0-10-25-38-88-103-110-162-172-184,Excretory patterns THEOPHYLLINE ingestion allopurinol asthma patients metabolic pathways theophylline.,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862735,9/16/2015 01:28:05,1739119746,9/16/2015 01:27:38,false,neodev,1,33739202,USA,MS,Madison,75.65.195.220,103,25,,,109,37,ASTHMA,THEOPHYLLINE,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways theophylline.,0-10-19-25-38-48-55-59-66-70-85-88-100-103-110-119-123-126-131-139-143-153-156-162-172-184,0-10-19-25-38-48-55-59-66-70-85,Excretory patterns after THEOPHYLLINE ingestion before and during the administration of,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862735,9/16/2015 01:28:46,1739120032,9/16/2015 01:28:03,false,points4rewards,1,20306700,USA,WA,Bothell,50.106.46.70,103,25,,,109,37,ASTHMA,THEOPHYLLINE,Excretory patterns ingestion ASTHMA,0-10-38-103,0-10-19-25-38,Excretory patterns after THEOPHYLLINE ingestion,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862735,9/16/2015 01:37:24,1739127103,9/16/2015 01:36:43,false,prodege,1,10959404,USA,CA,Studio City,108.217.110.104,103,25,,,109,37,ASTHMA,THEOPHYLLINE,ASTHMA,103,25,THEOPHYLLINE,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline.,103,25,103,25,109,37,-1,RO-may_treat,820114,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in asthma patients and in rats suggest the existence of three metabolic pathways of theophylline,asthma,theophylline
788862736,9/15/2015 22:43:34,1739063846,9/15/2015 22:43:20,false,instagc,1,31184650,USA,IA,Mason City,173.26.179.94,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"COBALAMIN DEFICIENCY,",78-88,0-4-14,Low COBALAMIN concentrations,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862736,9/15/2015 22:58:12,1739068811,9/15/2015 22:57:46,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"COBALAMIN DEFICIENCY,",78-88,4-78-88,"COBALAMIN cobalamin deficiency,","Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862736,9/15/2015 23:54:23,1739085909,9/15/2015 23:53:55,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"COBALAMIN DEFICIENCY,",78-88,0-4-14,Low COBALAMIN concentrations,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862736,9/15/2015 23:54:32,1739085980,9/15/2015 23:54:04,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"COBALAMIN DEFICIENCY,",78-88,4-14,COBALAMIN concentrations,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862736,9/16/2015 00:14:29,1739090978,9/16/2015 00:14:01,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"COBALAMIN DEFICIENCY,",78-88,4,COBALAMIN,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862736,9/16/2015 00:29:40,1739094233,9/16/2015 00:29:23,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"COBALAMIN DEFICIENCY,",78-88,4,COBALAMIN,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862736,9/16/2015 00:44:07,1739097886,9/16/2015 00:42:47,false,neodev,1.0,32114597,USA,"","",73.151.173.249,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"Low cobalamin concentrations COBALAMIN DEFICIENCY, values lower reference interval exclude cobalamin deficiency.",0-14-78-88-104-118-136-146-162-170-180-4,0-4-14,Low COBALAMIN concentrations,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862736,9/16/2015 01:15:57,1739112571,9/16/2015 01:15:39,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"in question has COBALAMIN DEFICIENCY, and values in",62-65-74-78-88-100-104-111,0-4-14-29-32,Low COBALAMIN concentrations do not,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862736,9/16/2015 01:28:03,1739119701,9/16/2015 01:27:03,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"Low cobalamin concentrations do not indicate that the patient in question has COBALAMIN DEFICIENCY,",0-4-14-29-32-36-45-50-54-62-65-74-78-88,0-4-14,Low COBALAMIN concentrations,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862736,9/16/2015 01:28:14,1739119831,9/16/2015 01:28:07,false,neodev,1.0,33739202,USA,MS,Madison,75.65.195.220,78,4,,,98,13,COBALAMIN DEFICIENCY,COBALAMIN,"that patient in question has COBALAMIN DEFICIENCY, and values in",54-62-65-74-78-88-100-104-111-45,0-4-14-29-32-36-180-54,Low COBALAMIN concentrations do not indicate patient deficiency.,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency.",78 88,4,78,4,98,13,-1,RO-may_prevent,820353,"Low cobalamin concentrations do not indicate that the patient in question has cobalamin deficiency, and values in the lower half of the reference interval do not exclude cobalamin deficiency",cobalamin deficiency,cobalamin
788862737,9/16/2015 00:00:48,1739087567,9/16/2015 00:00:20,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,151,76,,,157,87,NAUSEA,ONDANSETRON,opioid induced NAUSEA and emesis,136-143-151-158-162,76,"ONDANSETRON,","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862737,9/16/2015 01:31:17,1739121517,9/16/2015 01:30:21,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,151,76,,,157,87,NAUSEA,ONDANSETRON,"anti emetic ondansetron, placebo metoclopramide of opioid induced NAUSEA emesis (OIE)",41-46-76-89-101-133-136-143-151-162-169,41-46-76-89-97-101-136-143-151-162-169,"anti emetic ONDANSETRON, placebo and metoclopramide opioid induced nausea emesis (OIE)","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862737,9/16/2015 01:36:25,1739125346,9/16/2015 01:36:07,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,151,76,,,157,87,NAUSEA,ONDANSETRON,treatment of opioid induced NAUSEA and emesis,133-136-143-151-158-162-123,76-89-97-101,"ONDANSETRON, placebo and metoclopramide","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862737,9/16/2015 01:41:56,1739132255,9/16/2015 01:41:43,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,151,76,,,157,87,NAUSEA,ONDANSETRON,opioid induced NAUSEA and emesis (OIE),136-143-151-158-162-169,76,"ONDANSETRON,","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862737,9/16/2015 02:15:08,1739158336,9/16/2015 02:14:20,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,151,76,,,157,87,NAUSEA,ONDANSETRON,NAUSEA,151,76,"ONDANSETRON,","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862737,9/16/2015 03:12:54,1739211279,9/16/2015 03:12:42,false,elite,1,34356654,USA,DE,"",108.59.11.227,151,76,,,157,87,NAUSEA,ONDANSETRON,of opioid induced NAUSEA and emesis cancer patients.,133-136-143-151-158-162-185-178,62-66-73-76-89-97-101-119-123,"and safety of ONDANSETRON, placebo and metoclopramide the treatment","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862737,9/16/2015 03:22:34,1739220164,9/16/2015 03:22:18,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,151,76,,,157,87,NAUSEA,ONDANSETRON,of opioid induced NAUSEA and emesis,133-136-143-151-158-162,62-66-73-76-89,"and safety of ONDANSETRON, placebo","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862737,9/16/2015 03:24:54,1739222487,9/16/2015 03:24:43,false,instagc,1,33058612,USA,IL,Glenview,162.229.106.229,151,76,,,157,87,NAUSEA,ONDANSETRON,NAUSEA,151,76,"ONDANSETRON,","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862737,9/16/2015 03:32:19,1739229326,9/16/2015 03:31:53,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,151,76,,,157,87,NAUSEA,ONDANSETRON,opioid induced NAUSEA,136-143-151,76,"ONDANSETRON,","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862737,9/16/2015 03:56:56,1739252178,9/16/2015 03:56:13,false,clixsense,1,21665495,CAN,"","",24.105.69.70,151,76,,,157,87,NAUSEA,ONDANSETRON,opioid induced NAUSEA and emesis,136-143-151-158-162,76-89-97-101,"ONDANSETRON, placebo and metoclopramide","The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients.",151,76,151,76,157,87,-1,RO-may_prevent,820186,"The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients",nausea,ondansetron
788862738,9/15/2015 22:28:18,1739058786,9/15/2015 22:27:27,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,30,80,RIFAMPICIN,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862738,9/15/2015 22:35:30,1739061287,9/15/2015 22:34:23,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,30,80,RIFAMPICIN,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862738,9/15/2015 22:38:57,1739062542,9/15/2015 22:38:28,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,30,80-91,RIFAMPICIN (MDR),In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862738,9/15/2015 22:40:17,1739062991,9/15/2015 22:40:02,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,30,66-76-80,isoniazid and RIFAMPICIN,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862738,9/15/2015 22:56:03,1739068226,9/15/2015 22:55:47,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,30,30-80,tuberculosis RIFAMPICIN,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862738,9/15/2015 23:07:52,1739072260,9/15/2015 23:07:42,false,neodev,1,11382239,AUS,02,Strathfield,60.241.129.81,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,30,80,RIFAMPICIN,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862738,9/15/2015 23:18:27,1739075501,9/15/2015 23:17:49,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS 23.5% MBT resistant isoniazid rifampicin (MDR) fluoroquinolones,30-43-49-53-66-80-91-114,30-43-49-53-66-80-91-114,tuberculosis 23.5% MBT resistant isoniazid RIFAMPICIN (MDR) fluoroquinolones,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862738,9/15/2015 23:41:14,1739082455,9/15/2015 23:39:46,false,clixsense,1,6488338,USA,HI,Honolulu,72.130.214.250,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones,30-43-49-53-63-66-76-80-91-97-101-111-114,30-53-63-66-76-80-91-97-101-114-111,tuberculosis resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862738,9/15/2015 23:43:07,1739082880,9/15/2015 23:42:47,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,30,80,RIFAMPICIN,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862738,9/15/2015 23:51:23,1739084981,9/15/2015 23:50:14,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,30,80,,,42,90,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,30,80,RIFAMPICIN,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed.,30,80,30,80,42,90,-1,RO-may_prevent,820205,In patients with new detected tuberculosis 23.5% MBT resistant to isoniazid and rifampicin (MDR) and sensitive to fluoroquinolones were revealed,tuberculosis,rifampicin
788862739,9/15/2015 21:23:52,1739030456,9/15/2015 21:23:33,false,neodev,1.0,33758777,USA,"","",38.95.108.251,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,VENTRICULAR TACHYCARDIA,124-136,51,METOPROLOL,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862739,9/15/2015 21:24:50,1739031086,9/15/2015 21:24:38,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,VENTRICULAR TACHYCARDIA,124-136,51,METOPROLOL,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862739,9/15/2015 21:40:19,1739039591,9/15/2015 21:39:54,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,VENTRICULAR TACHYCARDIA,124-136,51,METOPROLOL,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862739,9/15/2015 21:41:39,1739040236,9/15/2015 21:41:07,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,"prajmaline metoprolol to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",28-102-105-117-124-136-148-152-164-51,28-51-105-117,"prajmaline METOPROLOL cardiogenic shock,","The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862739,9/15/2015 21:43:18,1739041154,9/15/2015 21:43:06,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,VENTRICULAR TACHYCARDIA,124-136,51,METOPROLOL,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862739,9/15/2015 21:49:18,1739044285,9/15/2015 21:49:03,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,VENTRICULAR TACHYCARDIA,124-136,51,METOPROLOL,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862739,9/15/2015 21:50:00,1739044583,9/15/2015 21:49:46,false,prodege,1,34271751,CAN,ON,Toronto,99.225.188.40,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,VENTRICULAR TACHYCARDIA,124-136,51,METOPROLOL,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862739,9/15/2015 21:50:24,1739044831,9/15/2015 21:49:58,false,clixsense,1,26492726,GBR,H3,Leeds,90.214.17.126,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,VENTRICULAR TACHYCARDIA,124-136,51,METOPROLOL,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862739,9/15/2015 21:50:59,1739045076,9/15/2015 21:50:24,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,VENTRICULAR TACHYCARDIA,124-136,51,METOPROLOL,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862739,9/15/2015 21:55:28,1739046994,9/15/2015 21:54:36,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,124,51,,,147,61,VENTRICULAR TACHYCARDIA,METOPROLOL,VENTRICULAR TACHYCARDIA,124-136,43-47-51,600 mgs METOPROLOL,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation.",124 136,51,124,51,147,61,-1,RO-may_treat,820132,"The patient took in 120 mgs prajmaline and 600 mgs metoprolol during the day of the case, which leads to cardiogenic shock, ventricular tachycardia and ventricular fibrillation",ventricular tachycardia,metoprolol
788862740,9/15/2015 21:22:32,1739029679,9/15/2015 21:22:12,false,neodev,1.0,33758777,USA,"","",38.95.108.251,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,69-78,15,RANITIDINE,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862740,9/15/2015 21:24:01,1739030523,9/15/2015 21:23:49,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,69-78,15,RANITIDINE,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862740,9/15/2015 21:36:03,1739037330,9/15/2015 21:35:43,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,69-78,15,RANITIDINE,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862740,9/15/2015 21:39:50,1739039327,9/15/2015 21:39:24,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,Treatment with ranitidine DUODENAL ULCER,0-10-69-78-15,0-10-15-26-30-32,Treatment with RANITIDINE for a maximum,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862740,9/15/2015 21:42:27,1739040674,9/15/2015 21:42:14,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,69-78,15,RANITIDINE,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862740,9/15/2015 21:48:15,1739043797,9/15/2015 21:47:49,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,69-78,15,RANITIDINE,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862740,9/15/2015 21:48:18,1739043832,9/15/2015 21:48:07,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,69-78,15,RANITIDINE,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862740,9/15/2015 21:48:28,1739043964,9/15/2015 21:48:11,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,69-78,15,RANITIDINE,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862740,9/15/2015 21:48:55,1739044138,9/15/2015 21:48:39,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,69-78,15,RANITIDINE,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862740,9/15/2015 21:49:39,1739044454,9/15/2015 21:49:06,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,69,15,,,83,25,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,69-78,15,RANITIDINE,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,69 78,15,69,15,83,25,-1,RO-may_prevent,820211,Treatment with ranitidine for a maximum of six weeks healed 97.1% of duodenal ulcer patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81,duodenal ulcer,ranitidine
788862741,9/16/2015 00:02:25,1739087869,9/16/2015 00:01:49,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,Fasting HYPOGLYCEMIA,505-513,481-489-496,Fasting plasma GLUCOSE,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862741,9/16/2015 01:43:12,1739133260,9/16/2015 01:42:45,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,513,496-505,GLUCOSE Fasting,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862741,9/16/2015 02:17:30,1739160601,9/16/2015 02:17:01,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,plasma glucose Fasting HYPOGLYCEMIA,489-496-505-513,481-489-496-505-513,Fasting plasma GLUCOSE Fasting hypoglycemia,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862741,9/16/2015 03:13:53,1739212224,9/16/2015 03:13:38,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,Hypoglycemia plasma glucose Fasting HYPOGLYCEMIA should be confirmed,489-496-505-513-526-533-536-456,475-481-489-496-505-513-526,Notes Fasting plasma GLUCOSE Fasting hypoglycemia should,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862741,9/16/2015 03:24:54,1739222486,9/16/2015 03:24:29,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,plasma glucose Fasting HYPOGLYCEMIA should be confirmed,489-496-505-513-526-533-536,481-489-496-505-513,Fasting plasma GLUCOSE Fasting hypoglycemia,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862741,9/16/2015 03:57:50,1739252988,9/16/2015 03:57:38,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,513,496,GLUCOSE,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862741,9/16/2015 04:02:12,1739256967,9/16/2015 04:01:25,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,Fasting HYPOGLYCEMIA,513-505,481-489-496-505-513,Fasting plasma GLUCOSE Fasting hypoglycemia,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862741,9/16/2015 04:15:40,1739269717,9/16/2015 04:15:07,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,513,489-496,plasma GLUCOSE,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862741,9/16/2015 04:22:22,1739275766,9/16/2015 04:21:16,false,instagc,1,33448981,USA,CA,Escondido,68.111.177.226,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,"Emotional instability, hypoglycemia Tachycardia, diaphoresis, tremor, change in mental status plasma glucose Fasting HYPOGLYCEMIA",9-19-126-182-195-208-216-223-226-233-489-496-505-513,9-19-182-195-208-216-223-226-233-475-481-489-496-505-513,"Emotional instability, Tachycardia, diaphoresis, tremor, change in mental status Notes Fasting plasma GLUCOSE Fasting hypoglycemia","History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862741,9/16/2015 04:35:18,1739289193,9/16/2015 04:34:29,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,513,496,,,525,503,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,513,489-496,plasma GLUCOSE,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (",513,496,513,496,525,503,-1,RO-may_treat,820051,"History  Emotional instability, frequent perceived need to eat    Low  Low   Nonspecific symptoms should not be attributed to hypoglycemia without supporting evidence Physical exam  Tachycardia, diaphoresis, tremor, change in mental status    High  Low   Physical exam findings are nonspecific and attributable to hypoglycemia only with supporting evidence   Laboratory and Other Studies for Hypoglycemia  Normal;          Laboratory and Other Studies for Hypoglycemia Test  Notes Fasting plasma glucose  Fasting hypoglycemia should be confirmed and performed with a simultaneous insulin level Random plasma glucose  Hypoglycemia on a random sample may indicate postabsorptive (""reactive"") hypoglycemia Oral glucose tolerance",hypoglycemia,glucose
788862742,9/15/2015 22:06:21,1739051560,9/15/2015 22:06:08,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,124,77,,,131,90,MEASLES,MEASLES VIRUS,MEASLES,124,54-61-65-74-77-85,matrix (M) antigens of MEASLES VIRUS,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862742,9/15/2015 22:23:47,1739057406,9/15/2015 22:21:57,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,124,77,,,131,90,MEASLES,MEASLES VIRUS,MEASLES convalescent sera,124-132-145,77-85,MEASLES VIRUS,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862742,9/15/2015 22:32:00,1739060060,9/15/2015 22:31:23,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,124,77,,,131,90,MEASLES,MEASLES VIRUS,MEASLES,124,77-85,MEASLES VIRUS,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862742,9/15/2015 22:35:21,1739061222,9/15/2015 22:33:00,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,124,77,,,131,90,MEASLES,MEASLES VIRUS,MEASLES convalescent sera,124-132-145,77-85,MEASLES VIRUS,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862742,9/15/2015 22:37:00,1739061817,9/15/2015 22:36:42,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,124,77,,,131,90,MEASLES,MEASLES VIRUS,MEASLES,124,77-85,MEASLES VIRUS,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862742,9/15/2015 22:53:55,1739067433,9/15/2015 22:53:11,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,124,77,,,131,90,MEASLES,MEASLES VIRUS,MEASLES,124,77-85,MEASLES VIRUS,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862742,9/15/2015 22:57:33,1739068636,9/15/2015 22:57:14,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,124,77,,,131,90,MEASLES,MEASLES VIRUS,MEASLES,124,61-65-77-85,(M) antigens MEASLES VIRUS,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862742,9/15/2015 23:06:24,1739071460,9/15/2015 23:06:13,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,124,77,,,131,90,MEASLES,MEASLES VIRUS,MEASLES,124,77-85,MEASLES VIRUS,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862742,9/15/2015 23:14:17,1739074439,9/15/2015 23:13:10,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,124,77,,,131,90,MEASLES,MEASLES VIRUS,"nucleoprotein matrix antigens measles virus MEASLES convalescent sera sera multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, atypical measles.",36-54-65-77-85-124-132-145-157-181-190-201-210-221-238-246-253-268-277,36-54-61-65-74-77-85-132-145-157-181-190-201-210-221-238-246-253-268-277,"nucleoprotein matrix (M) antigens of MEASLES VIRUS convalescent sera sera multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, atypical measles.","The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862742,9/15/2015 23:18:43,1739075574,9/15/2015 23:18:13,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,124,77,,,131,90,MEASLES,MEASLES VIRUS,MEASLES,124,77-85,MEASLES VIRUS,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles.",124,77 85,124,77,131,90,-1,RO-may_prevent,820347,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of measles virus was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical measles",measles,measles virus
788862743,9/15/2015 21:50:54,1739045039,9/15/2015 21:50:44,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,45,0,,,49,9,PAIN,CAPSAICIN,PAIN,45,0,CAPSAICIN,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862743,9/15/2015 21:56:46,1739047529,9/15/2015 21:56:29,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,45,0,,,49,9,PAIN,CAPSAICIN,PAIN,45,0,CAPSAICIN,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862743,9/15/2015 21:57:46,1739048036,9/15/2015 21:57:34,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,45,0,,,49,9,PAIN,CAPSAICIN,PAIN allodynia.,45-63,0-18,CAPSAICIN lidocaine,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862743,9/15/2015 21:57:59,1739048146,9/15/2015 21:57:31,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,45,0,,,49,9,PAIN,CAPSAICIN,PAIN,45,0,CAPSAICIN,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862743,9/15/2015 22:02:20,1739050199,9/15/2015 22:01:45,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,45,0,,,49,9,PAIN,CAPSAICIN,PAIN,45,0,CAPSAICIN,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862743,9/15/2015 22:02:46,1739050281,9/15/2015 22:02:32,false,instagc,1.0,21551272,GBR,I9,Dereham,89.243.154.52,45,0,,,49,9,PAIN,CAPSAICIN,PAIN,45,0,CAPSAICIN,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862743,9/15/2015 22:03:33,1739050624,9/15/2015 22:03:27,false,neodev,1,33238512,USA,AZ,Phoenix,70.176.34.46,45,0,,,49,9,PAIN,CAPSAICIN,5% patch relieve PAIN and decrease allodynia.,28-31-37-45-50-54-63,0-10-14-18,CAPSAICIN and the lidocaine,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862743,9/15/2015 22:13:33,1739053845,9/15/2015 22:12:29,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,45,0,,,49,9,PAIN,CAPSAICIN,PAIN,45,0,CAPSAICIN,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862743,9/15/2015 22:14:03,1739054017,9/15/2015 22:12:03,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,45,0,,,49,9,PAIN,CAPSAICIN,PAIN,45,0,CAPSAICIN,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862743,9/15/2015 22:27:57,1739058599,9/15/2015 22:27:47,false,neodev,1,30749660,USA,NC,Wake Forest,71.70.155.5,45,0,,,49,9,PAIN,CAPSAICIN,5% patch relieve PAIN and decrease allodynia.,28-31-37-45-50-54-63,0-10-14-18,CAPSAICIN and the lidocaine,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia.,45,0,45,0,49,9,-1,RO-may_prevent,820286,Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia,pain,Capsaicin
788862744,9/16/2015 00:01:24,1739087687,9/16/2015 00:01:06,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,168,125,,,175,136,MALARIA,CHLOROQUINE,National MALARIA Program,159-168-176,125,CHLOROQUINE,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862744,9/16/2015 01:42:22,1739132627,9/16/2015 01:42:10,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,168,125,,,175,136,MALARIA,CHLOROQUINE,National MALARIA Program,159-168-176,125,CHLOROQUINE,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862744,9/16/2015 02:16:10,1739159312,9/16/2015 02:15:41,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,168,125,,,175,136,MALARIA,CHLOROQUINE,MALARIA,168,125,CHLOROQUINE,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862744,9/16/2015 03:13:21,1739211747,9/16/2015 03:13:08,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,168,125,,,175,136,MALARIA,CHLOROQUINE,by the National MALARIA Program or with,152-155-159-168-176-184-187,111-117-122-125-137-140-152-159-155,total dose of CHLOROQUINE as recommended by the National,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862744,9/16/2015 03:24:00,1739221589,9/16/2015 03:23:09,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,168,125,,,175,136,MALARIA,CHLOROQUINE,by the National MALARIA Program,152-155-159-168-176,111-117-122-125-137-140,total dose of CHLOROQUINE as recommended,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862744,9/16/2015 03:33:02,1739230100,9/16/2015 03:32:38,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,168,125,,,175,136,MALARIA,CHLOROQUINE,National MALARIA Program,159-168-176,125,CHLOROQUINE,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862744,9/16/2015 03:57:22,1739252532,9/16/2015 03:57:10,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,168,125,,,175,136,MALARIA,CHLOROQUINE,MALARIA,168,125,CHLOROQUINE,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862744,9/16/2015 04:02:47,1739257446,9/16/2015 04:00:51,false,prodege,1,17379068,CAN,AB,Lethbridge,108.181.214.205,168,125,,,175,136,MALARIA,CHLOROQUINE,by the National MALARIA Program or with,152-155-159-168-176-184-187,111-117-122-125-137-140-152,total dose of CHLOROQUINE as recommended by,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862744,9/16/2015 04:14:20,1739268223,9/16/2015 04:13:36,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,168,125,,,175,136,MALARIA,CHLOROQUINE,MALARIA,168,125,CHLOROQUINE,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862744,9/16/2015 04:20:32,1739274173,9/16/2015 04:19:58,false,instagc,1.0,33448981,USA,CA,Escondido,68.111.177.226,168,125,,,175,136,MALARIA,CHLOROQUINE,symptomatic malaria by MALARIA,26-152-168-14,14-26-125,symptomatic malaria CHLOROQUINE,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg.",168,125,168,125,175,136,-1,RO-may_prevent,820343,"Children with symptomatic malaria in Bissau, Guinea-Bissau were randomly assigned to treatment with a 25 mg/kg total dose of chloroquine as recommended by the National Malaria Program or with a higher total dose of 50 mg/kg",Malaria,chloroquine
788862745,9/15/2015 21:19:35,1739028057,9/15/2015 21:19:16,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,TYPE 2 DIABETES MELLITUS,106-111-113-122,77,"INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862745,9/15/2015 21:20:33,1739028652,9/15/2015 21:20:15,false,neodev,1.0,33758777,USA,"","",38.95.108.251,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,TYPE 2 DIABETES MELLITUS,106-111-113-122,77,"INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862745,9/15/2015 21:22:39,1739029757,9/15/2015 21:22:27,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,type 1 and TYPE 2 DIABETES MELLITUS,95-100-102-106-111-113-122,77,"INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862745,9/15/2015 21:24:01,1739030524,9/15/2015 21:23:46,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,TYPE 2 DIABETES MELLITUS,106-111-113-122,77,"INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862745,9/15/2015 21:28:50,1739033313,9/15/2015 21:26:09,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,TYPE 2 DIABETES MELLITUS,106-111-113-122,77,"INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862745,9/15/2015 21:36:37,1739037628,9/15/2015 21:36:11,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,type 1 and TYPE 2 DIABETES MELLITUS are associated with cognitive impairment,95-100-102-106-111-113-122-131-135-146-151-161,36-52-62-65-73-77,"hippocampus sensitive to glucose and INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862745,9/15/2015 21:38:46,1739038787,9/15/2015 21:38:32,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,TYPE 2 DIABETES MELLITUS,106-111-113-122,77,"INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862745,9/15/2015 21:40:59,1739039971,9/15/2015 21:40:46,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,type 1 and TYPE 2 DIABETES MELLITUS,95-100-102-106-111-113-122,77,"INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862745,9/15/2015 21:43:16,1739041136,9/15/2015 21:42:52,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,type 1 and TYPE 2 DIABETES MELLITUS,95-100-102-106-111-113-122,77,"INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862745,9/15/2015 21:46:45,1739043038,9/15/2015 21:46:29,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,106,77,,,130,84,TYPE 2 DIABETES MELLITUS,INSULIN,TYPE 2 DIABETES MELLITUS,106-111-113-122,77,"INSULIN,","Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease.",106 111 113 122,77,106,77,130,84,-1,RO-may_treat,820109,"Moreover, brain regions such as the hippocampus are sensitive to glucose and insulin, and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for type 2 diabetes mellitus) increased risk for Alzheimer's disease",type 2 diabetes mellitus,insulin
788862746,9/15/2015 21:52:48,1739045859,9/15/2015 21:52:32,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,VON WILLEBRAND,111-115,86-101,ANTIHEMOPHILIC FACTOR,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862746,9/15/2015 22:00:07,1739049154,9/15/2015 21:59:51,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,antihemophilic factor VON WILLEBRAND factor preparations,86-101-111-115-126-133,86-101-111-115-126-133,ANTIHEMOPHILIC FACTOR von Willebrand factor preparations,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862746,9/15/2015 22:11:29,1739053141,9/15/2015 22:10:14,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,VON WILLEBRAND factor preparations,111-115-126-133,86-101,ANTIHEMOPHILIC FACTOR,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862746,9/15/2015 22:21:11,1739056571,9/15/2015 22:20:17,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,VON WILLEBRAND factor,111-115-126,86-101,ANTIHEMOPHILIC FACTOR,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862746,9/15/2015 22:21:38,1739056769,9/15/2015 22:20:17,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,VON WILLEBRAND factor,111-115-126,86-101,ANTIHEMOPHILIC FACTOR,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862746,9/15/2015 22:32:29,1739060247,9/15/2015 22:32:13,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,VON WILLEBRAND,111-115,86-101,ANTIHEMOPHILIC FACTOR,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862746,9/15/2015 22:39:23,1739062706,9/15/2015 22:39:11,false,instagc,1,23287154,USA,CA,San Jose,50.184.60.102,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,VON WILLEBRAND factor preparations,111-115-126-133,86-101,ANTIHEMOPHILIC FACTOR,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862746,9/15/2015 22:40:48,1739063107,9/15/2015 22:40:28,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,VON WILLEBRAND factor,111-115-126,86-101,ANTIHEMOPHILIC FACTOR,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862746,9/15/2015 22:43:55,1739063985,9/15/2015 22:42:38,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,VON WILLEBRAND or,111-115-146,86-101-111-115,ANTIHEMOPHILIC FACTOR von Willebrand,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862746,9/15/2015 22:44:49,1739064246,9/15/2015 22:43:34,false,neodev,1,17426565,CAN,BC,Burnaby,70.79.9.44,111,86,,,125,107,VON WILLEBRAND,ANTIHEMOPHILIC FACTOR,VON WILLEBRAND factor preparations,111-115-126-133,86-101,ANTIHEMOPHILIC FACTOR,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations.,111 115,86 101,111,86,125,107,-1,RO-may_treat,820012,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available antihemophilic factor or von Willebrand factor preparations or any ingredient in the formulations,von Willebrand,antihemophilic factor
788862747,9/15/2015 21:53:17,1739046034,9/15/2015 21:53:07,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,129,CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862747,9/15/2015 22:01:12,1739049682,9/15/2015 22:00:37,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,78-91-101-112-118-129,tripotassium dicitrato bismuthate (TDB) tablets CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862747,9/15/2015 22:12:38,1739053489,9/15/2015 22:12:13,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,129,CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862747,9/15/2015 22:23:16,1739057251,9/15/2015 22:22:16,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,129,CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862747,9/15/2015 22:24:24,1739057561,9/15/2015 22:23:51,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,129,CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862747,9/15/2015 22:33:25,1739060578,9/15/2015 22:33:11,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,129,CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862747,9/15/2015 22:40:13,1739062961,9/15/2015 22:39:57,false,instagc,1.0,23287154,USA,CA,San Jose,50.184.60.102,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,78-91-112-118-126-129-101,tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862747,9/15/2015 22:42:10,1739063443,9/15/2015 22:41:50,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,112-118-126-129,(TDB) tablets or CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862747,9/15/2015 22:45:28,1739064480,9/15/2015 22:44:59,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,21-30-129,duodenal ulcer CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862747,9/15/2015 22:47:11,1739065027,9/15/2015 22:45:52,false,neodev,1.0,17426565,CAN,BC,Burnaby,70.79.9.44,21,129,,,35,139,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,21-30,129,CIMETIDINE.,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.,21 30,129,21,129,35,139,-1,RO-may_prevent,820300,Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine,duodenal ulcer,cimetidine
788862748,9/16/2015 00:02:43,1739087961,9/16/2015 00:02:26,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,111,49,,,117,62,GOITER,THYROGLOBULIN,GOITER,111,43-49,serum THYROGLOBULIN,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862748,9/16/2015 01:43:26,1739133397,9/16/2015 01:43:13,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,111,49,,,117,62,GOITER,THYROGLOBULIN,GOITER and thyroid nodules;,111-118-122-130,49,THYROGLOBULIN,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862748,9/16/2015 02:18:03,1739161009,9/16/2015 02:17:33,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,111,49,,,117,62,GOITER,THYROGLOBULIN,GOITER,111,43-49,serum THYROGLOBULIN,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862748,9/16/2015 03:14:07,1739212411,9/16/2015 03:13:54,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,111,49,,,117,62,GOITER,THYROGLOBULIN,"past history of thyroid disorder, GOITER and thyroid nodules;",82-90-93-101-111-118-122-130-77,30-40-43-49-63-66-72-77-82,elevation of serum THYROGLOBULIN in women with past history,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862748,9/16/2015 03:25:19,1739222795,9/16/2015 03:24:55,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,111,49,,,117,62,GOITER,THYROGLOBULIN,"of thyroid disorder, GOITER and thyroid nodules;",90-93-101-111-118-122-130,30-40-43-49-63-66,elevation of serum THYROGLOBULIN in women,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862748,9/16/2015 03:58:03,1739253140,9/16/2015 03:57:52,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,111,49,,,117,62,GOITER,THYROGLOBULIN,GOITER,111,49,THYROGLOBULIN,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862748,9/16/2015 04:03:23,1739258099,9/16/2015 04:02:13,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,111,49,,,117,62,GOITER,THYROGLOBULIN,GOITER,111,49,THYROGLOBULIN,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862748,9/16/2015 04:16:03,1739270051,9/16/2015 04:15:41,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,111,49,,,117,62,GOITER,THYROGLOBULIN,GOITER,111,43-49,serum THYROGLOBULIN,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862748,9/16/2015 04:35:35,1739289530,9/16/2015 04:35:19,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,111,49,,,117,62,GOITER,THYROGLOBULIN,GOITER,111,43-49,serum THYROGLOBULIN,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862748,9/16/2015 04:45:14,1739299285,9/16/2015 04:44:49,false,gifthunterclub,1,30901412,GBR,G5,Margate,85.210.116.48,111,49,,,117,62,GOITER,THYROGLOBULIN,"of thyroid disorder, GOITER and thyroid nodules; biochemical evidence",90-93-101-111-118-122-130-220-232,30-40-43-49-63-66-72-93-101,"elevation of serum THYROGLOBULIN in women with thyroid disorder,","Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",111,49,111,49,117,62,-1,RO-may_treat,820103,"Noteworthy were 1) the marked elevation of serum thyroglobulin in women with past history of thyroid disorder, goiter and thyroid nodules; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation",goiter,thyroglobulin
788862749,9/15/2015 23:00:09,1739069436,9/15/2015 22:59:34,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,ANGINA,145,65-74-115,GLYCERYL TRINITRATE angina,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862749,9/15/2015 23:55:59,1739086416,9/15/2015 23:55:34,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,ANGINA,145,65-74,GLYCERYL TRINITRATE,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862749,9/15/2015 23:56:48,1739086658,9/15/2015 23:56:03,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,severe ANGINA attacks,138-145-152,65-74,GLYCERYL TRINITRATE,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862749,9/16/2015 00:17:30,1739091526,9/16/2015 00:17:11,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,ANGINA,145,65-74,GLYCERYL TRINITRATE,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862749,9/16/2015 00:31:27,1739094576,9/16/2015 00:31:11,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,ANGINA,145,65-74,GLYCERYL TRINITRATE,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862749,9/16/2015 00:48:55,1739098912,9/16/2015 00:47:30,false,neodev,1.0,32114597,USA,"","",73.151.173.249,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,Both verapamil propranolol significant reduction glyceryl trinitrate tablet pectoris severe ANGINA attacks compared to placebo.,0-5-19-40-52-65-74-85-122-138-145-152-160-172-169,0-5-15-19-40-52-62-65-74-85-92-105-115-122-138-145-152-160-172,"Both verapamil and propranolol significant reduction in GLYCERYL TRINITRATE tablet consumption, days angina pectoris severe angina attacks compared placebo.","Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862749,9/16/2015 01:19:30,1739114469,9/16/2015 01:18:43,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,verapamil propranolol glyceryl trinitrate angina pectoris ANGINA,5-19-65-74-115-122-145,5-19-62-65-74-115-122-145-172,verapamil propranolol in GLYCERYL TRINITRATE angina pectoris angina placebo.,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862749,9/16/2015 01:30:25,1739120994,9/16/2015 01:29:54,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,ANGINA attacks,145-152,62-65-74-85-92-105-115-110,"in GLYCERYL TRINITRATE tablet consumption, days with angina","Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862749,9/16/2015 01:38:28,1739129068,9/16/2015 01:38:13,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,ANGINA attacks,145-152,65-74,GLYCERYL TRINITRATE,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862749,9/16/2015 01:58:29,1739144804,9/16/2015 01:58:15,false,neodev,1.0,11291592,USA,MI,Taylor,99.170.106.105,145,65,,,151,84,ANGINA,GLYCERYL TRINITRATE,ANGINA,145,65-74,GLYCERYL TRINITRATE,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo.",145,65 74,145,65,151,84,-1,RO-may_prevent,820175,"Both verapamil and propranolol caused a significant reduction in glyceryl trinitrate tablet consumption, days with angina pectoris and in severe angina attacks compared to placebo",angina,glyceryl trinitrate
788862750,9/15/2015 23:59:46,1739087358,9/15/2015 23:59:28,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,97,153,,,103,162,ZOSTER,ACYCLOVIR,varicella ZOSTER,87-97,153-163,ACYCLOVIR therapy,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862750,9/16/2015 00:36:06,1739095758,9/16/2015 00:35:45,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,97,153,,,103,162,ZOSTER,ACYCLOVIR,varicella ZOSTER,87-97,143-148-153,high dose ACYCLOVIR,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862750,9/16/2015 01:29:00,1739120156,9/16/2015 01:28:03,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,97,153,,,103,162,ZOSTER,ACYCLOVIR,biopsy specimen viral culture papules varicella ZOSTER eventually acyclovir therapy debridement.,14-21-34-40-57-87-97-109-153-163-175,14-21-34-40-57-87-97-153-163-171-175,biopsy specimen viral culture papules varicella zoster ACYCLOVIR therapy and debridement.,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862750,9/16/2015 01:35:09,1739124066,9/16/2015 01:34:40,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,97,153,,,103,162,ZOSTER,ACYCLOVIR,subsequently revealed varicella ZOSTER,65-78-87-97,133-143-148-153-163-171-175,prolonged high dose ACYCLOVIR therapy and debridement.,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862750,9/16/2015 01:41:11,1739131684,9/16/2015 01:40:56,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,97,153,,,103,162,ZOSTER,ACYCLOVIR,varicella ZOSTER,87-97,153,ACYCLOVIR,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862750,9/16/2015 02:12:35,1739156195,9/16/2015 02:12:07,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,97,153,,,103,162,ZOSTER,ACYCLOVIR,varicella ZOSTER,87-97,153,ACYCLOVIR,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862750,9/16/2015 03:12:14,1739210623,9/16/2015 03:12:01,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,97,153,,,103,162,ZOSTER,ACYCLOVIR,subsequently revealed varicella ZOSTER that eventually responded prolonged,65-78-87-97-104-109-120-133,133-143-148-153-163-171-175-120,responded prolonged high dose ACYCLOVIR therapy and debridement.,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862750,9/16/2015 03:13:20,1739211731,9/16/2015 03:13:10,false,prodege,1.0,31508822,CAN,AB,Calgary,206.75.77.133,97,153,,,103,162,ZOSTER,ACYCLOVIR,varicella ZOSTER,87-97,153-163,ACYCLOVIR therapy,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862750,9/16/2015 03:20:57,1739218501,9/16/2015 03:20:38,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,97,153,,,103,162,ZOSTER,ACYCLOVIR,subsequently revealed varicella ZOSTER that eventually responded,65-78-87-97-104-109-120,143-148-153-163-171-175,high dose ACYCLOVIR therapy and debridement.,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862750,9/16/2015 03:24:18,1739221920,9/16/2015 03:24:06,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,97,153,,,103,162,ZOSTER,ACYCLOVIR,varicella ZOSTER,87-97,153,ACYCLOVIR,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement.,97,153,97,153,103,162,-1,RO-may_prevent,820308,Findings of a biopsy specimen and viral culture of these papules subsequently revealed varicella-zoster that eventually responded to prolonged high-dose acyclovir therapy and debridement,zoster,acyclovir
788862751,9/15/2015 21:24:09,1739030644,9/15/2015 21:23:54,false,neodev,1.0,33758777,USA,"","",38.95.108.251,58,91,,,64,105,RABIES,RABIES VACCINE,RABIES,58,91-98,RABIES VACCINE.,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862751,9/15/2015 21:25:02,1739031168,9/15/2015 21:24:52,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,58,91,,,64,105,RABIES,RABIES VACCINE,Rhesus diploid RABIES vaccine,43-50-58-65,91-98,RABIES VACCINE.,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862751,9/15/2015 21:41:08,1739040008,9/15/2015 21:40:26,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,58,91,,,64,105,RABIES,RABIES VACCINE,Rhesus diploid RABIES vaccine,43-50-58-65,91-98,RABIES VACCINE.,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862751,9/15/2015 21:42:07,1739040482,9/15/2015 21:41:40,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,58,91,,,64,105,RABIES,RABIES VACCINE,Rhesus diploid RABIES vaccine rabies vaccine.,43-50-58-65-91-98,58-65-73-91-98,"rabies vaccine (adsorbed), RABIES VACCINE.","Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862751,9/15/2015 21:43:29,1739041282,9/15/2015 21:43:19,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,58,91,,,64,105,RABIES,RABIES VACCINE,Rhesus diploid RABIES vaccine a,50-58-65-85-43,91-98,RABIES VACCINE.,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862751,9/15/2015 21:49:30,1739044375,9/15/2015 21:49:19,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,58,91,,,64,105,RABIES,RABIES VACCINE,RABIES,58,91-98,RABIES VACCINE.,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862751,9/15/2015 21:50:47,1739044982,9/15/2015 21:50:01,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,58,91,,,64,105,RABIES,RABIES VACCINE,RABIES vaccine,58-65,91-98,RABIES VACCINE.,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862751,9/15/2015 21:51:37,1739045345,9/15/2015 21:51:01,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,58,91,,,64,105,RABIES,RABIES VACCINE,Rhesus diploid RABIES vaccine,43-50-58-65,91-98,RABIES VACCINE.,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862751,9/15/2015 21:52:40,1739045838,9/15/2015 21:51:55,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,58,91,,,64,105,RABIES,RABIES VACCINE,Rhesus diploid RABIES vaccine a,50-58-65-85-43,91-98,RABIES VACCINE.,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862751,9/15/2015 21:55:43,1739047084,9/15/2015 21:55:27,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,58,91,,,64,105,RABIES,RABIES VACCINE,Rhesus diploid RABIES vaccine,43-50-58-65,91-98,RABIES VACCINE.,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine.",58,91 98,58,91,64,105,-1,RO-may_prevent,820153,"Berlin BS, Mitchell JR, Burgoyne GH et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine",rabies,rabies vaccine
788862752,9/16/2015 01:44:11,1739133993,9/16/2015 01:43:57,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE.,95-106-112,44,DIGITALIS,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862752,9/16/2015 02:19:27,1739162345,9/16/2015 02:18:59,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE.,95-106-112,44,DIGITALIS,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862752,9/16/2015 03:14:51,1739213100,9/16/2015 03:14:38,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,not adequately treat CONGESTIVE HEART FAILURE.,74-78-89-95-106-112,29-34-39-44-54-58-68-78-89-112-95,used only when DIGITALIS and diuretics could adequately treat congestive failure.,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862752,9/16/2015 03:27:34,1739224842,9/16/2015 03:26:49,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,not adequately treat CONGESTIVE HEART FAILURE.,74-78-89-95-106-112,29-34-39-44-54-58-68-74-78-89,used only when DIGITALIS and diuretics could not adequately treat,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862752,9/16/2015 03:58:40,1739253722,9/16/2015 03:58:29,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE.,95-106-112,44,DIGITALIS,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862752,9/16/2015 04:04:34,1739259067,9/16/2015 04:04:13,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE.,95-106-112,44,DIGITALIS,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862752,9/16/2015 04:17:19,1739271106,9/16/2015 04:17:02,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE.,95-106-112,44-54-58,DIGITALIS and diuretics,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862752,9/16/2015 04:36:32,1739290635,9/16/2015 04:36:20,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE.,95-106-112,44,DIGITALIS,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862752,9/16/2015 04:45:55,1739300020,9/16/2015 04:45:43,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,digitalis and diuretics treat CONGESTIVE HEART FAILURE.,44-54-89-95-106-112-58,29-34-39-44-54-58-68-95-106-112,used only when DIGITALIS and diuretics could congestive heart failure.,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862752,9/16/2015 05:01:05,1739316015,9/16/2015 04:59:53,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,95,44,,,119,53,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE.,95-106-112,11-24-29-34-39-44-54-58-68-74-78-89-95-106-112,vasodilators were used only when DIGITALIS and diuretics could not adequately treat congestive heart failure.,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure.",95 106 112,44,95,44,119,53,-1,RO-may_prevent,820309,"Initially, vasodilators were used only when digitalis and diuretics could not adequately treat congestive heart failure",congestive heart failure,digitalis
788862753,9/15/2015 21:52:17,1739045673,9/15/2015 21:52:04,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES:,429-434-436,391,INSULIN,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862753,9/15/2015 21:59:29,1739048858,9/15/2015 21:59:13,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES:,429-434-436,391-399,INSULIN secretion,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862753,9/15/2015 22:00:34,1739049380,9/15/2015 22:00:05,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES:,429-434-436,391-399,INSULIN secretion,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862753,9/15/2015 22:09:20,1739052550,9/15/2015 22:08:33,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES:,429-434-436,391-399,INSULIN secretion,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862753,9/15/2015 22:19:30,1739055992,9/15/2015 22:18:22,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES:,429-434-436,391,INSULIN,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862753,9/15/2015 22:19:42,1739056072,9/15/2015 22:18:36,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES:,429-434-436,391,INSULIN,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862753,9/15/2015 22:31:54,1739060039,9/15/2015 22:31:36,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES:,429-434-436,391-399,INSULIN secretion,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862753,9/15/2015 22:38:44,1739062462,9/15/2015 22:38:24,false,instagc,1.0,23287154,USA,CA,San Jose,50.184.60.102,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,insulin secretion before diagnosis of TYPE 2 DIABETES:,391-409-416-426-429-434-436-399,391-399-409-416-426-429-434-436,INSULIN secretion before diagnosis of type 2 diabetes:,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862753,9/15/2015 22:39:37,1739062816,9/15/2015 22:38:55,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES:,429-434-436,366-374-387-391-399-409-416,"insulin sensitivity, and INSULIN secretion before diagnosis","placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862753,9/15/2015 22:43:31,1739063842,9/15/2015 22:43:25,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,429,391,,,444,398,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES:,429-434-436,391-399,INSULIN secretion,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre.",429 434 436,391,429,391,444,398,-1,RO-may_treat,820094,"placebo-controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre",type 2 diabetes,insulin
788862754,9/15/2015 23:58:35,1739087113,9/15/2015 23:58:14,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,POSTMENOPAUSAL OSTEOPOROSIS.,115-130,51-60-70-77,receptor modulator (SERM) RALOXIFENE,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862754,9/15/2015 23:59:05,1739087214,9/15/2015 23:58:46,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,treatments of POSTMENOPAUSAL OSTEOPOROSIS.,101-112-115-130,70-77,(SERM) RALOXIFENE,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862754,9/16/2015 00:54:33,1739100530,9/16/2015 00:53:30,false,neodev,1.0,32114597,USA,"","",73.151.173.249,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,Various bisphosphonates estrogen receptor modulator (SERM) approved treatments of POSTMENOPAUSAL OSTEOPOROSIS.,8-42-51-60-70-92-101-112-115-130-0,51-60-70-77-88-92-101,receptor modulator (SERM) RALOXIFENE are approved treatments,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862754,9/16/2015 01:23:59,1739117159,9/16/2015 01:23:21,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,bisphosphonates estrogen receptor modulator (SERM) raloxifene POSTMENOPAUSAL OSTEOPOROSIS.,8-42-51-60-70-77-115-130,8-42-51-60-70-77-115-130,bisphosphonates estrogen receptor modulator (SERM) RALOXIFENE postmenopausal osteoporosis.,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862754,9/16/2015 01:32:22,1739122255,9/16/2015 01:31:55,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,POSTMENOPAUSAL OSTEOPOROSIS.,115-130,77-88-92-101-112-115-130,RALOXIFENE are approved treatments of postmenopausal osteoporosis.,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862754,9/16/2015 01:40:07,1739130901,9/16/2015 01:39:46,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,POSTMENOPAUSAL OSTEOPOROSIS.,115-130,70-77,(SERM) RALOXIFENE,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862754,9/16/2015 02:10:37,1739154616,9/16/2015 02:09:50,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,POSTMENOPAUSAL OSTEOPOROSIS.,115-130,42-51-70-77-60,estrogen receptor modulator (SERM) RALOXIFENE,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862754,9/16/2015 02:38:25,1739179520,9/16/2015 02:37:51,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,POSTMENOPAUSAL OSTEOPOROSIS.,115-130,77,RALOXIFENE,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862754,9/16/2015 02:47:13,1739188006,9/16/2015 02:46:51,false,zoombucks,1.0,4688131,CAN,BC,Vancouver,75.157.35.92,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,POSTMENOPAUSAL OSTEOPOROSIS.,115-130,77,RALOXIFENE,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862754,9/16/2015 03:09:37,1739208606,9/16/2015 03:09:26,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,115,77,,,142,87,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE,raloxifene approved treatments of POSTMENOPAUSAL OSTEOPOROSIS.,92-101-112-115-130-77,51-60-70-77-88-92-101-42,estrogen receptor modulator (SERM) RALOXIFENE are approved treatments,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.,115 130,77,115,77,142,87,-1,RO-may_prevent,820354,Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis,postmenopausal osteoporosis,raloxifene
788862755,9/16/2015 00:03:18,1739088079,9/16/2015 00:03:04,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,neonatal HYPOTHYROIDISM,50-59,83,THYROXINE,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862755,9/16/2015 01:43:57,1739133825,9/16/2015 01:43:43,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,neonatal HYPOTHYROIDISM,50-59,83,THYROXINE,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862755,9/16/2015 02:18:58,1739161875,9/16/2015 02:18:31,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,neonatal HYPOTHYROIDISM,50-59,83,THYROXINE,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862755,9/16/2015 03:14:37,1739212876,9/16/2015 03:14:23,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,screening for neonatal HYPOTHYROIDISM based on thyroxine or thyrotrophin,36-46-50-59-74-80-83-101-98,36-59-74-80-83-98-101-50,screening neonatal hypothyroidism based on THYROXINE or thyrotrophin,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862755,9/16/2015 03:26:48,1739224151,9/16/2015 03:26:08,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,screening for neonatal HYPOTHYROIDISM based on thyroxine,36-46-50-59-74-80-83,59-74-80-83-98-101-93,hypothyroidism based on THYROXINE (T4) or thyrotrophin,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862755,9/16/2015 03:58:29,1739253513,9/16/2015 03:58:18,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,59,83,THYROXINE,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862755,9/16/2015 04:04:11,1739258734,9/16/2015 04:03:49,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,neonatal HYPOTHYROIDISM,50-59,83,THYROXINE,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862755,9/16/2015 04:17:00,1739270825,9/16/2015 04:16:26,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,neonatal HYPOTHYROIDISM,59-50,83-93-101-114,THYROXINE (T4) thyrotrophin (TSH),We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862755,9/16/2015 04:36:19,1739290414,9/16/2015 04:35:59,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,neonatal HYPOTHYROIDISM,50-59,83-93,THYROXINE (T4),We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862755,9/16/2015 04:45:42,1739299733,9/16/2015 04:45:27,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,59,83,,,73,92,HYPOTHYROIDISM,THYROXINE,screening for neonatal HYPOTHYROIDISM based on thyroxine dried blood spots,36-46-50-59-74-80-83-130-136-142,59-74-80-83-98-101-50,neonatal hypothyroidism based on THYROXINE or thyrotrophin,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland.,59,83,59,83,73,92,-1,RO-may_prevent,820380,We have assessed the feasibility of screening for neonatal hypothyroidism based on thyroxine (T4) or thyrotrophin (TSH) assays on dried blood spots collected for the phenylketonuria (PKU) screening programme in Scotland,hypothyroidism,thyroxine
788862756,9/16/2015 01:45:37,1739135050,9/16/2015 01:45:26,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,119,142,,,130,147,HEPATITIS B,HBSAG,HEPATITIS B,119-129,131-133-141-150-160-162,"s antigen (HBSAG), hepatitis B e","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862756,9/16/2015 02:21:04,1739163773,9/16/2015 02:20:26,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,119,142,,,130,147,HEPATITIS B,HBSAG,HEPATITIS B,119-129,119-129-133-141,"hepatitis B antigen (HBSAG),","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862756,9/16/2015 03:15:40,1739213725,9/16/2015 03:15:27,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,119,142,,,130,147,HEPATITIS B,HBSAG,(HCV) serum markers as HEPATITIS B s antigen,102-108-116-119-129-131-133-96,119-131-133-141-150-160-162-164-102,"serum hepatitis s antigen (HBSAG), hepatitis B e antigen","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862756,9/16/2015 03:30:22,1739227434,9/16/2015 03:29:23,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,119,142,,,130,147,HEPATITIS B,HBSAG,serum markers as HEPATITIS B s antigen,102-108-116-119-129-131-133,131-133-141-150,"s antigen (HBSAG), hepatitis","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862756,9/16/2015 04:05:57,1739260228,9/16/2015 04:05:17,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,119,142,,,130,147,HEPATITIS B,HBSAG,HEPATITIS B s antigen,119-129-131-133,131-133-141-150-160-162-164,"s antigen (HBSAG), hepatitis B e antigen","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862756,9/16/2015 04:19:04,1739272865,9/16/2015 04:18:25,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,119,142,,,130,147,HEPATITIS B,HBSAG,"HEPATITIS B s antigen (HBsAg),",119-129-131-133-141,119-129-131-133-141-150-160-162-164-172,"hepatitis B s antigen (HBSAG), hepatitis B e antigen (HBeAg),","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862756,9/16/2015 04:37:41,1739291765,9/16/2015 04:37:09,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,119,142,,,130,147,HEPATITIS B,HBSAG,HEPATITIS B,119-129,129-131-133-141-119,"hepatitis B s antigen (HBSAG),","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862756,9/16/2015 05:04:10,1739318924,9/16/2015 05:02:55,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,119,142,,,130,147,HEPATITIS B,HBSAG,"serum markers as HEPATITIS B s antigen (HBsAg),",102-108-116-119-129-131-133-141,131-133-141-150-160-162-164-172,"s antigen (HBSAG), hepatitis B e antigen (HBeAg),","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862756,9/16/2015 05:11:46,1739326758,9/16/2015 05:11:30,false,elite,1.0,31883685,GBR,"","",79.66.244.188,119,142,,,130,147,HEPATITIS B,HBSAG,HEPATITIS B,119-129,141,"(HBSAG),","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862756,9/16/2015 05:46:50,1739364333,9/16/2015 05:46:43,false,neodev,1.0,34429821,USA,CA,San Jose,50.118.172.120,119,142,,,130,147,HEPATITIS B,HBSAG,serum markers as HEPATITIS B s antigen,102-108-116-119-129-131-133,131-133-141-150-160-162,"s antigen (HBSAG), hepatitis B e","Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM.",119 129,,119,142,130,147,-1,RO-may_prevent,820202,"Incidence of an anti-IFN activitywas compared with hepatitis B virus (HBV) or hepatitis C virus (HCV) serum markers as hepatitis B s antigen (HBsAg), hepatitis B e antigen (HBeAg), antibodies to HBsAg (anti-HBsAg), antibodies to HBeAg (anti-HBeAg), seroconversion, HBV DNA, HCV RNA, and serum soluble intracellular adhesion molecule I (sICAM",hepatitis B,HBsAg
788862757,9/16/2015 00:00:19,1739087482,9/16/2015 00:00:01,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,122-131,84-95-99,RANITIDINE 150 mg,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862757,9/16/2015 01:30:20,1739120973,9/16/2015 01:29:36,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,ranitidine 300 mg ranitidine 150 mg DUODENAL ULCER,36-47-51-84-95-99-122-131,36-47-51-84-95-99-122-131,ranitidine 300 mg RANITIDINE 150 mg duodenal ulcer,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862757,9/16/2015 01:36:06,1739124831,9/16/2015 01:35:29,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER patients treated in two Italian multicentre trials.,122-131-137-146-154-157-161-169-181,84-95-99-102-108-115-118-122-131-137-146,"RANITIDINE 150 mg twice daily, in 509 duodenal ulcer patients treated","The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862757,9/16/2015 01:41:42,1739132002,9/16/2015 01:41:27,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,122-131,84,RANITIDINE,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862757,9/16/2015 02:14:18,1739157774,9/16/2015 02:13:30,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,122-131,84,RANITIDINE,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862757,9/16/2015 03:12:41,1739211081,9/16/2015 03:12:28,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,"daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",108-115-118-122-131-137-146-154-157-161-169-181,66-74-80-84-95-99-102-169-122,"bedtime dose, and RANITIDINE 150 mg twice duodenal multicentre","The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862757,9/16/2015 03:22:17,1739219858,9/16/2015 03:21:49,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,in 509 DUODENAL ULCER patients treated,115-118-122-131-137-146,66-74-80-84-95-99-102,"bedtime dose, and RANITIDINE 150 mg twice","The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862757,9/16/2015 03:24:43,1739222358,9/16/2015 03:24:31,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,122-131,84,RANITIDINE,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862757,9/16/2015 03:31:53,1739228908,9/16/2015 03:31:21,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,DUODENAL ULCER,122-131,84-95-99,RANITIDINE 150 mg,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862757,9/16/2015 03:53:10,1739249028,9/16/2015 03:53:04,false,elite,1,33798502,USA,VA,Manassas,207.244.79.135,122,84,,,136,94,DUODENAL ULCER,RANITIDINE,"bedtime 150 twice daily, in 509 DUODENAL ULCER patients treated in",95-102-108-115-118-122-131-137-146-154-66,59-66-74-80-84-95-99-102-122,"single bedtime dose, and RANITIDINE 150 mg twice duodenal","The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials.",122 131,84,122,84,136,94,-1,RO-may_prevent,820334,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and ranitidine 150 mg twice daily, in 509 duodenal ulcer patients treated in two Italian multicentre trials",duodenal ulcer,ranitidine
788862758,9/15/2015 22:43:18,1739063762,9/15/2015 22:42:52,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,38,12,,,42,25,PAIN,ACETAMINOPHEN,PAIN,38,12,ACETAMINOPHEN,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862758,9/15/2015 22:57:45,1739068697,9/15/2015 22:57:30,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,38,12,,,42,25,PAIN,ACETAMINOPHEN,PAIN,38,12-38,ACETAMINOPHEN pain,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862758,9/15/2015 23:53:55,1739085800,9/15/2015 23:53:39,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,38,12,,,42,25,PAIN,ACETAMINOPHEN,PAIN,38,12,ACETAMINOPHEN,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862758,9/15/2015 23:54:03,1739085859,9/15/2015 23:53:18,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,38,12,,,42,25,PAIN,ACETAMINOPHEN,acetaminophen prevent the PAIN,12-26-38-34,5-12-26-34-38,giving ACETAMINOPHEN prevent the pain,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862758,9/16/2015 00:13:58,1739090856,9/16/2015 00:13:33,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,38,12,,,42,25,PAIN,ACETAMINOPHEN,PAIN,38,12,ACETAMINOPHEN,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862758,9/16/2015 00:29:22,1739094170,9/16/2015 00:29:05,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,38,12,,,42,25,PAIN,ACETAMINOPHEN,PAIN,38,12,ACETAMINOPHEN,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862758,9/16/2015 00:42:45,1739097449,9/16/2015 00:41:27,false,neodev,1.0,32114597,USA,"","",73.151.173.249,38,12,,,42,25,PAIN,ACETAMINOPHEN,acetaminophen prevent PAIN immunization.,12-38-50-26,12-26-38-50,ACETAMINOPHEN prevent pain immunization.,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862758,9/16/2015 00:55:37,1739100930,9/16/2015 00:54:32,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,38,12,,,42,25,PAIN,ACETAMINOPHEN,acetaminophen prevent the PAIN,12-26-34-38,0-5-12-26-34-38,Will giving ACETAMINOPHEN prevent the pain,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862758,9/16/2015 01:15:39,1739112408,9/16/2015 01:15:16,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,38,12,,,42,25,PAIN,ACETAMINOPHEN,acetaminophen PAIN immunization.,12-38-50,12-50,ACETAMINOPHEN immunization.,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862758,9/16/2015 01:27:35,1739119445,9/16/2015 01:27:03,false,neodev,1.0,33739202,USA,MS,Madison,75.65.195.220,38,12,,,42,25,PAIN,ACETAMINOPHEN,Will giving acetaminophen prevent the PAIN of the immunization.,5-12-26-34-38-43-46-50-0,0-5-12-26-34-38-46-50,Will giving ACETAMINOPHEN prevent the pain the immunization.,Will giving acetaminophen prevent the pain of the immunization.,38,12,38,12,42,25,-1,RO-may_treat,820062,Will giving acetaminophen prevent the pain of the immunization,pain,acetaminophen
788862759,9/15/2015 21:13:31,1739022724,9/15/2015 21:10:37,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,TINEA VERSICOLOR,496-502,496-502-519-531-534,tinea versicolor SULCONAZOLE 1% cream,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862759,9/15/2015 21:17:32,1739026797,9/15/2015 21:16:37,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,TINEA VERSICOLOR,496-502,519,SULCONAZOLE,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862759,9/15/2015 21:18:01,1739027188,9/15/2015 21:17:02,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,TINEA VERSICOLOR Sulconazole 1% cream,496-502-519-531-534,496-502-519-531-534,tinea versicolor SULCONAZOLE 1% cream,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862759,9/15/2015 21:18:30,1739027435,9/15/2015 21:17:54,false,neodev,1.0,33758777,USA,"","",38.95.108.251,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,TINEA VERSICOLOR,496-502,519,SULCONAZOLE,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862759,9/15/2015 21:21:22,1739029116,9/15/2015 21:21:06,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,TINEA VERSICOLOR Sulconazole,496-502-519,496-502-519,tinea versicolor SULCONAZOLE,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862759,9/15/2015 21:22:42,1739029771,9/15/2015 21:22:26,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,TINEA VERSICOLOR,496-502,519,SULCONAZOLE,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862759,9/15/2015 21:33:40,1739035978,9/15/2015 21:33:19,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,"Dermatophytoses, TINEA VERSICOLOR Sulconazole 1% cream",479-496-502-519-531-534,479-496-502-519-531-534-540,"Dermatophytoses, tinea versicolor SULCONAZOLE 1% cream or.","50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862759,9/15/2015 21:34:34,1739036490,9/15/2015 21:34:21,false,instagc,1.0,26024737,GBR,H2,Preston,78.144.133.234,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,TINEA VERSICOLOR Sulconazole,496-502-519,519,SULCONAZOLE,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862759,9/15/2015 21:37:25,1739037998,9/15/2015 21:37:08,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,TINEA VERSICOLOR Sulconazole,496-502-519,519,SULCONAZOLE,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862759,9/15/2015 21:39:48,1739039312,9/15/2015 21:39:34,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,496,519,,,512,530,TINEA VERSICOLOR,SULCONAZOLE,TINEA VERSICOLOR Sulconazole 1% cream,496-502-519-531-534,496-502-519-531-534,tinea versicolor SULCONAZOLE 1% cream,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or.",496 502,519,496,519,512,530,-1,RO-may_treat,820028,"50, 100, 150, 200 mg tablet Vulvovaginal candidiasis       Itraconazole 100 mg capsules, 10 mg/mL solution Tinea unguium, other onychomycoses       Ketoconazole 2% cream, 1 to 2% shampoo; 200 mg tablet Dermatophytoses, skin candidiasis       Miconazole 1 to 2% liquid (aerosol), 2% powder (aerosol), 1 to 2% cream and lotion, 1% solution, 2% powder or tincture; 100 to 200 mg vaginal suppositories Dermatophytoses, candidiasis (skin, vulvovaginal) Oxiconazole 1% cream or lotion Dermatophytoses, tinea versicolor       Sulconazole 1% cream or",tinea versicolor,Sulconazole
788862760,9/15/2015 23:59:13,1739087229,9/15/2015 23:58:59,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,3,38,,,18,43,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS,3-9,38,HBSAG,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862760,9/16/2015 00:35:17,1739095476,9/16/2015 00:34:57,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,3,38,,,18,43,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS,3-9,23-28-35-38-44-48,high levels of HBSAG and HBcAb,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862760,9/16/2015 01:26:38,1739118858,9/16/2015 01:26:00,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,3,38,,,18,43,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS HBsAg HBcAb HBsAb,3-9-38-48-129,3-9-38-48-129,serum hepatitis HBSAG HBcAb HBsAb,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862760,9/16/2015 01:34:16,1739123506,9/16/2015 01:32:53,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,3,38,,,18,43,SERUM HEPATITIS,HBSAG,In SERUM HEPATITIS the high levels,0-3-9-19-23-28,23-28-35-38-44-48-54,high levels of HBSAG and HBcAb were,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862760,9/16/2015 01:40:41,1739131253,9/16/2015 01:40:27,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,3,38,,,18,43,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS,3-9,38,HBSAG,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862760,9/16/2015 02:11:24,1739155271,9/16/2015 02:10:58,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,3,38,,,18,43,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS,3-9,38,HBSAG,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862760,9/16/2015 02:48:45,1739189614,9/16/2015 02:48:37,false,zoombucks,1,4688131,CAN,BC,Vancouver,75.157.35.92,3,38,,,18,43,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS,3-9,38,HBSAG,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862760,9/16/2015 03:11:46,1739210366,9/16/2015 03:09:53,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,3,38,,,18,43,SERUM HEPATITIS,HBSAG,In SERUM HEPATITIS the high levels HBcAb were observed,0-3-9-19-23-28-54-59-48,23-28-35-38-44-48-54-59,high levels of HBSAG and HBcAb were observed,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862760,9/16/2015 03:12:56,1739211317,9/16/2015 03:12:15,false,prodege,1,31508822,CAN,AB,Calgary,206.75.77.133,3,38,,,18,43,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS,3-9,38,HBSAG,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862760,9/16/2015 03:20:06,1739217870,9/16/2015 03:19:42,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,3,38,,,18,43,SERUM HEPATITIS,HBSAG,In SERUM HEPATITIS the high levels of HBsAg,0-3-9-19-23-28-38-35,23-28-35-38-44-48-54-59,high levels of HBSAG and HBcAb were observed,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",3 9,38,3,38,18,43,-1,RO-may_prevent,820327,"In serum hepatitis the high levels of HBsAg and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level",serum hepatitis,HBsAg
788862761,9/15/2015 22:06:37,1739051634,9/15/2015 22:06:22,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,"IMMUNODEFICIENCY (CD4 cell counts),",55-77-82-72,14-20-29,ZEBRA ANTIBODY levels,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862761,9/15/2015 22:24:37,1739057611,9/15/2015 22:23:48,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,IMMUNODEFICIENCY,55,14-20-29,ZEBRA ANTIBODY levels,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862761,9/15/2015 22:32:32,1739060271,9/15/2015 22:32:01,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,IMMUNODEFICIENCY,55,14-20,ZEBRA ANTIBODY,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862761,9/15/2015 22:36:11,1739061562,9/15/2015 22:35:28,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,IMMUNODEFICIENCY,55,14-20-29,ZEBRA ANTIBODY levels,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862761,9/15/2015 22:37:40,1739062042,9/15/2015 22:37:01,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,IMMUNODEFICIENCY,55,14-20,ZEBRA ANTIBODY,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862761,9/15/2015 22:54:27,1739067722,9/15/2015 22:53:56,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,IMMUNODEFICIENCY,55,20-55,ANTIBODY immunodeficiency,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862761,9/15/2015 22:57:50,1739068729,9/15/2015 22:57:34,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,IMMUNODEFICIENCY,55,14-20-29,ZEBRA ANTIBODY levels,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862761,9/15/2015 23:06:35,1739071541,9/15/2015 23:06:25,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,IMMUNODEFICIENCY,55,14-20,ZEBRA ANTIBODY,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862761,9/15/2015 23:15:17,1739074654,9/15/2015 23:14:17,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,"ZEBRA antibody the IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, HIV p24 antigen ZEBRA antibodies HIV",14-20-41-55-72-77-82-91-95-109-113-117-192-198-233,14-20-55-72-77-82-91-109-113-117-192-198-233,"ZEBRA ANTIBODY immunodeficiency (CD4 cell counts), CDC HIV p24 antigen ZEBRA antibodies HIV","Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862761,9/15/2015 23:19:05,1739075687,9/15/2015 23:18:44,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,55,20,,,71,28,IMMUNODEFICIENCY,ANTIBODY,"IMMUNODEFICIENCY (CD4 cell counts),",55-77-82-72,14-20,ZEBRA ANTIBODY,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",55,20,55,20,71,28,-1,RO-may_treat,820107,"Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection",immunodeficiency,antibody
788862762,9/15/2015 22:07:20,1739051948,9/15/2015 22:07:02,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,86,140,,,90,148,PAIN,KETAMINE,stroking PAIN scores,77-86-91,121-140-149,alfentanil KETAMINE infusions.,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862762,9/15/2015 22:26:22,1739058135,9/15/2015 22:25:11,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,86,140,,,90,148,PAIN,KETAMINE,stroking PAIN scores,77-86-91,140-149,KETAMINE infusions.,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862762,9/15/2015 22:33:42,1739060641,9/15/2015 22:32:52,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,86,140,,,90,148,PAIN,KETAMINE,PAIN,86,140,KETAMINE,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862762,9/15/2015 22:37:43,1739062058,9/15/2015 22:37:00,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,86,140,,,90,148,PAIN,KETAMINE,PAIN,86,140-149,KETAMINE infusions.,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862762,9/15/2015 22:38:53,1739062528,9/15/2015 22:38:40,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,86,140,,,90,148,PAIN,KETAMINE,stroking PAIN scores,77-86-91,140-149,KETAMINE infusions.,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862762,9/15/2015 22:55:22,1739068023,9/15/2015 22:54:56,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,86,140,,,90,148,PAIN,KETAMINE,PAIN,86,86-140,pain KETAMINE,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862762,9/15/2015 22:58:46,1739069009,9/15/2015 22:58:13,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,86,140,,,90,148,PAIN,KETAMINE,stroking PAIN scores,77-86-91,140-149,KETAMINE infusions.,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862762,9/15/2015 23:07:30,1739072074,9/15/2015 23:06:56,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,86,140,,,90,148,PAIN,KETAMINE,stroking PAIN scores,77-86-91,140-149,KETAMINE infusions.,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862762,9/15/2015 23:16:58,1739075045,9/15/2015 23:16:16,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,86,140,,,90,148,PAIN,KETAMINE,stroking PAIN scores alfentanil ketamine infusions.,77-86-91-121-140-149,77-86-91-121-140-149,stroking pain scores alfentanil KETAMINE infusions.,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862762,9/15/2015 23:20:06,1739075984,9/15/2015 23:19:27,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,86,140,,,90,148,PAIN,KETAMINE,PAIN,86,140,KETAMINE,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions.",86,140,86,140,90,148,-1,RO-may_prevent,820311,"Dose-dependent increases in cold and cold pain thresholds, and reductions in stroking pain scores were noted in both the alfentanil and the ketamine infusions",pain,ketamine
788862763,9/16/2015 02:22:48,1739165358,9/16/2015 02:22:05,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"THROMBOEMBOLISM,",48,111,HEPARIN,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862763,9/16/2015 03:16:24,1739214511,9/16/2015 03:16:13,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"with symptomatic venous THROMBOEMBOLISM, long term treatment with",24-29-41-48-65-70-75-85,90-94-104-111-119-122-131-134-148,low molecular weight HEPARIN is possibly as effective safe,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862763,9/16/2015 03:33:24,1739230381,9/16/2015 03:32:11,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"with symptomatic venous THROMBOEMBOLISM,",24-29-41-48,90-94-104-111-119-122-131-134,low molecular weight HEPARIN is possibly as effective,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862763,9/16/2015 04:07:45,1739261944,9/16/2015 04:07:20,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"symptomatic venous THROMBOEMBOLISM,",29-41-48,90-94-104-111,low molecular weight HEPARIN,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862763,9/16/2015 04:20:48,1739274453,9/16/2015 04:20:29,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"THROMBOEMBOLISM,",48,111,HEPARIN,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862763,9/16/2015 04:39:09,1739293131,9/16/2015 04:38:55,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"symptomatic venous THROMBOEMBOLISM,",29-41-48,90-94-104-111,low molecular weight HEPARIN,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862763,9/16/2015 05:07:10,1739321939,9/16/2015 05:06:09,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"with symptomatic venous THROMBOEMBOLISM, long term treatment with low - molecular weight heparin",24-29-41-48-65-70-75-85-90-93-94-104-111,90-94-104-111-119-122-131-134-144-148,low molecular weight HEPARIN is possibly as effective and safe,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862763,9/16/2015 05:12:36,1739327542,9/16/2015 05:12:22,false,elite,1.0,31883685,GBR,"","",79.66.244.188,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"symptomatic venous THROMBOEMBOLISM,",29-41-48,90-94-104-111,low molecular weight HEPARIN,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862763,9/16/2015 05:49:01,1739366706,9/16/2015 05:48:41,false,clixsense,1.0,27969116,NLD,"","",91.213.37.165,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"symptomatic venous THROMBOEMBOLISM,",29-41-48,90-94-104-111,low molecular weight HEPARIN,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862763,9/16/2015 05:58:21,1739377018,9/16/2015 05:56:57,false,points4rewards,1.0,28703583,USA,"","",184.53.32.197,48,111,,,63,118,THROMBOEMBOLISM,HEPARIN,"THROMBOEMBOLISM, treatment with vitamin K antagonists.",48-166-176-181-189-191,111-119-122-131-134-144-148-153-156-161-166,HEPARIN is possibly as effective and safe as long term treatment,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists.",48,111,48,111,63,118,-1,RO-may_prevent,820199,"CONCLUSION  In patients with symptomatic venous thromboembolism, long-term treatment with low-molecular-weight heparin is possibly as effective and safe as long-term treatment with vitamin-K antagonists",thromboembolism,heparin
788862764,9/15/2015 21:23:15,1739030089,9/15/2015 21:22:53,false,neodev,1.0,33758777,USA,"","",38.95.108.251,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,VIRAL HEPATITIS B,112-118-128,55-65,"HEPATITIS B,","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862764,9/15/2015 21:24:26,1739030831,9/15/2015 21:24:15,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,VIRAL HEPATITIS B infection.,112-118-128-130,55-65,"HEPATITIS B,","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862764,9/15/2015 21:37:47,1739038225,9/15/2015 21:37:22,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,VIRAL HEPATITIS B infection.,112-118-128-130,55-65,"HEPATITIS B,","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862764,9/15/2015 21:40:43,1739039809,9/15/2015 21:40:13,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,"hepatitis B, VIRAL HEPATITIS B infection.",55-65-112-118-128-130,55-65-96,"HEPATITIS B, epidemiology","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862764,9/15/2015 21:42:52,1739040957,9/15/2015 21:42:42,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,VIRAL HEPATITIS B,112-118-128,55-65,"HEPATITIS B,","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862764,9/15/2015 21:48:49,1739044091,9/15/2015 21:48:33,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,VIRAL HEPATITIS B,112-118-128,55-65,"HEPATITIS B,","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862764,9/15/2015 21:49:29,1739044369,9/15/2015 21:49:12,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,VIRAL HEPATITIS B infection.,112-118-128-130,55-65,"HEPATITIS B,","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862764,9/15/2015 21:49:35,1739044404,9/15/2015 21:48:42,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,VIRAL HEPATITIS B,112-118-128,55-65,"HEPATITIS B,","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862764,9/15/2015 21:49:59,1739044573,9/15/2015 21:49:31,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,VIRAL HEPATITIS B infection.,112-118-128-130,55-65,"HEPATITIS B,","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862764,9/15/2015 21:50:32,1739044882,9/15/2015 21:50:11,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,112,55,,,129,66,VIRAL HEPATITIS B,HEPATITIS B,VIRAL HEPATITIS B infection.,112-118-128-130,55-65,"HEPATITIS B,","Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection.",112 118 128,55 65,112,55,129,66,-1,RO-may_prevent,820225,"Changes in the pattern of transmission of new cases of hepatitis B, inform us of changes in the epidemiology of viral hepatitis B infection",viral hepatitis B,hepatitis B
788862765,9/15/2015 21:02:53,1739012011,9/15/2015 21:02:44,false,neodev,1,11014811,GBR,G6,Hull,87.102.82.212,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,in CONGESTIVE HEART FAILURE.,125-142-153-159,106,DIGOXIN,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862765,9/15/2015 21:03:05,1739012228,9/15/2015 21:02:40,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,CONGESTIVE HEART FAILURE.,142-153-159,106,DIGOXIN,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862765,9/15/2015 21:05:03,1739014385,9/15/2015 21:03:55,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,CONGESTIVE HEART FAILURE.,142-153-159,106-114,DIGOXIN clearances,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862765,9/15/2015 21:11:55,1739020974,9/15/2015 21:11:43,false,prodege,1.0,3587109,CAN,NS,Sydney,142.177.43.123,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,CONGESTIVE HEART FAILURE.,142-153-159,106,DIGOXIN,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862765,9/15/2015 21:12:12,1739021235,9/15/2015 21:10:32,false,clixsense,1.0,10032240,USA,FL,Naples,76.101.211.223,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,in patients with CONGESTIVE HEART FAILURE.,125-128-137-142-153-159,89-97-102-106-114-125-128,urinary urea and DIGOXIN clearances in patients,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862765,9/15/2015 21:13:14,1739022336,9/15/2015 21:12:17,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,CONGESTIVE HEART FAILURE.,142-153-159,106,DIGOXIN,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862765,9/15/2015 21:15:19,1739024881,9/15/2015 21:14:59,false,neodev,1.0,33758777,USA,"","",38.95.108.251,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,CONGESTIVE HEART FAILURE.,142-153-159,106,DIGOXIN,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862765,9/15/2015 21:17:00,1739026287,9/15/2015 21:16:26,false,elite,1.0,28548715,USA,VA,Manassas,198.7.59.107,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,CONGESTIVE HEART FAILURE.,142-153-159,106,DIGOXIN,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862765,9/15/2015 21:19:14,1739027874,9/15/2015 21:19:07,false,neodev,1,33644825,USA,FL,Fort Lauderdale,65.111.173.161,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,in patients with CONGESTIVE HEART FAILURE.,125-128-137-142-153-159,89-97-102-106-114-125-128,urinary urea and DIGOXIN clearances in patients,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862765,9/15/2015 21:19:34,1739028047,9/15/2015 21:19:15,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,142,106,,,166,113,CONGESTIVE HEART FAILURE,DIGOXIN,CONGESTIVE HEART FAILURE.,142-153-159,106,DIGOXIN,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.",142 153 159,106,142,106,166,113,-1,RO-may_prevent,820193,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure",congestive heart failure,digoxin
788862766,9/15/2015 22:04:08,1739050802,9/15/2015 22:03:52,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B viral DNA,79-85-95-97-103,39-44-48-52,"anti HCV and HBSAG,","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862766,9/15/2015 22:19:15,1739055890,9/15/2015 22:17:18,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B,79-85-95,52,"HBSAG,","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862766,9/15/2015 22:28:45,1739058966,9/15/2015 22:26:29,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B viral DNA,79-85-95-97-103,52,"HBSAG,","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862766,9/15/2015 22:30:09,1739059437,9/15/2015 22:29:09,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B viral DNA,79-85-95-97-103,52-59,"HBSAG, 1","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862766,9/15/2015 22:35:39,1739061343,9/15/2015 22:34:58,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B,79-85-95,52-59,"HBSAG, 1","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862766,9/15/2015 22:50:42,1739066039,9/15/2015 22:49:49,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B,79-85-95,52-85-95,"HBSAG, hepatitis B","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862766,9/15/2015 22:56:35,1739068336,9/15/2015 22:56:21,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B viral DNA,79-85-95-103-97,39-44-48-52,"anti HCV and HBSAG,","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862766,9/15/2015 23:05:27,1739071157,9/15/2015 23:05:14,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B viral DNA,79-85-95-97-103,52,"HBSAG,","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862766,9/15/2015 23:10:16,1739073293,9/15/2015 23:09:28,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B viral DNA,79-85-95-97-103,39-44-48-52,"anti HCV and HBSAG,","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862766,9/15/2015 23:16:31,1739074935,9/15/2015 23:14:39,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,79,52,,,94,57,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B,79-85-95,39-44-48-52-59,"anti HCV and HBSAG, 1","Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA.",79 85,52,79,52,94,57,-1,RO-may_prevent,820177,"Among 4 Asian patients with coexisting anti-HCV and HBsAg, 1 was found to have serum hepatitis B viral DNA and the other 3 had hepatitis C viral RNA",serum hepatitis,HBsAg
788862767,9/15/2015 22:07:36,1739052010,9/15/2015 22:07:21,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,Anticoagulants Aspirin Warfarin MYOCARDIAL INFARCTION ACP Journal Club.,129-144-152-161-172-184-188-196,129-144-152-161-172-184-188-196,Anticoagulants ASPIRIN Warfarin Myocardial infarction ACP Journal Club.,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862767,9/15/2015 22:27:27,1739058439,9/15/2015 22:26:23,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,MYOCARDIAL INFARCTION,161-172,144,ASPIRIN,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862767,9/15/2015 22:34:22,1739060868,9/15/2015 22:33:44,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,MYOCARDIAL INFARCTION,161-172,144,ASPIRIN,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862767,9/15/2015 22:38:27,1739062365,9/15/2015 22:37:45,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,MYOCARDIAL INFARCTION,161-172,144,ASPIRIN,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862767,9/15/2015 22:39:37,1739062808,9/15/2015 22:38:55,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,MYOCARDIAL INFARCTION,161-172,144,ASPIRIN,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862767,9/15/2015 22:55:45,1739068137,9/15/2015 22:55:23,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,MYOCARDIAL INFARCTION Club.,161-172-196,144-161-172,ASPIRIN Myocardial infarction,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862767,9/15/2015 22:58:59,1739069044,9/15/2015 22:58:47,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,MYOCARDIAL INFARCTION,161-172,144,ASPIRIN,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862767,9/15/2015 23:07:41,1739072194,9/15/2015 23:07:31,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,MYOCARDIAL INFARCTION,161-172,144,ASPIRIN,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862767,9/15/2015 23:17:48,1739075332,9/15/2015 23:16:59,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,Anticoagulants Aspirin Warfarin MYOCARDIAL INFARCTION ACP,129-144-152-161-172-184,0-73-84-129-144-152-161-172,Warfarin myocardial infarction Anticoagulants ASPIRIN Warfarin Myocardial infarction,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862767,9/15/2015 23:33:56,1739080285,9/15/2015 23:33:47,false,prodege,1,1859229,USA,LA,Denham Springs,98.181.38.122,161,144,,,182,151,MYOCARDIAL INFARCTION,ASPIRIN,myocardial infarction Anticoagulants Aspirin Warfarin MYOCARDIAL INFARCTION ACP Journal Club.,84-129-144-152-161-172-184-188-196-73,109-119-129-144-152-161-172-73,myocardial bleeding Keywords: Anticoagulants ASPIRIN Warfarin Myocardial infarction,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club.,161 172,144,161,144,182,151,-1,RO-may_prevent,820361,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants Aspirin Warfarin Myocardial infarction  ACP Journal Club,Myocardial infarction,Aspirin
788862768,9/16/2015 01:44:25,1739134089,9/16/2015 01:44:12,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,21,68,,,26,77,NIDDM,METFORMIN,"NIDDM subjects,",21-27,68,METFORMIN,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862768,9/16/2015 02:19:57,1739162836,9/16/2015 02:19:28,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,21,68,,,26,77,NIDDM,METFORMIN,NIDDM,21,68,METFORMIN,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862768,9/16/2015 03:15:05,1739213230,9/16/2015 03:14:52,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,21,68,,,26,77,NIDDM,METFORMIN,"In poorly controlled NIDDM subjects, the primary mechanism which",0-3-10-21-27-37-41-49-62,3-10-41-49-59-62-68-78-87-96-21,poorly controlled NIDDM primary mechanism by which METFORMIN improves glycemic control,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862768,9/16/2015 03:28:33,1739225678,9/16/2015 03:27:34,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,21,68,,,26,77,NIDDM,METFORMIN,"In poorly controlled NIDDM subjects,",0-3-10-21-27,49-59-62-68-78-87,mechanism by which METFORMIN improves glycemic,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862768,9/16/2015 03:58:50,1739253823,9/16/2015 03:58:40,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,21,68,,,26,77,NIDDM,METFORMIN,NIDDM,21,68,METFORMIN,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862768,9/16/2015 04:04:56,1739259332,9/16/2015 04:04:35,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,21,68,,,26,77,NIDDM,METFORMIN,NIDDM,21,68,METFORMIN,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862768,9/16/2015 04:17:39,1739271491,9/16/2015 04:17:21,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,21,68,,,26,77,NIDDM,METFORMIN,"NIDDM subjects,",21-27,68,METFORMIN,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862768,9/16/2015 04:36:45,1739290808,9/16/2015 04:36:32,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,21,68,,,26,77,NIDDM,METFORMIN,NIDDM,21,68,METFORMIN,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862768,9/16/2015 04:46:03,1739300123,9/16/2015 04:45:55,false,gifthunterclub,1,30901412,GBR,G5,Margate,85.210.116.48,21,68,,,26,77,NIDDM,METFORMIN,"In poorly controlled NIDDM subjects, the primary metformin",0-3-10-21-27-37-41-68,49-59-62-68-78-87-96-21,NIDDM mechanism by which METFORMIN improves glycemic control,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862768,9/16/2015 05:02:00,1739316864,9/16/2015 05:01:06,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,21,68,,,26,77,NIDDM,METFORMIN,"In poorly controlled NIDDM subjects,",0-3-10-21-27,49-59-62-68-78-87-96,mechanism by which METFORMIN improves glycemic control,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",21,68,21,68,26,77,-1,RO-may_treat,820122,"In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis",NIDDM,metformin
788862769,9/15/2015 22:35:52,1739061440,9/15/2015 22:35:31,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,77,139,,,84,152,MEASLES,MEASLES VIRUS,MEASLES,77,139-147,MEASLES VIRUS,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862769,9/15/2015 22:39:35,1739062806,9/15/2015 22:38:58,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,77,139,,,84,152,MEASLES,MEASLES VIRUS,MEASLES,77,139-147,MEASLES VIRUS,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862769,9/15/2015 22:39:56,1739062893,9/15/2015 22:39:37,false,instagc,1.0,23287154,USA,CA,San Jose,50.184.60.102,77,139,,,84,152,MEASLES,MEASLES VIRUS,MEASLES surveillance,77-85,124-136-139-147,elimination of MEASLES VIRUS,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862769,9/15/2015 22:40:00,1739062906,9/15/2015 22:39:38,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,77,139,,,84,152,MEASLES,MEASLES VIRUS,MEASLES,77,139-147,MEASLES VIRUS,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862769,9/15/2015 22:56:27,1739068321,9/15/2015 22:56:04,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,77,139,,,84,152,MEASLES,MEASLES VIRUS,MEASLES,77,77-139-147,measles MEASLES VIRUS,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862769,9/15/2015 23:19:14,1739075741,9/15/2015 23:18:28,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,77,139,,,84,152,MEASLES,MEASLES VIRUS,MEASLES measles virus measles wild type virus strains.,77-139-147-197-205-210-215-221,77-139-147-197-205-210-215-221,measles MEASLES VIRUS measles wild type virus strains.,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862769,9/15/2015 23:42:01,1739082636,9/15/2015 23:41:15,false,clixsense,1.0,6488338,USA,HI,Honolulu,72.130.214.250,77,139,,,84,152,MEASLES,MEASLES VIRUS,MEASLES measles virus,77-139-147,139-147-77,measles MEASLES VIRUS,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862769,9/15/2015 23:43:54,1739083041,9/15/2015 23:43:08,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,77,139,,,84,152,MEASLES,MEASLES VIRUS,"MEASLES surveillance worldwide,",77-85-98,124-136-139-147-153-156,"elimination of MEASLES VIRUS by 2010,","One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862769,9/15/2015 23:51:51,1739085103,9/15/2015 23:51:24,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,77,139,,,84,152,MEASLES,MEASLES VIRUS,MEASLES,77,139-147-156-162,"MEASLES VIRUS 2010, is","One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862769,9/16/2015 00:10:24,1739089939,9/16/2015 00:09:39,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,77,139,,,84,152,MEASLES,MEASLES VIRUS,MEASLES,77,139-147,MEASLES VIRUS,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains.",77,139 147,77,139,84,152,-1,RO-may_prevent,820333,"One of World Health Organization's proposed methods for the establishment of measles surveillance worldwide, to achieve the elimination of measles virus by 2010, is the genetic characterization of measles wild-type virus strains",measles,measles virus
788862770,9/15/2015 21:52:03,1739045556,9/15/2015 21:51:50,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,PNEUMOCYSTIS CARINII PNEUMONIA,118-131-139,78,PENTAMIDINE,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862770,9/15/2015 21:59:11,1739048753,9/15/2015 21:58:59,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,PNEUMOCYSTIS CARINII PNEUMONIA,118-131-139,78-90,PENTAMIDINE aerosol,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862770,9/15/2015 22:00:03,1739049133,9/15/2015 21:59:40,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,PNEUMOCYSTIS CARINII PNEUMONIA (PCP),118-131-139-149,78-90,PENTAMIDINE aerosol,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862770,9/15/2015 22:08:32,1739052297,9/15/2015 22:07:12,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,PNEUMOCYSTIS CARINII PNEUMONIA,118-131-139,78-90,PENTAMIDINE aerosol,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862770,9/15/2015 22:18:16,1739055568,9/15/2015 22:17:34,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,PNEUMOCYSTIS CARINII PNEUMONIA,118-131-139,78-90,PENTAMIDINE aerosol,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862770,9/15/2015 22:18:35,1739055701,9/15/2015 22:16:57,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,PNEUMOCYSTIS CARINII PNEUMONIA,118-131-139,78,PENTAMIDINE,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862770,9/15/2015 22:31:35,1739059956,9/15/2015 22:31:20,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,PNEUMOCYSTIS CARINII PNEUMONIA,118-131-139,78-90,PENTAMIDINE aerosol,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862770,9/15/2015 22:38:23,1739062319,9/15/2015 22:38:05,false,instagc,1.0,23287154,USA,CA,San Jose,50.184.60.102,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,treatment of PNEUMOCYSTIS CARINII PNEUMONIA,105-115-118-131-139,78-90,PENTAMIDINE aerosol,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862770,9/15/2015 22:38:54,1739062529,9/15/2015 22:38:24,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,PNEUMOCYSTIS CARINII PNEUMONIA,118-131-139,64-75-78-90,advantages of PENTAMIDINE aerosol,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862770,9/15/2015 22:42:04,1739063425,9/15/2015 22:39:23,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,118,78,,,148,89,PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE,PNEUMOCYSTIS CARINII PNEUMONIA,118-131-139,78-118-131-139,PENTAMIDINE Pneumocystis carinii pneumonia,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",118 131 139,78,118,78,148,89,-1,RO-may_prevent,820358,"From the pharmacological point of view, these studies prove the advantages of pentamidine aerosol in the treatment of Pneumocystis carinii pneumonia (PCP) and provide information on extrarenal excretion mechanisms and deep compartments",Pneumocystis carinii pneumonia,pentamidine
788862771,9/15/2015 21:21:53,1739029393,9/15/2015 21:21:34,false,neodev,1.0,33758777,USA,"","",38.95.108.251,285,224,,,293,238,DWARFISM,GROWTH HORMONE,DWARFISM,285,224-231,"GROWTH HORMONE,","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862771,9/15/2015 21:23:36,1739030307,9/15/2015 21:23:24,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,285,224,,,293,238,DWARFISM,GROWTH HORMONE,DWARFISM,285,224-231,"GROWTH HORMONE,","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862771,9/15/2015 21:34:09,1739036266,9/15/2015 21:33:15,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,285,224,,,293,238,DWARFISM,GROWTH HORMONE,Hypofunction: DWARFISM in child;,271-285-294-297,224-231,"GROWTH HORMONE,","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862771,9/15/2015 21:39:01,1739038927,9/15/2015 21:38:21,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,285,224,,,293,238,DWARFISM,GROWTH HORMONE,Hypofunction: DWARFISM,271-285,195-205-224-231-336-342-359-372,"endocrine glands GROWTH HORMONE, gland functions parathyroids Hyperfunction:","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862771,9/15/2015 21:41:57,1739040386,9/15/2015 21:41:43,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,285,224,,,293,238,DWARFISM,GROWTH HORMONE,DWARFISM,285,224-231,"GROWTH HORMONE,","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862771,9/15/2015 21:47:11,1739043327,9/15/2015 21:46:40,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,285,224,,,293,238,DWARFISM,GROWTH HORMONE,Hypofunction: DWARFISM,271-285,224-231,"GROWTH HORMONE,","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862771,9/15/2015 21:47:53,1739043653,9/15/2015 21:47:40,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,285,224,,,293,238,DWARFISM,GROWTH HORMONE,DWARFISM,285,224-231,"GROWTH HORMONE,","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862771,9/15/2015 21:47:55,1739043661,9/15/2015 21:47:37,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,285,224,,,293,238,DWARFISM,GROWTH HORMONE,DWARFISM,285,224-231,"GROWTH HORMONE,","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862771,9/15/2015 21:48:20,1739043853,9/15/2015 21:47:53,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,285,224,,,293,238,DWARFISM,GROWTH HORMONE,DWARFISM,285,224-231,"GROWTH HORMONE,","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862771,9/15/2015 21:48:24,1739043939,9/15/2015 21:48:00,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,285,224,,,293,238,DWARFISM,GROWTH HORMONE,DWARFISM,285,224-231,"GROWTH HORMONE,","Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",285,224 231,285,224,293,238,-1,RO-may_treat,820036,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for growth hormone, which acts directly on cells)  Hypofunction: Dwarfism in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes",Dwarfism,growth hormone
788862772,9/15/2015 23:56:23,1739086541,9/15/2015 23:56:00,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"MYOCARDIAL INFARCTION (MI),",134-145-156,82-90-107-113,aspirin (ACETYLSALICYLIC ACID; ASA),"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862772,9/15/2015 23:57:24,1739086852,9/15/2015 23:56:49,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"MYOCARDIAL INFARCTION (MI),",134-145-156,82-90-107,aspirin (ACETYLSALICYLIC ACID;,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862772,9/16/2015 00:18:04,1739091643,9/16/2015 00:17:31,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"MYOCARDIAL INFARCTION (MI),",134-145-156,90-107-113-82,aspirin (ACETYLSALICYLIC ACID; ASA),"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862772,9/16/2015 00:31:53,1739094675,9/16/2015 00:31:27,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"MYOCARDIAL INFARCTION (MI),",134-145-156,90-107-113,(ACETYLSALICYLIC ACID; ASA),"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862772,9/16/2015 00:50:03,1739099196,9/16/2015 00:48:58,false,neodev,1.0,32114597,USA,"","",73.151.173.249,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"aspirin (acetylsalicylic acid; ASA) MYOCARDIAL INFARCTION (MI), clinical authoritative recommendations about use; published drug utilisation",82-90-107-113-134-145-156-228-250-264-280-305-315-320-290,74-82-90-107-113-118-121-134-145-156-191-203-216-228-237-250-264-280-315-320-332,"whether aspirin (ACETYLSALICYLIC ACID; ASA) is underused myocardial infarction (MI), evidence efficacy safety clinical trials; authoritative recommendations about drug utilisation studies.","This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862772,9/16/2015 01:20:16,1739115016,9/16/2015 01:19:31,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"aspirin (acetylsalicylic acid; ASA) MYOCARDIAL INFARCTION (MI),",82-90-107-113-134-145-156,82-90-107-113-134-145-156,"aspirin (ACETYLSALICYLIC ACID; ASA) myocardial infarction (MI),","This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862772,9/16/2015 01:30:57,1739121314,9/16/2015 01:30:26,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"is MYOCARDIAL INFARCTION (MI),",118-134-145-156,90-107-113-118-121-131-134-145-156,"(ACETYLSALICYLIC ACID; ASA) is underused in myocardial infarction (MI),","This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862772,9/16/2015 01:38:45,1739129528,9/16/2015 01:38:29,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"MYOCARDIAL INFARCTION (MI),",134-145-156,82-90-107-113,aspirin (ACETYLSALICYLIC ACID; ASA),"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862772,9/16/2015 01:58:59,1739145181,9/16/2015 01:58:30,false,neodev,1.0,11291592,USA,MI,Taylor,99.170.106.105,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"MYOCARDIAL INFARCTION (MI),",134-145-156,90-107-113,(ACETYLSALICYLIC ACID; ASA),"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862772,9/16/2015 02:07:46,1739152461,9/16/2015 02:07:24,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,134,91,,,159,111,MYOCARDIAL INFARCTION (MI,ACETYLSALICYLIC ACID,"MYOCARDIAL INFARCTION (MI),",134-145-156,82-90-107-113,aspirin (ACETYLSALICYLIC ACID; ASA),"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies.",134 145 156,107,134,91,159,111,-1,RO-may_prevent,820223,"This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies",myocardial infarction (MI,acetylsalicylic acid
788862773,9/15/2015 23:58:58,1739087180,9/15/2015 23:58:37,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,98,46,,,102,57,PAIN,BUPIVACAINE,"PAIN,",98,46,BUPIVACAINE,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862773,9/15/2015 23:59:36,1739087295,9/15/2015 23:59:05,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,98,46,,,102,57,PAIN,BUPIVACAINE,"management of PAIN, postoperative pulmonary dysfunction",84-95-98-104-118-128,46,BUPIVACAINE,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862773,9/16/2015 01:26:00,1739118475,9/16/2015 01:25:30,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,98,46,,,102,57,PAIN,BUPIVACAINE,"bupivacaine PAIN, postoperative pulmonary dysfunction",46-98-104-118-128,46-104-118-128,BUPIVACAINE postoperative pulmonary dysfunction,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862773,9/16/2015 01:32:52,1739122562,9/16/2015 01:32:23,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,98,46,,,102,57,PAIN,BUPIVACAINE,"the management of PAIN, postoperative pulmonary dysfunction",80-84-95-98-104-118-128,32-37-43-46-58-62-70-77-80-84-95-98,"safe doses of BUPIVACAINE was without effect in the management of pain,","instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862773,9/16/2015 01:40:26,1739131082,9/16/2015 01:40:08,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,98,46,,,102,57,PAIN,BUPIVACAINE,"PAIN,",98,46,BUPIVACAINE,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862773,9/16/2015 02:10:56,1739154860,9/16/2015 02:10:38,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,98,46,,,102,57,PAIN,BUPIVACAINE,"PAIN,",98,46,BUPIVACAINE,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862773,9/16/2015 02:40:16,1739181179,9/16/2015 02:38:26,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,98,46,,,102,57,PAIN,BUPIVACAINE,"PAIN,",98,46,BUPIVACAINE,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862773,9/16/2015 02:47:56,1739188662,9/16/2015 02:47:15,false,zoombucks,1.0,4688131,CAN,BC,Vancouver,75.157.35.92,98,46,,,102,57,PAIN,BUPIVACAINE,"PAIN,",98,46,BUPIVACAINE,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862773,9/16/2015 03:09:52,1739208731,9/16/2015 03:09:38,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,98,46,,,102,57,PAIN,BUPIVACAINE,"the management of PAIN, postoperative pulmonary dysfunction and stress response group patients.",80-84-95-98-104-118-128-140-148-172-181-155,32-37-43-46-58-62-70-84,safe doses of BUPIVACAINE was without effect management,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862773,9/16/2015 03:12:13,1739210635,9/16/2015 03:11:50,false,prodege,1.0,31508822,CAN,AB,Calgary,206.75.77.133,98,46,,,102,57,PAIN,BUPIVACAINE,"the management of PAIN,",80-84-95-98,46,BUPIVACAINE,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients.",98,46,98,46,102,57,-1,RO-may_prevent,820217,"instillation of therapeutically safe doses of bupivacaine was without effect in the management of pain, postoperative pulmonary dysfunction and the stress response in this group of patients",pain,bupivacaine
788862774,9/15/2015 21:51:11,1739045117,9/15/2015 21:50:55,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,33,74,,,37,84,GOUT,COLCHICINE,"GOUT,",33,74,COLCHICINE,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862774,9/15/2015 21:57:26,1739047834,9/15/2015 21:56:47,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,33,74,,,37,84,GOUT,COLCHICINE,"GOUT,",33,74,COLCHICINE,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862774,9/15/2015 21:58:02,1739048169,9/15/2015 21:57:48,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,33,74,,,37,84,GOUT,COLCHICINE,"GOUT,",33,74,COLCHICINE,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862774,9/15/2015 21:58:31,1739048409,9/15/2015 21:58:01,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,33,74,,,37,84,GOUT,COLCHICINE,"GOUT,",33,74,COLCHICINE,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862774,9/15/2015 22:02:52,1739050351,9/15/2015 22:02:20,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,33,74,,,37,84,GOUT,COLCHICINE,"GOUT,",33,74,COLCHICINE,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862774,9/15/2015 22:03:02,1739050426,9/15/2015 22:02:47,false,instagc,1.0,21551272,GBR,I9,Dereham,89.243.154.52,33,74,,,37,84,GOUT,COLCHICINE,"GOUT,",33,74,COLCHICINE,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862774,9/15/2015 22:14:48,1739054279,9/15/2015 22:13:34,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,33,74,,,37,84,GOUT,COLCHICINE,"GOUT,",33,74,COLCHICINE,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862774,9/15/2015 22:15:14,1739054411,9/15/2015 22:14:06,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,33,74,,,37,84,GOUT,COLCHICINE,"GOUT,",33,74,COLCHICINE,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862774,9/15/2015 22:29:50,1739059300,9/15/2015 22:29:36,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,33,74,,,37,84,GOUT,COLCHICINE,"GOUT,",33,74,COLCHICINE,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862774,9/15/2015 22:34:32,1739060898,9/15/2015 22:34:19,false,neodev,1.0,31984900,CAN,AB,Edmonton,208.123.223.144,33,74,,,37,84,GOUT,COLCHICINE,"acute episodes of GOUT, administration of a",15-21-30-33-39-54-57,59-64-71-74-85-88-92,full course of COLCHICINE is the preferred,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy.",33,74,33,74,37,84,-1,RO-may_prevent,820244,"For control of acute episodes of gout, administration of a full course of colchicine is the preferred method of therapy",gout,colchicine
788862775,9/15/2015 21:51:49,1739045456,9/15/2015 21:51:33,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,107,138,,,118,143,HEPATITIS B,HBSAG,HEPATITIS B,107-117,,,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862775,9/15/2015 21:58:57,1739048626,9/15/2015 21:58:29,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,107,138,,,118,143,HEPATITIS B,HBSAG,"HEPATITIS B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg)",107-117-119-128-131-137-145-154-157-163-167-176-179,107-117-119-128-131-137-145-154-157-163-167-176-179,"hepatitis B serology in serum (HBSAG, antibody to HBsAg and antibody to HBcAg)","Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862775,9/15/2015 21:59:37,1739048935,9/15/2015 21:59:05,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,107,138,,,118,143,HEPATITIS B,HBSAG,HEPATITIS B serology,107-117-119,137,"(HBSAG,","Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862775,9/15/2015 22:00:02,1739049125,9/15/2015 21:58:48,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,107,138,,,118,143,HEPATITIS B,HBSAG,HEPATITIS B serology,107-117-119,137-145-154-157-163-167-176-179,"(HBSAG, antibody to HBsAg and antibody to HBcAg)","Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862775,9/15/2015 22:07:11,1739051840,9/15/2015 22:04:48,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,107,138,,,118,143,HEPATITIS B,HBSAG,HEPATITIS B serology,107-117-119,137,"(HBSAG,","Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862775,9/15/2015 22:16:57,1739055040,9/15/2015 22:15:35,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,107,138,,,118,143,HEPATITIS B,HBSAG,HEPATITIS B,107-117,137,"(HBSAG,","Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862775,9/15/2015 22:17:31,1739055271,9/15/2015 22:16:04,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,107,138,,,118,143,HEPATITIS B,HBSAG,HEPATITIS B serology,107-117-119,137,"(HBSAG,","Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862775,9/15/2015 22:31:20,1739059858,9/15/2015 22:30:05,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,107,138,,,118,143,HEPATITIS B,HBSAG,HEPATITIS B serology,107-117-119,137,"(HBSAG,","Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862775,9/15/2015 22:38:03,1739062196,9/15/2015 22:37:17,false,instagc,1.0,23287154,USA,CA,San Jose,50.184.60.102,107,138,,,118,143,HEPATITIS B,HBSAG,HEPATITIS B serology in serum,107-117-119-128-131,137-145-154-157-163-167-176-179,"(HBSAG, antibody to HBsAg and antibody to HBcAg)","Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862775,9/15/2015 22:38:23,1739062314,9/15/2015 22:37:51,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,107,138,,,118,143,HEPATITIS B,HBSAG,HEPATITIS B serology in serum,107-117-119-128-131,137-145-154-157-163-167-176-179,"(HBSAG, antibody to HBsAg and antibody to HBcAg)","Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused.",107 117,,107,138,118,143,-1,RO-may_prevent,820184,"Forty-five blood recipients were considered susceptible to hepatitis B virus infection because testing for hepatitis B serology in serum (HBsAg, antibody to HBsAg and antibody to HBcAg) was negative before being transfused",hepatitis B,HBsAg
788862776,9/15/2015 21:08:07,1739017252,9/15/2015 21:07:18,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,197,268,,,206,279,HEPATITIS,HEPATITIS A,chronic HEPATITIS C,189-197-207,268-278,HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862776,9/15/2015 21:13:19,1739022456,9/15/2015 21:13:03,false,prodege,1.0,3587109,CAN,NS,Sydney,142.177.43.123,197,268,,,206,279,HEPATITIS,HEPATITIS A,HEPATITIS C,197-207,268-278,HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862776,9/15/2015 21:15:42,1739025238,9/15/2015 21:15:21,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,197,268,,,206,279,HEPATITIS,HEPATITIS A,chronic HEPATITIS C,189-197-207,268-278,HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862776,9/15/2015 21:16:09,1739025581,9/15/2015 21:15:46,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,197,268,,,206,279,HEPATITIS,HEPATITIS A,HEPATITIS C,197-207,268-278,HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862776,9/15/2015 21:17:35,1739026843,9/15/2015 21:17:06,false,neodev,1.0,33758777,USA,"","",38.95.108.251,197,268,,,206,279,HEPATITIS,HEPATITIS A,HEPATITIS,197,268-278,HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862776,9/15/2015 21:20:54,1739028859,9/15/2015 21:20:42,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,197,268,,,206,279,HEPATITIS,HEPATITIS A,chronic HEPATITIS C,189-197-207,268-278,HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862776,9/15/2015 21:22:13,1739029554,9/15/2015 21:21:34,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,197,268,,,206,279,HEPATITIS,HEPATITIS A,HEPATITIS,197,268-278,HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862776,9/15/2015 21:32:54,1739035614,9/15/2015 21:32:18,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,197,268,,,206,279,HEPATITIS,HEPATITIS A,chronic HEPATITIS C,189-197-207,242-255-265-268-278,Association Incidence of HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862776,9/15/2015 21:34:06,1739036235,9/15/2015 21:33:53,false,instagc,1.0,26024737,GBR,H2,Preston,78.144.133.234,197,268,,,206,279,HEPATITIS,HEPATITIS A,HEPATITIS C,197-207,268-278,HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862776,9/15/2015 21:36:07,1739037358,9/15/2015 21:35:08,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,197,268,,,206,279,HEPATITIS,HEPATITIS A,chronic HEPATITIS C,189-197-207,268-278,HEPATITIS A,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",197,268 278,197,268,206,279,-1,RO-may_prevent,820368,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of hepatitis A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:",hepatitis,hepatitis A
788862777,9/15/2015 22:36:38,1739061692,9/15/2015 22:36:20,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A,43-53,79-89-91,HEPATITIS A prophylaxis,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862777,9/15/2015 22:41:28,1739063248,9/15/2015 22:40:50,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A,43-53,79-89-91,HEPATITIS A prophylaxis,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862777,9/15/2015 22:42:39,1739063595,9/15/2015 22:42:21,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A,43-53,79-89-91,HEPATITIS A prophylaxis,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862777,9/15/2015 22:57:07,1739068498,9/15/2015 22:56:49,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A,43-53,79-89,HEPATITIS A,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862777,9/15/2015 23:43:07,1739082885,9/15/2015 23:42:41,false,clixsense,1.0,6488338,USA,HI,Honolulu,72.130.214.250,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A hepatitis A,43-53-127-137,79-89-127-137,HEPATITIS A hepatitis A,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862777,9/15/2015 23:44:52,1739083288,9/15/2015 23:44:21,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A,43-53,79,HEPATITIS,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862777,9/15/2015 23:53:01,1739085569,9/15/2015 23:52:23,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A,43-53,79-89,HEPATITIS A,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862777,9/16/2015 00:10:23,1739089938,9/16/2015 00:10:07,false,instagc,1.0,31888345,USA,CA,Hayward,24.7.3.180,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A,43-53,79-89-91,HEPATITIS A prophylaxis,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862777,9/16/2015 00:12:24,1739090459,9/16/2015 00:11:35,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A,43-53,79-89,HEPATITIS A,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862777,9/16/2015 00:28:46,1739094026,9/16/2015 00:28:25,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,43,79,,,54,88,HEPATITIS A,HEPATITIS,HEPATITIS A,43-53,79-89,HEPATITIS A,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.",43 53,79,43,79,54,88,-1,RO-may_prevent,820299,"Bryan JP, Nelson M. Testing of antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines",hepatitis A,hepatitis
788862778,9/15/2015 21:18:57,1739027710,9/15/2015 21:18:40,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,19,40-48,INSULIN resistance,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862778,9/15/2015 21:19:51,1739028224,9/15/2015 21:19:31,false,neodev,1.0,33758777,USA,"","",38.95.108.251,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,19,40,INSULIN,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862778,9/15/2015 21:22:14,1739029562,9/15/2015 21:22:02,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,19,40-48,INSULIN resistance,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862778,9/15/2015 21:23:32,1739030246,9/15/2015 21:23:22,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,19,40,INSULIN,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862778,9/15/2015 21:23:57,1739030510,9/15/2015 21:22:43,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,19,40-48,INSULIN resistance,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862778,9/15/2015 21:35:47,1739037197,9/15/2015 21:35:30,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,Hyperlipidemia and HYPERGLYCEMIA due to insulin,0-15-19-33-37-40,19-33-37-40-48-59-63,hyperglycemia due to INSULIN resistance and nonalcoholic,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862778,9/15/2015 21:38:18,1739038492,9/15/2015 21:38:09,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,19,40-48,INSULIN resistance,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862778,9/15/2015 21:40:28,1739039670,9/15/2015 21:40:16,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,Hyperlipidemia and HYPERGLYCEMIA,0-15-19,19-33-37-40-48,hyperglycemia due to INSULIN resistance,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862778,9/15/2015 21:42:18,1739040599,9/15/2015 21:41:10,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,Hyperlipidemia and HYPERGLYCEMIA,0-15-19,40-48,INSULIN resistance,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862778,9/15/2015 21:46:08,1739042719,9/15/2015 21:45:41,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,19,40,,,32,47,HYPERGLYCEMIA,INSULIN,Hyperlipidemia and HYPERGLYCEMIA,0-15-19,19-33-37-40-48,hyperglycemia due to INSULIN resistance,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy.,19,40,19,40,32,47,-1,RO-may_treat,820052,Hyperlipidemia and hyperglycemia due to insulin resistance and nonalcoholic steatohepatitis may occur with lipodystrophy,hyperglycemia,insulin
788862779,9/15/2015 21:04:28,1739013728,9/15/2015 21:03:52,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,VENOUS THROMBOSIS,14-21,87,"HEPARIN,","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862779,9/15/2015 21:09:50,1739018622,9/15/2015 21:08:52,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,VENOUS THROMBOSIS,14-21,82-87-77,"full dose HEPARIN,","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862779,9/15/2015 21:12:26,1739021450,9/15/2015 21:12:17,false,prodege,1.0,3587109,CAN,NS,Sydney,142.177.43.123,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,VENOUS THROMBOSIS,14-21,87,"HEPARIN,","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862779,9/15/2015 21:12:45,1739021738,9/15/2015 21:12:37,false,clixsense,1.0,10032240,USA,FL,Naples,76.101.211.223,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,"However, once VENOUS THROMBOSIS has already occurred,",0-9-14-21-32-36-44,73-77-82-87-96-107-110,"use full dose HEPARIN, preferably by the","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862779,9/15/2015 21:14:28,1739023975,9/15/2015 21:13:55,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,VENOUS THROMBOSIS,14-21,87,"HEPARIN,","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862779,9/15/2015 21:15:58,1739025422,9/15/2015 21:15:40,false,neodev,1.0,33758777,USA,"","",38.95.108.251,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,VENOUS THROMBOSIS,14-21,87,"HEPARIN,","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862779,9/15/2015 21:19:58,1739028297,9/15/2015 21:19:46,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,VENOUS THROMBOSIS,14-21,77-82-87,"full dose HEPARIN,","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862779,9/15/2015 21:20:52,1739028814,9/15/2015 21:20:24,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,VENOUS THROMBOSIS,14-21,87,"HEPARIN,","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862779,9/15/2015 21:30:13,1739034151,9/15/2015 21:29:34,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,"VENOUS THROMBOSIS has already occurred, full dose heparin,",14-21-32-36-44-77-82-87,73-77-82-87-176,"use full dose HEPARIN, thromboplastin","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862779,9/15/2015 21:30:13,1739034152,9/15/2015 21:29:36,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,14,87,,,31,94,VENOUS THROMBOSIS,HEPARIN,VENOUS THROMBOSIS,14-21,87,"HEPARIN,","However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",14 21,87,14,87,31,94,-1,RO-may_prevent,820388,"However, once venous thrombosis has already occurred, it is necessary to use full-dose heparin, preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times",venous thrombosis,heparin
788862780,9/15/2015 21:22:51,1739029886,9/15/2015 21:22:33,false,neodev,1.0,33758777,USA,"","",38.95.108.251,38,4,,,42,13,PAIN,CAPSAICIN,PAIN,38,4,CAPSAICIN,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862780,9/15/2015 21:24:14,1739030690,9/15/2015 21:24:02,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,38,4,,,42,13,PAIN,CAPSAICIN,PAIN,38,4-14-22-27,"CAPSAICIN induced pain intensity,","The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862780,9/15/2015 21:37:19,1739037955,9/15/2015 21:36:07,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,38,4,,,42,13,PAIN,CAPSAICIN,"PAIN area,",38-43,4-14-22-27,"CAPSAICIN induced pain intensity,","The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862780,9/15/2015 21:40:11,1739039476,9/15/2015 21:39:51,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,38,4,,,42,13,PAIN,CAPSAICIN,"capsaicin induced pain intensity, PAIN area, the area secondary hyperalgesia,",4-14-22-27-38-43-49-53-61-71,0-4-14-22-27-38-43,"The CAPSAICIN induced pain intensity, pain area,","The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862780,9/15/2015 21:42:41,1739040835,9/15/2015 21:42:28,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,38,4,,,42,13,PAIN,CAPSAICIN,"PAIN area,",38-43,4-14-22-27,"CAPSAICIN induced pain intensity,","The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862780,9/15/2015 21:48:32,1739043981,9/15/2015 21:48:19,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,38,4,,,42,13,PAIN,CAPSAICIN,PAIN,38,4,CAPSAICIN,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862780,9/15/2015 21:48:41,1739044027,9/15/2015 21:48:29,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,38,4,,,42,13,PAIN,CAPSAICIN,PAIN,38,4,CAPSAICIN,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862780,9/15/2015 21:49:11,1739044244,9/15/2015 21:48:56,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,38,4,,,42,13,PAIN,CAPSAICIN,PAIN,38,4,CAPSAICIN,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862780,9/15/2015 21:49:30,1739044386,9/15/2015 21:48:16,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,38,4,,,42,13,PAIN,CAPSAICIN,PAIN,38,4,CAPSAICIN,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862780,9/15/2015 21:50:09,1739044645,9/15/2015 21:49:41,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,38,4,,,42,13,PAIN,CAPSAICIN,PAIN,38,4-14-22,CAPSAICIN induced pain,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds.",38,4,38,4,42,13,-1,RO-may_prevent,820278,"The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds",pain,capsaicin
788862781,9/15/2015 21:53:06,1739045969,9/15/2015 21:52:49,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,483,556,GLUCOSE,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862781,9/15/2015 22:00:35,1739049385,9/15/2015 22:00:08,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,pharmacokinetic interactions; HYPOGLYCEMIA reported 1 Dosage adjustments,453-469-483-496-507-511-518,550-556-564,blood GLUCOSE concentrations,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862781,9/15/2015 22:12:12,1739053358,9/15/2015 22:11:30,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,483,550-556-564,blood GLUCOSE concentrations,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862781,9/15/2015 22:22:16,1739056943,9/15/2015 22:21:40,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,483,556,GLUCOSE,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862781,9/15/2015 22:23:47,1739057405,9/15/2015 22:23:29,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,pharmacokinetic interactions; HYPOGLYCEMIA Dosage,453-469-483-511,550-556-564,blood GLUCOSE concentrations,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862781,9/15/2015 22:33:09,1739060478,9/15/2015 22:32:30,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,483,556,GLUCOSE,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862781,9/15/2015 22:39:36,1739062810,9/15/2015 22:39:24,false,instagc,1.0,23287154,USA,CA,San Jose,50.184.60.102,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,483,550-556-564,blood GLUCOSE concentrations,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862781,9/15/2015 22:41:49,1739063327,9/15/2015 22:41:18,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,pharmacokinetic interactions; HYPOGLYCEMIA,469-483-453,542-550-556-564,monitor blood GLUCOSE concentrations,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862781,9/15/2015 22:44:59,1739064310,9/15/2015 22:43:56,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,483,483-556,hypoglycemia GLUCOSE,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862781,9/15/2015 22:45:51,1739064670,9/15/2015 22:44:50,false,neodev,1.0,17426565,CAN,BC,Burnaby,70.79.9.44,483,556,,,495,563,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,483,550-556-564,blood GLUCOSE concentrations,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",483,556,483,556,495,563,-1,RO-may_treat,820026,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",hypoglycemia,glucose
788862782,9/15/2015 21:54:35,1739046660,9/15/2015 21:54:20,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,114,CIMETIDINE,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862782,9/15/2015 22:03:50,1739050696,9/15/2015 22:03:36,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,114-125-129,CIMETIDINE 800 mg,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862782,9/15/2015 22:17:18,1739055179,9/15/2015 22:16:27,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,114-125-129,CIMETIDINE 800 mg,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862782,9/15/2015 22:26:28,1739058168,9/15/2015 22:26:14,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,114,CIMETIDINE,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862782,9/15/2015 22:29:05,1739059065,9/15/2015 22:28:14,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,114,CIMETIDINE,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862782,9/15/2015 22:34:57,1739061098,9/15/2015 22:34:39,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,114,CIMETIDINE,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862782,9/15/2015 22:49:48,1739065781,9/15/2015 22:49:12,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,42-114-51,duodenal ulcer CIMETIDINE,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862782,9/15/2015 22:53:00,1739067080,9/15/2015 22:52:40,false,instagc,1.0,20043586,USA,NY,Gansevoort,67.248.253.125,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,114-125-129,CIMETIDINE 800 mg,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862782,9/15/2015 22:56:20,1739068275,9/15/2015 22:56:02,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,114-125-129-132,CIMETIDINE 800 mg daily,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862782,9/15/2015 23:05:12,1739071071,9/15/2015 23:04:59,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,42,114,,,56,124,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,42-51,114,CIMETIDINE,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily.",42 51,114,42,114,56,124,-1,RO-may_prevent,820293,"In a double blind study, 35 patients with duodenal ulcer diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive cimetidine 800 mg plus sulpiride 200 mg daily",duodenal ulcer,cimetidine
788862783,9/15/2015 21:52:31,1739045789,9/15/2015 21:52:17,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS,73,105,ISONIAZID;,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862783,9/15/2015 21:59:50,1739049026,9/15/2015 21:59:30,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS drugs: rifampicin; isoniazid; pyrazinamide; p - aminosalicylic acid;,73-86-93-105-116-130-131-132-147,73-86-93-105-116-130-132-147,tuberculosis drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid;,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862783,9/15/2015 22:10:13,1739052821,9/15/2015 22:09:21,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS,73,105,ISONIAZID;,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862783,9/15/2015 22:20:15,1739056262,9/15/2015 22:19:32,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS,73,105,ISONIAZID;,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862783,9/15/2015 22:20:16,1739056275,9/15/2015 22:19:43,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS,73,105,ISONIAZID;,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862783,9/15/2015 22:32:12,1739060139,9/15/2015 22:31:56,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS,73,105,ISONIAZID;,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862783,9/15/2015 22:39:11,1739062617,9/15/2015 22:38:45,false,instagc,1.0,23287154,USA,CA,San Jose,50.184.60.102,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS drugs:,73-86,105,ISONIAZID;,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862783,9/15/2015 22:40:27,1739063034,9/15/2015 22:39:38,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS drugs:,73-86,93-105-116-130-132-147-153-166-179-192-196,rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862783,9/15/2015 22:42:37,1739063576,9/15/2015 22:42:05,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS,73,73-105,tuberculosis ISONIAZID;,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862783,9/15/2015 22:43:24,1739063790,9/15/2015 22:42:55,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,73,105,,,85,114,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS,73,105,ISONIAZID;,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,73,105,73,105,85,114,-1,RO-may_prevent,820160,Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested,tuberculosis,isoniazid
788862784,9/15/2015 21:07:06,1739016453,9/15/2015 21:05:52,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,13,24,,,19,37,ANGINA,NITROGLYCERIN,ANGINA,13,24,NITROGLYCERIN,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862784,9/15/2015 21:13:02,1739022068,9/15/2015 21:12:52,false,prodege,1.0,3587109,CAN,NS,Sydney,142.177.43.123,13,24,,,19,37,ANGINA,NITROGLYCERIN,ANGINA,13,24,NITROGLYCERIN,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862784,9/15/2015 21:15:17,1739024851,9/15/2015 21:13:07,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,13,24,,,19,37,ANGINA,NITROGLYCERIN,ANGINA,13,24-38,NITROGLYCERIN consumption,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862784,9/15/2015 21:15:44,1739025246,9/15/2015 21:15:26,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,13,24,,,19,37,ANGINA,NITROGLYCERIN,ANGINA,13,24,NITROGLYCERIN,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862784,9/15/2015 21:17:04,1739026317,9/15/2015 21:16:46,false,neodev,1.0,33758777,USA,"","",38.95.108.251,13,24,,,19,37,ANGINA,NITROGLYCERIN,ANGINA,13,24,NITROGLYCERIN,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862784,9/15/2015 21:20:41,1739028716,9/15/2015 21:20:29,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,13,24,,,19,37,ANGINA,NITROGLYCERIN,ANGINA,13,24-38,NITROGLYCERIN consumption,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862784,9/15/2015 21:21:32,1739029234,9/15/2015 21:21:21,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,13,24,,,19,37,ANGINA,NITROGLYCERIN,ANGINA,13,24,NITROGLYCERIN,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862784,9/15/2015 21:32:17,1739035284,9/15/2015 21:31:48,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,13,24,,,19,37,ANGINA,NITROGLYCERIN,Frequency of ANGINA and nitroglycerin patient diaries.,10-13-20-24-74-82-0,13-20-24-38-50-55-82,angina and NITROGLYCERIN consumption were assessed diaries.,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862784,9/15/2015 21:33:52,1739036086,9/15/2015 21:33:42,false,instagc,1.0,26024737,GBR,H2,Preston,78.144.133.234,13,24,,,19,37,ANGINA,NITROGLYCERIN,ANGINA,13,24,NITROGLYCERIN,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862784,9/15/2015 21:35:07,1739036824,9/15/2015 21:33:59,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,13,24,,,19,37,ANGINA,NITROGLYCERIN,ANGINA,13,24,NITROGLYCERIN,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries.,13,24,13,24,19,37,-1,RO-may_prevent,820305,Frequency of angina and nitroglycerin consumption were assessed by weekly patient diaries,angina,nitroglycerin
788862785,9/15/2015 22:36:19,1739061608,9/15/2015 22:35:53,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,DEPRESSION,80,40,CLOMIPRAMINE,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862785,9/15/2015 22:40:46,1739063106,9/15/2015 22:39:37,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,concomitant DEPRESSION,68-80,40,CLOMIPRAMINE,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862785,9/15/2015 22:42:19,1739063498,9/15/2015 22:40:18,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,DEPRESSION,80,40,CLOMIPRAMINE,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862785,9/15/2015 22:56:48,1739068411,9/15/2015 22:56:28,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,DEPRESSION,80,40-80,CLOMIPRAMINE depression,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862785,9/15/2015 23:42:40,1739082806,9/15/2015 23:42:02,false,clixsense,1.0,6488338,USA,HI,Honolulu,72.130.214.250,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,OCD DEPRESSION,56-80,40-53-56-80,CLOMIPRAMINE in OCD depression,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862785,9/15/2015 23:44:20,1739083122,9/15/2015 23:43:55,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,OCD without concomitant DEPRESSION,56-60-68-80,24-28-37-40-53-56,the efficacy of CLOMIPRAMINE in OCD,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862785,9/15/2015 23:52:23,1739085276,9/15/2015 23:51:52,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,concomitant DEPRESSION,68-80,40,CLOMIPRAMINE,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862785,9/16/2015 00:10:05,1739089877,9/16/2015 00:09:53,false,instagc,1,31888345,USA,CA,Hayward,24.7.3.180,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,DEPRESSION,80,40,CLOMIPRAMINE,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862785,9/16/2015 00:11:35,1739090280,9/16/2015 00:10:25,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,concomitant DEPRESSION,68-80,40,CLOMIPRAMINE,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862785,9/16/2015 00:28:25,1739093966,9/16/2015 00:27:56,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,80,40,,,90,52,DEPRESSION,CLOMIPRAMINE,OCD without concomitant DEPRESSION,56-60-68-80,40,CLOMIPRAMINE,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect.,80,40,80,40,90,52,-1,RO-may_treat,820121,Thirdly the evidence of the efficacy of clomipramine in OCD without concomitant depression reported by Montgomery 1980 and supported by other studies suggests that 5-HT uptake inhibitors have a specifically anti-obsessional effect,depression,clomipramine
788862786,9/15/2015 22:59:33,1739069222,9/15/2015 22:59:05,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,140,107,,,155,112,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B,140-146-156,146-156,hepatitis B,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862786,9/15/2015 23:55:32,1739086255,9/15/2015 23:55:09,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,140,107,,,155,112,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B antibody,140-146-156-158,90-98-106,surface antigen (HBSAG),The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862786,9/15/2015 23:56:02,1739086440,9/15/2015 23:55:31,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,140,107,,,155,112,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B antibody,140-146-156-158,90-98-106,surface antigen (HBSAG),The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862786,9/16/2015 00:17:10,1739091463,9/16/2015 00:15:30,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,140,107,,,155,112,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS,140-146,78-88-90-98-106,hepatitis B surface antigen (HBSAG),The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862786,9/16/2015 00:31:11,1739094507,9/16/2015 00:30:34,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,140,107,,,155,112,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B antibody,140-146-156-158,78-88-90-98-106,hepatitis B surface antigen (HBSAG),The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862786,9/16/2015 00:47:28,1739098614,9/16/2015 00:46:38,false,neodev,1.0,32114597,USA,"","",73.151.173.249,140,107,,,155,112,SERUM HEPATITIS,HBSAG,hepatitis B antigen (HBsAg) 21% were positive for SERUM HEPATITIS B antibody,78-88-98-106-122-127-136-140-146-156-158-118,4-16-27-30-49-59-78-88-90-98-106-114-118-122-127-140-146-156-158-167,serological results 82 Whites 1.2% positive hepatitis B surface antigen (HBSAG) and 21% were positive serum hepatitis B antibody (HBAb.,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862786,9/16/2015 01:18:42,1739114108,9/16/2015 01:17:53,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,140,107,,,155,112,SERUM HEPATITIS,HBSAG,serological serum hepatitis B antigen (HBsAg) SERUM HEPATITIS B antibody (HBAb.,4-72-78-88-98-106-140-146-156-158-167,4-72-78-88-90-98-106-140-146-156-158-167,serological serum hepatitis B surface antigen (HBSAG) serum hepatitis B antibody (HBAb.,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862786,9/16/2015 01:29:53,1739120697,9/16/2015 01:29:18,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,140,107,,,155,112,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B antibody,140-146-156-158,72-78-88-90-98-106,serum hepatitis B surface antigen (HBSAG),The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862786,9/16/2015 01:38:12,1739128606,9/16/2015 01:37:43,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,140,107,,,155,112,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B antibody,140-146-156-158,78-88-90-98-106-72,serum hepatitis B surface antigen (HBSAG),The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862786,9/16/2015 01:58:14,1739144582,9/16/2015 01:57:11,false,neodev,1,11291592,USA,MI,Taylor,99.170.106.105,140,107,,,155,112,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B antibody,140-146-156-158,78-90-98-106-88,hepatitis B surface antigen (HBSAG),The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb.,140 146,,140,107,155,112,-1,RO-may_prevent,820277,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B surface antigen (HBsAg) and 21% were positive for serum hepatitis B antibody (HBAb,serum hepatitis,HBsAg
788862787,9/15/2015 21:54:18,1739046563,9/15/2015 21:54:08,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,83,31,,,87,44,PAIN,ACETAMINOPHEN,PAIN.,83,31,ACETAMINOPHEN,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862787,9/15/2015 22:03:34,1739050626,9/15/2015 22:02:58,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,83,31,,,87,44,PAIN,ACETAMINOPHEN,osteoarthritis PAIN.,68-83,31,ACETAMINOPHEN,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862787,9/15/2015 22:16:25,1739054872,9/15/2015 22:15:57,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,83,31,,,87,44,PAIN,ACETAMINOPHEN,osteoarthritis PAIN.,68-83,31,ACETAMINOPHEN,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862787,9/15/2015 22:26:14,1739058040,9/15/2015 22:25:16,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,83,31,,,87,44,PAIN,ACETAMINOPHEN,PAIN.,83,31,ACETAMINOPHEN,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862787,9/15/2015 22:28:12,1739058706,9/15/2015 22:27:37,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,83,31,,,87,44,PAIN,ACETAMINOPHEN,osteoarthritis PAIN.,68-83,31,ACETAMINOPHEN,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862787,9/15/2015 22:34:38,1739060910,9/15/2015 22:34:24,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,83,31,,,87,44,PAIN,ACETAMINOPHEN,osteoarthritis PAIN.,68-83,31,ACETAMINOPHEN,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862787,9/15/2015 22:49:11,1739065581,9/15/2015 22:48:16,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,83,31,,,87,44,PAIN,ACETAMINOPHEN,osteoarthritis PAIN.,68-83,31-68-83,ACETAMINOPHEN osteoarthritis pain.,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862787,9/15/2015 22:52:39,1739066896,9/15/2015 22:52:21,false,instagc,1,20043586,USA,NY,Gansevoort,67.248.253.125,83,31,,,87,44,PAIN,ACETAMINOPHEN,osteoarthritis PAIN.,68-83,31,ACETAMINOPHEN,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862787,9/15/2015 22:56:01,1739068215,9/15/2015 22:55:46,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,83,31,,,87,44,PAIN,ACETAMINOPHEN,PAIN.,83,31,ACETAMINOPHEN,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862787,9/15/2015 23:03:42,1739070567,9/15/2015 23:03:39,false,clixsense,1,6340330,USA,NY,Canajoharie,67.248.115.74,83,31,,,87,44,PAIN,ACETAMINOPHEN,efficacious for osteoarthritis PAIN.,52-64-68-83,11-17-28-31-45-52-64,Asked Questions Is ACETAMINOPHEN really efficacious for,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain.,83,31,83,31,87,44,-1,RO-may_treat,820096,Frequently Asked Questions  Is acetaminophen really efficacious for osteoarthritis pain,pain,acetaminophen
788862788,9/15/2015 22:59:05,1739069070,9/15/2015 22:58:43,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,18,49,,,22,59,GOUT,COLCHICINE,GOUT,18,49-77,COLCHICINE gout,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862788,9/15/2015 23:55:08,1739086118,9/15/2015 23:54:44,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,18,49,,,22,59,GOUT,COLCHICINE,GOUT Flare,18-23,49,COLCHICINE,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862788,9/15/2015 23:55:30,1739086235,9/15/2015 23:55:07,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,18,49,,,22,59,GOUT,COLCHICINE,Treatment of GOUT,5-15-18,36-42-46-49-60-64-74,Oral Use of COLCHICINE for treatment of,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862788,9/16/2015 00:15:29,1739091143,9/16/2015 00:15:00,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,18,49,,,22,59,GOUT,COLCHICINE,GOUT,18,49,COLCHICINE,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862788,9/16/2015 00:30:33,1739094399,9/16/2015 00:29:59,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,18,49,,,22,59,GOUT,COLCHICINE,GOUT,18,49,COLCHICINE,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862788,9/16/2015 00:46:36,1739098415,9/16/2015 00:45:45,false,neodev,1.0,32114597,USA,"","",73.151.173.249,18,49,,,22,59,GOUT,COLCHICINE,152 Treatment GOUT Flare Oral Use not recommended in patients with renal impairment prevention gout flares.,0-5-18-23-36-42-91-95-107-110-119-124-130-172-186-191,36-42-46-49-60-64-74-91-95-110-130-149-163-172-186,Oral Use of COLCHICINE for treatment of not recommended patients impairment receiving drug prevention gout,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862788,9/16/2015 01:17:52,1739113686,9/16/2015 01:16:58,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,18,49,,,22,59,GOUT,COLCHICINE,GOUT Flare colchicine gout flare renal impairment gout flares.,18-23-49-77-82-124-130-186-191,18-23-49-77-82-124-130-186-191,Gout Flare COLCHICINE gout flare renal impairment gout flares.,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862788,9/16/2015 01:29:17,1739120320,9/16/2015 01:28:47,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,18,49,,,22,59,GOUT,COLCHICINE,152 Treatment of GOUT,0-5-15-18,36-42-46-49-60-64-74-77-82,Oral Use of COLCHICINE for treatment of gout flare,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862788,9/16/2015 01:37:42,1739127647,9/16/2015 01:37:25,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,18,49,,,22,59,GOUT,COLCHICINE,GOUT Flare,18-23,49,COLCHICINE,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862788,9/16/2015 01:39:09,1739129966,9/16/2015 01:38:36,false,instagc,1,16469970,USA,OK,Broken Arrow,72.192.89.181,18,49,,,22,59,GOUT,COLCHICINE,GOUT Flare,18-23,49,COLCHICINE,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,18,49,18,49,22,59,-1,RO-may_prevent,820146,152  Treatment of Gout Flare  >     Oral  Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares,Gout,colchicine
788862789,9/15/2015 21:23:31,1739030230,9/15/2015 21:23:17,false,neodev,1.0,33758777,USA,"","",38.95.108.251,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,PULMONARY EMBOLISM.,74-84,21,HEPARIN,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862789,9/15/2015 21:24:37,1739030938,9/15/2015 21:24:27,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,PULMONARY EMBOLISM.,74-84,0-4-14-21,Low molecular weight HEPARIN,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862789,9/15/2015 21:39:50,1739039322,9/15/2015 21:37:50,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,PULMONARY EMBOLISM.,74-84,0-3-4-14-21,Low - molecular weight HEPARIN,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862789,9/15/2015 21:41:06,1739039992,9/15/2015 21:40:44,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,molecular weight heparin vs heparin treatment PULMONARY EMBOLISM.,4-14-21-29-32-47-74-84,0-4-14-21-29-32-40-74-84,Low molecular weight HEPARIN vs heparin in pulmonary embolism.,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862789,9/15/2015 21:43:05,1739041018,9/15/2015 21:42:53,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,PULMONARY EMBOLISM.,74-84,0-4-14-21,Low molecular weight HEPARIN,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862789,9/15/2015 21:49:02,1739044218,9/15/2015 21:48:51,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,PULMONARY EMBOLISM.,74-84,21,HEPARIN,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862789,9/15/2015 21:49:45,1739044489,9/15/2015 21:49:29,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,PULMONARY EMBOLISM.,74-84,0-4-14-21,Low molecular weight HEPARIN,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862789,9/15/2015 21:49:56,1739044555,9/15/2015 21:49:36,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,PULMONARY EMBOLISM.,74-84,21,HEPARIN,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862789,9/15/2015 21:50:22,1739044798,9/15/2015 21:49:59,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,of patients with PULMONARY EMBOLISM.,57-60-69-74-84,0-4-14-21-29-32-40,Low molecular weight HEPARIN vs heparin in,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862789,9/15/2015 21:51:52,1739045494,9/15/2015 21:50:38,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,74,21,,,92,28,PULMONARY EMBOLISM,HEPARIN,PULMONARY EMBOLISM.,74-84,0-4-14-21,Low molecular weight HEPARIN,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.,74 84,21,74,21,92,28,-1,RO-may_prevent,820306,Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism,pulmonary embolism,heparin
788862790,9/15/2015 23:56:47,1739086655,9/15/2015 23:56:24,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,HYPERALDOSTERONISM.,108,60,"SPIRONOLACTONE,","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862790,9/15/2015 23:57:43,1739086950,9/15/2015 23:57:25,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,primary HYPERALDOSTERONISM.,100-108,60,"SPIRONOLACTONE,","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862790,9/16/2015 00:18:51,1739091825,9/16/2015 00:18:05,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,primary HYPERALDOSTERONISM.,100-108,60,"SPIRONOLACTONE,","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862790,9/16/2015 00:32:05,1739094720,9/16/2015 00:31:54,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,HYPERALDOSTERONISM.,108,60,"SPIRONOLACTONE,","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862790,9/16/2015 00:50:39,1739099441,9/16/2015 00:50:04,false,neodev,1.0,32114597,USA,"","",73.151.173.249,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,"Do not use response aldosterone spironolactone, test for primary HYPERALDOSTERONISM.",2-5-9-28-60-91-96-100-108-13,5-9-13-28-40-60-76-79-81-91-100-108-2,"Do not use response aldosterone antagonist, SPIRONOLACTONE, as a screening test primary hyperaldosteronism.","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862790,9/16/2015 01:20:50,1739115357,9/16/2015 01:20:16,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,"aldosterone antagonist, spironolactone, primary HYPERALDOSTERONISM.",28-40-60-108-100,28-40-60-100-108,"aldosterone antagonist, SPIRONOLACTONE, primary hyperaldosteronism.","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862790,9/16/2015 01:31:13,1739121482,9/16/2015 01:30:57,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,screening test for primary HYPERALDOSTERONISM.,91-96-100-108-81,40-52-57-60-76-79-81-91,"antagonist, such as SPIRONOLACTONE, as a screening test","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862790,9/16/2015 01:38:59,1739129817,9/16/2015 01:38:46,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,HYPERALDOSTERONISM.,108,60,"SPIRONOLACTONE,","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862790,9/16/2015 01:59:09,1739145332,9/16/2015 01:58:59,false,neodev,1.0,11291592,USA,MI,Taylor,99.170.106.105,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,HYPERALDOSTERONISM.,108,60,"SPIRONOLACTONE,","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862790,9/16/2015 02:08:01,1739152600,9/16/2015 02:07:48,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,108,60,,,126,74,HYPERALDOSTERONISM,SPIRONOLACTONE,HYPERALDOSTERONISM.,108,60,"SPIRONOLACTONE,","• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism.",108,60,108,60,126,74,-1,RO-may_treat,820055,"• Do not use response to an aldosterone antagonist, such as spironolactone, as a screening test for primary hyperaldosteronism",hyperaldosteronism,spironolactone
788862791,9/15/2015 21:44:37,1739041886,9/15/2015 21:44:01,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,45,0,,,49,8,PAIN,NAPROXEN,Naproxen effective in reducing PAIN surgery trauma,0-23-33-36-45-150-139,0-23-36-54-97,NAPROXEN effective reducing swelling analgesic,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862791,9/15/2015 21:50:42,1739044957,9/15/2015 21:50:31,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,45,0,,,49,8,PAIN,NAPROXEN,PAIN,45,0,NAPROXEN,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862791,9/15/2015 21:56:28,1739047396,9/15/2015 21:55:43,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,45,0,,,49,8,PAIN,NAPROXEN,reducing PAIN and swelling,45-50-54-36,0,NAPROXEN,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862791,9/15/2015 21:57:28,1739047864,9/15/2015 21:56:48,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,45,0,,,49,8,PAIN,NAPROXEN,PAIN,45,0,NAPROXEN,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862791,9/15/2015 21:57:33,1739047918,9/15/2015 21:57:09,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,45,0,,,49,8,PAIN,NAPROXEN,PAIN swelling,45-54,0,NAPROXEN,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862791,9/15/2015 22:01:45,1739049956,9/15/2015 22:01:18,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,45,0,,,49,8,PAIN,NAPROXEN,PAIN,45,0,NAPROXEN,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862791,9/15/2015 22:02:31,1739050227,9/15/2015 22:02:13,false,instagc,1.0,21551272,GBR,I9,Dereham,89.243.154.52,45,0,,,49,8,PAIN,NAPROXEN,PAIN swelling,45-54,0,NAPROXEN,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862791,9/15/2015 22:03:23,1739050573,9/15/2015 22:03:08,false,neodev,1.0,33238512,USA,AZ,Phoenix,70.176.34.46,45,0,,,49,8,PAIN,NAPROXEN,effective in reducing PAIN and swelling in,23-33-36-45-50-54-63,0-9-17-20,NAPROXEN appears to be,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862791,9/15/2015 22:11:59,1739053299,9/15/2015 22:10:41,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,45,0,,,49,8,PAIN,NAPROXEN,PAIN,45,0,NAPROXEN,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862791,9/15/2015 22:12:28,1739053455,9/15/2015 22:10:10,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,45,0,,,49,8,PAIN,NAPROXEN,PAIN,45,0,NAPROXEN,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea.,45,0,45,0,49,8,-1,RO-may_prevent,820315,Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea,pain,Naproxen
788862792,9/15/2015 21:18:01,1739027178,9/15/2015 21:17:33,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,89,60,,,98,69,VARICELLA,ACYCLOVIR,abortive VARICELLA exanthema,80-89-99,60,ACYCLOVIR,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862792,9/15/2015 21:18:49,1739027651,9/15/2015 21:18:31,false,neodev,1.0,33758777,USA,"","",38.95.108.251,89,60,,,98,69,VARICELLA,ACYCLOVIR,VARICELLA,89,60,ACYCLOVIR,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862792,9/15/2015 21:19:27,1739027977,9/15/2015 21:18:05,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,89,60,,,98,69,VARICELLA,ACYCLOVIR,abortive VARICELLA exanthema,80-89-99,60,ACYCLOVIR,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862792,9/15/2015 21:21:37,1739029260,9/15/2015 21:21:24,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,89,60,,,98,69,VARICELLA,ACYCLOVIR,abortive VARICELLA exanthema,80-89-99,60,ACYCLOVIR,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862792,9/15/2015 21:22:53,1739029916,9/15/2015 21:22:43,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,89,60,,,98,69,VARICELLA,ACYCLOVIR,VARICELLA,89,60,ACYCLOVIR,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862792,9/15/2015 21:31:10,1739034700,9/15/2015 21:30:37,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,89,60,,,98,69,VARICELLA,ACYCLOVIR,abortive VARICELLA exanthema,80-89-99,60,ACYCLOVIR,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862792,9/15/2015 21:34:01,1739036188,9/15/2015 21:33:41,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,89,60,,,98,69,VARICELLA,ACYCLOVIR,abortive VARICELLA exanthema without further complications.,80-89-99-109-117-125,13-26-36-56-60-70-80-89-21,treated with varicella hyperimmunoglobulin and ACYCLOVIR developed abortive varicella,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862792,9/15/2015 21:35:01,1739036794,9/15/2015 21:34:52,false,instagc,1.0,26024737,GBR,H2,Preston,78.144.133.234,89,60,,,98,69,VARICELLA,ACYCLOVIR,VARICELLA,89,60,ACYCLOVIR,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862792,9/15/2015 21:37:40,1739038170,9/15/2015 21:37:26,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,89,60,,,98,69,VARICELLA,ACYCLOVIR,abortive VARICELLA exanthema,80-89-99,60,ACYCLOVIR,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862792,9/15/2015 21:39:52,1739039357,9/15/2015 21:39:41,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,89,60,,,98,69,VARICELLA,ACYCLOVIR,treated hyperimmunoglobulin acyclovir developed abortive VARICELLA exanthema without further,36-60-70-80-89-99-109-117-13,13-26-36-56-60-70-80-89-99,treated varicella hyperimmunoglobulin and ACYCLOVIR developed abortive varicella exanthema,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications.,89,60,89,60,98,69,-1,RO-may_prevent,820359,The newborns treated with varicella hyperimmunoglobulin and acyclovir developed abortive varicella exanthema without further complications,varicella,acyclovir
788862793,9/15/2015 21:10:34,1739019621,9/15/2015 21:08:12,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,123,87,,,127,94,PAIN,ASPIRIN,chronic PAIN.,115-123,87,ASPIRIN,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862793,9/15/2015 21:13:29,1739022652,9/15/2015 21:13:20,false,prodege,1.0,3587109,CAN,NS,Sydney,142.177.43.123,123,87,,,127,94,PAIN,ASPIRIN,treatment PAIN.,102-123,87,ASPIRIN,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862793,9/15/2015 21:16:36,1739026003,9/15/2015 21:16:10,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,123,87,,,127,94,PAIN,ASPIRIN,chronic PAIN.,115-123,87,ASPIRIN,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862793,9/15/2015 21:16:57,1739026263,9/15/2015 21:15:47,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,123,87,,,127,94,PAIN,ASPIRIN,chronic PAIN.,115-123,87,ASPIRIN,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862793,9/15/2015 21:17:53,1739027025,9/15/2015 21:17:36,false,neodev,1.0,33758777,USA,"","",38.95.108.251,123,87,,,127,94,PAIN,ASPIRIN,PAIN.,123,87,ASPIRIN,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862793,9/15/2015 21:21:05,1739028929,9/15/2015 21:20:55,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,123,87,,,127,94,PAIN,ASPIRIN,chronic PAIN.,115-123,87,ASPIRIN,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862793,9/15/2015 21:22:24,1739029617,9/15/2015 21:22:14,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,123,87,,,127,94,PAIN,ASPIRIN,PAIN.,123,87,ASPIRIN,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862793,9/15/2015 21:33:18,1739035796,9/15/2015 21:32:55,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,123,87,,,127,94,PAIN,ASPIRIN,tromethamine and aspirin treatment of chronic PAIN.,70-87-102-112-115-123-83,60-70-83-87-95-98-102-115-123-112,ketorolac tromethamine and ASPIRIN in the treatment of chronic pain.,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862793,9/15/2015 21:34:20,1739036370,9/15/2015 21:34:06,false,instagc,1.0,26024737,GBR,H2,Preston,78.144.133.234,123,87,,,127,94,PAIN,ASPIRIN,PAIN.,123,87,ASPIRIN,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862793,9/15/2015 21:39:34,1739039220,9/15/2015 21:39:23,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,123,87,,,127,94,PAIN,ASPIRIN,PAIN.,123,87,ASPIRIN,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.",123,87,123,87,127,94,-1,RO-may_prevent,820365,"Rubin P, Yee JP, Ruoff G. Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain",pain,aspirin
788862794,9/15/2015 21:53:32,1739046161,9/15/2015 21:53:18,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,38,61,,,45,72,MALARIA,CHLOROQUINE,"MALARIA,",38,61,CHLOROQUINE,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862794,9/15/2015 22:01:57,1739050042,9/15/2015 22:01:14,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,38,61,,,45,72,MALARIA,CHLOROQUINE,"MALARIA,",38,61,CHLOROQUINE,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862794,9/15/2015 22:13:15,1739053660,9/15/2015 22:12:40,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,38,61,,,45,72,MALARIA,CHLOROQUINE,"drug resistant MALARIA,",23-28-38,61,CHLOROQUINE,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862794,9/15/2015 22:23:46,1739057401,9/15/2015 22:23:16,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,38,61,,,45,72,MALARIA,CHLOROQUINE,"drug resistant MALARIA,",23-38-28,61,CHLOROQUINE,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862794,9/15/2015 22:25:36,1739057885,9/15/2015 22:24:28,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,38,61,,,45,72,MALARIA,CHLOROQUINE,"MALARIA,",38,61,CHLOROQUINE,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862794,9/15/2015 22:33:40,1739060633,9/15/2015 22:33:26,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,38,61,,,45,72,MALARIA,CHLOROQUINE,"MALARIA,",38,61,CHLOROQUINE,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862794,9/15/2015 22:40:27,1739063033,9/15/2015 22:40:14,false,instagc,1.0,23287154,USA,CA,San Jose,50.184.60.102,38,61,,,45,72,MALARIA,CHLOROQUINE,"drug resistant MALARIA,",23-28-38,50-52-58-61,2 doses of CHLOROQUINE,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862794,9/15/2015 22:42:43,1739063613,9/15/2015 22:42:11,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,38,61,,,45,72,MALARIA,CHLOROQUINE,"drug resistant MALARIA,",23-28-38,50-52-58-61,2 doses of CHLOROQUINE,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862794,9/15/2015 22:46:07,1739064727,9/15/2015 22:45:28,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,38,61,,,45,72,MALARIA,CHLOROQUINE,"MALARIA,",38,61-38,"malaria, CHLOROQUINE","We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862794,9/15/2015 22:48:26,1739065334,9/15/2015 22:47:13,false,neodev,1.0,17426565,CAN,BC,Burnaby,70.79.9.44,38,61,,,45,72,MALARIA,CHLOROQUINE,"drug resistant MALARIA,",23-28-38,61,CHLOROQUINE,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.",38,61,38,61,45,72,-1,RO-may_prevent,820261,"We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached",malaria,chloroquine
788862795,9/15/2015 22:05:50,1739051401,9/15/2015 22:04:29,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM:,132,55-69-74-101-115-46,Combined levothyroxine plus liothyronine LEVOTHYROXINE alone,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862795,9/15/2015 22:21:03,1739056533,9/15/2015 22:19:42,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM:,132,101,LEVOTHYROXINE,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862795,9/15/2015 22:31:01,1739059765,9/15/2015 22:30:14,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM:,132,101,LEVOTHYROXINE,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862795,9/15/2015 22:32:04,1739060080,9/15/2015 22:30:49,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,primary HYPOTHYROIDISM:,124-132,101,LEVOTHYROXINE,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862795,9/15/2015 22:36:16,1739061573,9/15/2015 22:35:55,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM:,132,101,LEVOTHYROXINE,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862795,9/15/2015 22:52:00,1739066406,9/15/2015 22:51:11,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM:,132,101-132,LEVOTHYROXINE hypothyroidism:,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862795,9/15/2015 22:57:00,1739068456,9/15/2015 22:56:47,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM:,132,101,LEVOTHYROXINE,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862795,9/15/2015 23:05:51,1739071256,9/15/2015 23:05:40,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,primary HYPOTHYROIDISM:,124-132,101,LEVOTHYROXINE,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862795,9/15/2015 23:12:00,1739073850,9/15/2015 23:10:45,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,primary HYPOTHYROIDISM:,124-132,55-69-74-101-124-132,levothyroxine plus liothyronine LEVOTHYROXINE primary hypothyroidism:,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862795,9/15/2015 23:17:16,1739075182,9/15/2015 23:16:57,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,132,101,,,146,114,HYPOTHYROIDISM,LEVOTHYROXINE,primary HYPOTHYROIDISM:,124-132,101,LEVOTHYROXINE,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.",132,101,132,101,146,114,-1,RO-may_prevent,820154,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial",hypothyroidism,levothyroxine
788862796,9/16/2015 00:01:48,1739087763,9/16/2015 00:01:25,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,"HYPERSENSITIVITY reactions,",283-300,324-339-351-362-365,carcinogenesis PREDNISONE Cytotoxic 40 mg,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862796,9/16/2015 01:42:44,1739132952,9/16/2015 01:42:23,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,"HYPERSENSITIVITY reactions,",283-300,339,PREDNISONE,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862796,9/16/2015 02:16:59,1739160073,9/16/2015 02:16:11,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,"HYPERSENSITIVITY reactions,",283-300,339,PREDNISONE,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862796,9/16/2015 03:13:37,1739211956,9/16/2015 03:13:22,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,"vomiting, mild myelosuppression, HYPERSENSITIVITY reactions, infertility, carcinogenesis",250-260-265-283-300-311-324,250-260-283-300-311-324-339-351-362-365-265,"vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis PREDNISONE Cytotoxic 40 mg","infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862796,9/16/2015 03:24:28,1739222054,9/16/2015 03:24:01,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,"vomiting, mild myelosuppression, HYPERSENSITIVITY reactions, infertility, carcinogenesis",250-260-265-283-300-311-324,300-311-324-339-351-362-365-368-371,"reactions, infertility, carcinogenesis PREDNISONE Cytotoxic 40 mg m2 po","infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862796,9/16/2015 03:33:25,1739230409,9/16/2015 03:33:03,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,"HYPERSENSITIVITY reactions,",283-300,339-351-362-365,PREDNISONE Cytotoxic 40 mg,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862796,9/16/2015 03:57:37,1739252789,9/16/2015 03:57:23,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,HYPERSENSITIVITY,283,339,PREDNISONE,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862796,9/16/2015 04:03:43,1739258294,9/16/2015 04:02:47,false,prodege,1.0,17379068,CAN,AB,Lethbridge,108.181.214.205,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,"vomiting, mild myelosuppression, HYPERSENSITIVITY reactions, infertility, carcinogenesis",250-260-265-283-300-311-324,300-311-324-339-351-362-365,"reactions, infertility, carcinogenesis PREDNISONE Cytotoxic 40 mg","infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862796,9/16/2015 04:15:06,1739269121,9/16/2015 04:14:21,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,"HYPERSENSITIVITY reactions,",283-300,339-351,PREDNISONE Cytotoxic,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862796,9/16/2015 04:21:15,1739274837,9/16/2015 04:20:33,false,instagc,1.0,33448981,USA,CA,Escondido,68.111.177.226,283,339,,,299,349,HYPERSENSITIVITY,PREDNISONE,"desquamation, Raynaud's phenomenon, hypersensitivity reactions Anorexia, nausea, vomiting, mild myelosuppression, HYPERSENSITIVITY reactions, infertility, carcinogenesis Glucose intolerance, immune suppression, bone and muscle loss",26-40-50-62-79-232-242-250-260-265-283-300-311-324-408-416-429-436-449-454-458-465,26-40-50-62-79-232-242-250-260-265-283-300-311-324-339-351-362-365-408-416-429-436-449-454-458-465,"desquamation, Raynaud's phenomenon, hypersensitivity reactions Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis PREDNISONE Cytotoxic 40 mg Glucose intolerance, immune suppression, bone and muscle loss","infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg.",283,339,283,339,299,349,-1,RO-may_treat,820049,"infiltrates and fibrosis, desquamation, Raynaud's phenomenon, hypersensitivity reactions Procarbazine  Inhibition of DNA, RNA and protein synthesis, perhaps due to methyl intermediates  100 mg/m2 po (days 1-7)  Activity against HD  Anorexia, nausea, vomiting, mild myelosuppression, hypersensitivity reactions, infertility, carcinogenesis Prednisone  Cytotoxic  40 mg/m2 po (days 1-14)  Activity against HD  Glucose intolerance, immune suppression, bone and muscle loss BEACOPP (escalated)  See individual drugs below        Repeat every 21 days for 8 cycles Bleomycin  Oxidative cleavage of DNA  10 mg",hypersensitivity,Prednisone
788862797,9/16/2015 00:03:03,1739088035,9/16/2015 00:02:44,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,59,72,,,65,80,PLAQUE,FLUORIDE,PLAQUE fluid fluoride,59-66-72,59-66-72,plaque fluid FLUORIDE,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862797,9/16/2015 01:43:42,1739133644,9/16/2015 01:43:26,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,59,72,,,65,80,PLAQUE,FLUORIDE,PLAQUE fluid,59-66,59-66-72,plaque fluid FLUORIDE,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862797,9/16/2015 02:18:30,1739161380,9/16/2015 02:18:04,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,59,72,,,65,80,PLAQUE,FLUORIDE,PLAQUE fluid fluoride,59-66-72,59-66-72,plaque fluid FLUORIDE,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862797,9/16/2015 03:14:22,1739212604,9/16/2015 03:14:08,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,59,72,,,65,80,PLAQUE,FLUORIDE,between salivary and PLAQUE fluid fluoride at 30 and 60,38-46-55-59-66-72-81-84-87-91,38-46-55-59-66-72-81-84-87-91,between salivary and plaque fluid FLUORIDE at 30 and 60,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862797,9/16/2015 03:26:06,1739223578,9/16/2015 03:25:20,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,59,72,,,65,80,PLAQUE,FLUORIDE,between salivary and PLAQUE fluid,38-46-55-59-66,59-66-72-81-84-87-91-94,plaque fluid FLUORIDE at 30 and 60 min,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862797,9/16/2015 03:58:18,1739253370,9/16/2015 03:58:03,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,59,72,,,65,80,PLAQUE,FLUORIDE,PLAQUE fluid fluoride,59-66-72,59-66-72,plaque fluid FLUORIDE,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862797,9/16/2015 04:03:48,1739258340,9/16/2015 04:03:24,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,59,72,,,65,80,PLAQUE,FLUORIDE,PLAQUE fluid fluoride,59-66-72,59-66-72,plaque fluid FLUORIDE,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862797,9/16/2015 04:16:25,1739270342,9/16/2015 04:16:05,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,59,72,,,65,80,PLAQUE,FLUORIDE,PLAQUE fluid fluoride,59-66-72,59-66-72,plaque fluid FLUORIDE,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862797,9/16/2015 04:35:57,1739289995,9/16/2015 04:35:36,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,59,72,,,65,80,PLAQUE,FLUORIDE,PLAQUE fluid fluoride,59-66-72,59-66-72,plaque fluid FLUORIDE,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862797,9/16/2015 04:45:26,1739299483,9/16/2015 04:45:15,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,59,72,,,65,80,PLAQUE,FLUORIDE,correlation between salivary and PLAQUE fluid fluoride at,38-46-55-59-66-72-81-16,46-55-59-66-72-81-84-87-104-110,"salivary and plaque fluid FLUORIDE at 30 and rinse administration,","A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse.",59,72,59,72,65,80,-1,RO-may_prevent,820391,"A strong linear correlation was found between salivary and plaque-fluid fluoride at 30 and 60 min after rinse administration, showing that plaque-fluid fluoride is influenced by the concentration of salivary fluoride after administration of this rinse",plaque,fluoride
788862798,9/15/2015 22:37:30,1739061994,9/15/2015 22:36:39,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,puerperal ovarian vein THROMBOPHLEBITIS,49-59-72-67,119-127-135-126,HEPARIN - induced thrombocytopenia,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862798,9/15/2015 22:41:17,1739063213,9/15/2015 22:40:50,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,puerperal ovarian vein THROMBOPHLEBITIS,49-59-67-72,119-127-135,HEPARIN induced thrombocytopenia,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862798,9/15/2015 22:41:49,1739063326,9/15/2015 22:41:29,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,puerperal ovarian vein THROMBOPHLEBITIS,49-59-67-72,119-127-135,HEPARIN induced thrombocytopenia,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862798,9/15/2015 22:42:51,1739063649,9/15/2015 22:42:41,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,puerperal ovarian vein THROMBOPHLEBITIS,49-59-67-72,119-127-135,HEPARIN induced thrombocytopenia,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862798,9/15/2015 22:57:29,1739068625,9/15/2015 22:57:08,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,THROMBOPHLEBITIS,72,72-119,thrombophlebitis HEPARIN,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862798,9/15/2015 23:43:51,1739083034,9/15/2015 23:43:08,false,clixsense,1.0,6488338,USA,HI,Honolulu,72.130.214.250,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,puerperal ovarian vein THROMBOPHLEBITIS heparin thrombocytopenia,49-59-67-72-135-119,59-67-72-119-135-49,puerperal ovarian vein thrombophlebitis HEPARIN thrombocytopenia,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862798,9/15/2015 23:53:39,1739085755,9/15/2015 23:53:02,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,puerperal ovarian vein THROMBOPHLEBITIS,49-59-67-72,119-127-135,HEPARIN induced thrombocytopenia,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862798,9/16/2015 00:10:32,1739089989,9/16/2015 00:10:24,false,instagc,1.0,31888345,USA,CA,Hayward,24.7.3.180,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,puerperal ovarian vein THROMBOPHLEBITIS,49-59-67-72,119-127-135,HEPARIN induced thrombocytopenia,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862798,9/16/2015 00:13:32,1739090767,9/16/2015 00:12:25,false,clixsense,1.0,26531841,CAN,ON,Toronto,64.231.8.24,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,ovarian vein THROMBOPHLEBITIS,59-67-72,119-127-135,HEPARIN induced thrombocytopenia,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862798,9/16/2015 00:29:04,1739094090,9/16/2015 00:28:46,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,72,119,,,88,126,THROMBOPHLEBITIS,HEPARIN,puerperal ovarian vein THROMBOPHLEBITIS,49-59-67-72,119-135-127,HEPARIN induced thrombocytopenia,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,72,119,72,119,88,126,-1,RO-may_treat,820136,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis--occurring independently from heparin-induced thrombocytopenia (surgical treatment necessary in most cases)--occurrence of puerperal ovarian vein thrombophlebitis in relation to heparin-induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation,thrombophlebitis,heparin
788862799,9/15/2015 21:19:15,1739027869,9/15/2015 21:18:58,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,MEGALOBLASTIC,92,57-63,FOLIC ACID,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862799,9/15/2015 21:20:13,1739028490,9/15/2015 21:19:53,false,neodev,1.0,33758777,USA,"","",38.95.108.251,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,MEGALOBLASTIC,92,57-63,FOLIC ACID,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862799,9/15/2015 21:22:26,1739029632,9/15/2015 21:22:15,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,MEGALOBLASTIC,92,57-63,FOLIC ACID,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862799,9/15/2015 21:23:45,1739030370,9/15/2015 21:23:34,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,MEGALOBLASTIC,92,57-63,FOLIC ACID,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862799,9/15/2015 21:26:02,1739031624,9/15/2015 21:24:05,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,MEGALOBLASTIC changes,92-106,57-63,FOLIC ACID,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862799,9/15/2015 21:36:10,1739037387,9/15/2015 21:35:48,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,B12 and the MEGALOBLASTIC,80-84-88-92,40-44-54-57-63-68-72-80-30,cirrhosis and dysbolism of FOLIC ACID and vitamin B12,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862799,9/15/2015 21:38:31,1739038660,9/15/2015 21:38:19,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,MEGALOBLASTIC,92,57-63,FOLIC ACID,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862799,9/15/2015 21:40:45,1739039815,9/15/2015 21:40:29,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,MEGALOBLASTIC changes,92-106,57-63,FOLIC ACID,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862799,9/15/2015 21:42:51,1739040956,9/15/2015 21:42:19,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,MEGALOBLASTIC changes and clinical,92-106-114-118,44-54-57-63,dysbolism of FOLIC ACID,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862799,9/15/2015 21:46:28,1739042864,9/15/2015 21:46:09,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,92,57,,,105,67,MEGALOBLASTIC,FOLIC ACID,MEGALOBLASTIC,92,57-63,FOLIC ACID,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed.,92,57 63,92,57,105,67,-1,RO-may_treat,820113,The correlation between liver cirrhosis and dysbolism of folic acid and vitamin B12 and the megaloblastic changes and clinical significance were discussed,megaloblastic,folic acid
788862800,9/15/2015 21:21:31,1739029231,9/15/2015 21:21:17,false,neodev,1.0,33758777,USA,"","",38.95.108.251,51,38,,,55,44,BURN,IODINE,BURN.,51,38,IODINE,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862800,9/15/2015 21:23:22,1739030151,9/15/2015 21:23:12,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,51,38,,,55,44,BURN,IODINE,iodine vapor BURN.,38-45-51,38-45-51,IODINE vapor burn.,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862800,9/15/2015 21:24:48,1739031051,9/15/2015 21:24:39,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,51,38,,,55,44,BURN,IODINE,BURN.,51,38,IODINE,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862800,9/15/2015 21:33:11,1739035770,9/15/2015 21:31:32,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,51,38,,,55,44,BURN,IODINE,iodine vapor BURN.,38-45-51,38-45-51,IODINE vapor burn.,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862800,9/15/2015 21:38:20,1739038540,9/15/2015 21:37:58,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,51,38,,,55,44,BURN,IODINE,iodine vapor BURN.,38-45-51,27-30-32-38-45-51,24 h after IODINE vapor burn.,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862800,9/15/2015 21:41:42,1739040264,9/15/2015 21:41:32,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,51,38,,,55,44,BURN,IODINE,iodine vapor BURN.,45-51-38,38-45-51,IODINE vapor burn.,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862800,9/15/2015 21:46:39,1739042997,9/15/2015 21:45:48,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,51,38,,,55,44,BURN,IODINE,iodine vapor BURN.,38-45-51,38-45-51,IODINE vapor burn.,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862800,9/15/2015 21:47:36,1739043483,9/15/2015 21:47:16,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,51,38,,,55,44,BURN,IODINE,BURN.,51,38,IODINE,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862800,9/15/2015 21:47:38,1739043495,9/15/2015 21:47:27,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,51,38,,,55,44,BURN,IODINE,BURN.,51,38,IODINE,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862800,9/15/2015 21:47:59,1739043692,9/15/2015 21:47:44,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,51,38,,,55,44,BURN,IODINE,vapor BURN.,45-51,38,IODINE,This effect is significant 24 h after iodine vapor burn.,51,38,51,38,55,44,-1,RO-may_treat,820117,This effect is significant 24 h after iodine vapor burn,burn,iodine
788862801,9/16/2015 02:22:04,1739164740,9/16/2015 02:21:39,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,UNSTABLE ANGINA,109-118,56,TIROFIBAN,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862801,9/16/2015 03:16:12,1739214317,9/16/2015 03:15:54,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,cardiac events in patients with UNSTABLE ANGINA or acute myocardial,85-92-95-104-109-118-125-128-134-77,37-42-51-56-66-69-77-85-95,IIIa blockade with TIROFIBAN on adverse cardiac events patients,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862801,9/16/2015 03:32:10,1739229149,9/16/2015 03:31:40,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,in patients with UNSTABLE ANGINA or acute myocardial infarction,92-95-104-109-118-125-128-134-145,37-42-51-56-66-69-77,IIIa blockade with TIROFIBAN on adverse cardiac,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862801,9/16/2015 04:07:19,1739261441,9/16/2015 04:06:48,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,UNSTABLE ANGINA,109-118,56,TIROFIBAN,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862801,9/16/2015 04:20:28,1739274157,9/16/2015 04:20:03,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,UNSTABLE ANGINA or acute myocardial infarction,109-118-125-128-134-145,56,TIROFIBAN,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862801,9/16/2015 04:38:55,1739292956,9/16/2015 04:38:33,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,UNSTABLE ANGINA,109-118,56,TIROFIBAN,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862801,9/16/2015 05:06:07,1739320898,9/16/2015 05:05:21,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,in patients with UNSTABLE ANGINA or acute myocardial,92-95-104-109-118-125-128-134,20-33-37-42-51-56-66-69-77-85-92-95,glycoprotein IIb IIIa blockade with TIROFIBAN on adverse cardiac events in patients,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862801,9/16/2015 05:12:21,1739327300,9/16/2015 05:12:07,false,elite,1.0,31883685,GBR,"","",79.66.244.188,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,UNSTABLE ANGINA,109-118,56,TIROFIBAN,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862801,9/16/2015 05:48:38,1739366270,9/16/2015 05:48:14,false,clixsense,1.0,27969116,NLD,"","",91.213.37.165,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,platelet glycoprotein IIb IIIa blockade UNSTABLE ANGINA acute myocardial,11-20-33-37-42-109-118-128-134,11-20-37-42-51-56-66-69-77-33,platelet glycoprotein IIb IIIa blockade with TIROFIBAN on adverse cardiac,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862801,9/16/2015 05:56:52,1739375297,9/16/2015 05:55:02,false,points4rewards,1.0,28703583,USA,"","",184.53.32.197,109,56,,,124,65,UNSTABLE ANGINA,TIROFIBAN,Effects of platelet glycoprotein UNSTABLE ANGINA or acute myocardial,0-8-11-20-109-118-128-134-125,56-167-176,TIROFIBAN coronary angioplasty.,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.,109 118,56,109,56,124,65,-1,RO-may_treat,820081,Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty,unstable angina,tirofiban
788862802,9/15/2015 21:18:21,1739027392,9/15/2015 21:18:02,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,179,119,,,183,128,PAIN,LIDOCAINE,PAIN visual analog scale,179-184-191-198,119,LIDOCAINE,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862802,9/15/2015 21:19:11,1739027840,9/15/2015 21:18:51,false,neodev,1.0,33758777,USA,"","",38.95.108.251,179,119,,,183,128,PAIN,LIDOCAINE,PAIN,179,119,LIDOCAINE,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862802,9/15/2015 21:21:14,1739029007,9/15/2015 21:19:32,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,179,119,,,183,128,PAIN,LIDOCAINE,PAIN visual analog scale (VAS.,179-184-191-198-204,116-119,2% LIDOCAINE,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862802,9/15/2015 21:21:50,1739029364,9/15/2015 21:21:39,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,179,119,,,183,128,PAIN,LIDOCAINE,PAIN,179,116-119,2% LIDOCAINE,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862802,9/15/2015 21:23:06,1739030017,9/15/2015 21:22:55,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,179,119,,,183,128,PAIN,LIDOCAINE,PAIN,179,119,LIDOCAINE,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862802,9/15/2015 21:32:13,1739035267,9/15/2015 21:31:13,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,179,119,,,183,128,PAIN,LIDOCAINE,PAIN visual analog scale,179-184-191-198,116-119,2% LIDOCAINE,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862802,9/15/2015 21:34:26,1739036400,9/15/2015 21:34:02,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,179,119,,,183,128,PAIN,LIDOCAINE,measured using a PAIN visual analog scale,162-171-177-179-184-191-198,71-83-100-113-116-119-129-132-136-146-157-65,nerve stimulation (TENS) infiltration of 2% LIDOCAINE in the relief episiotomy pain,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862802,9/15/2015 21:37:52,1739038256,9/15/2015 21:37:41,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,179,119,,,183,128,PAIN,LIDOCAINE,PAIN visual,179-184,119,LIDOCAINE,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862802,9/15/2015 21:40:03,1739039425,9/15/2015 21:39:49,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,179,119,,,183,128,PAIN,LIDOCAINE,PAIN visual analog scale,179-184-191-198,100-113-116-119-132,infiltration of 2% LIDOCAINE the,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862802,9/15/2015 21:40:34,1739039699,9/15/2015 21:39:47,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,179,119,,,183,128,PAIN,LIDOCAINE,PAIN visual analog scale,179-184-191-198,119,LIDOCAINE,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS.,179,119,179,119,183,128,-1,RO-may_prevent,820379,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% lidocaine in the relief of episiotomy pain measured using a pain visual analog scale (VAS,pain,lidocaine
788862803,9/15/2015 23:59:27,1739087288,9/15/2015 23:59:14,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,226,189,GLUCAGON,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862803,9/16/2015 00:35:45,1739095622,9/16/2015 00:35:19,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,226,189-198,GLUCAGON concentrations,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862803,9/16/2015 01:28:01,1739119688,9/16/2015 01:26:39,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,"glucagon renal hepatic glutamine gluconeogenesis, postabsorptive glucagon glucagon HYPOGLYCEMIA a isotopic net balance techniques, systemic, renal, hepatic glucose renal hepatic glucose glutamine.",24-36-46-54-64-111-140-189-226-250-267-280-284-292-319-329-340-348-368-378-400-413,24-36-46-54-64-140-189-226-267-280-284-292-329-340-348-368-378-400-413,"glucagon renal hepatic glutamine gluconeogenesis, glucagon GLUCAGON hypoglycemia isotopic net balance techniques, renal, hepatic glucose renal hepatic glucose glutamine.","To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862803,9/16/2015 01:34:39,1739123778,9/16/2015 01:34:17,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,226,166-169-177-189-198-213-219-226,to produce circulating GLUCAGON concentrations found during hypoglycemia,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862803,9/16/2015 01:40:56,1739131450,9/16/2015 01:40:42,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,226,189-198,GLUCAGON concentrations,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862803,9/16/2015 02:12:06,1739155823,9/16/2015 02:11:25,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,226,189,GLUCAGON,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862803,9/16/2015 03:12:00,1739210499,9/16/2015 03:11:47,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,"concentrations found during HYPOGLYCEMIA and, using a combination",198-213-219-226-239-244-250-252,166-169-177-189-198-213-219-226,to produce circulating GLUCAGON concentrations found during hypoglycemia,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862803,9/16/2015 03:13:09,1739211525,9/16/2015 03:12:57,false,prodege,1.0,31508822,CAN,AB,Calgary,206.75.77.133,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,226,189,GLUCAGON,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862803,9/16/2015 03:20:37,1739218206,9/16/2015 03:20:07,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,concentrations found during HYPOGLYCEMIA,198-213-219-226,169-177-189-198-213-219-226,produce circulating GLUCAGON concentrations found during hypoglycemia,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862803,9/16/2015 03:24:05,1739221720,9/16/2015 03:23:40,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,226,189,,,238,197,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,226,189,GLUCAGON,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",226,189,226,189,238,197,-1,RO-may_treat,820115,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating glucagon concentrations found during hypoglycemia and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine",hypoglycemia,glucagon
788862804,9/15/2015 23:58:14,1739087006,9/15/2015 23:57:44,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,177,189,,,186,198,VARICELLA,ACYCLOVIR,VARICELLA:,177,189,ACYCLOVIR,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862804,9/15/2015 23:58:45,1739087134,9/15/2015 23:58:14,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,177,189,,,186,198,VARICELLA,ACYCLOVIR,Varicella herpes zoster VARICELLA:,149-160-167-177,160-167-177-189-200-213-229-149,Varicella herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster:,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862804,9/16/2015 00:32:30,1739094774,9/16/2015 00:32:20,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,177,189,,,186,198,VARICELLA,ACYCLOVIR,Varicella herpes zoster VARICELLA: acyclovir famciclovir valacyclovir,149-160-167-177-189-200-213,160-167-177-189-200-213-229,herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster:,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862804,9/16/2015 00:53:28,1739100275,9/16/2015 00:52:23,false,neodev,1.0,32114597,USA,"","",73.151.173.249,177,189,,,186,198,VARICELLA,ACYCLOVIR,MMR Varicella zoster Herpesviridae Varicella herpes zoster VARICELLA: acyclovir famciclovir valacyclovir Zoster: immuneglobulin Cell culture antigen nucleic acid detection.,61-94-104-117-149-160-167-177-189-200-213-229-302-322-327-336-356-361-348,61-65-73-82-94-104-117-131-139-149-160-167-177-189-200-213-229-238-249-266-111,MMR vaccine Antibody detection Varicella zoster virus Herpesviridae droplet contact Varicella herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster: acyclovir famciclovir Varicella,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862804,9/16/2015 01:23:20,1739116787,9/16/2015 01:21:58,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,177,189,,,186,198,VARICELLA,ACYCLOVIR,German measles congenital rubella None MMR vaccine Antibody Varicella zoster virus Herpesviridae Varicella herpes zoster VARICELLA: acyclovir famciclovir valacyclovir Zoster: acyclovir famciclovir Varicella vaccine varicella zoster immuneglobulin Cell antigen nucleic acid,18-25-34-45-56-61-65-73-94-104-111-117-149-160-167-177-189-200-213-229-238-249-266-276-285-295-302-322-336-348-356,18-25-34-45-56-61-73-94-104-111-117-149-160-167-177-189-200-213-229-238-249-266-276-285-295-302-322-336-348-356-361,German measles congenital rubella None MMR Antibody Varicella zoster virus Herpesviridae Varicella herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster: acyclovir famciclovir Varicella vaccine varicella zoster immuneglobulin Cell antigen nucleic acid detection.,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862804,9/16/2015 01:31:54,1739121872,9/16/2015 01:31:32,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,177,189,,,186,198,VARICELLA,ACYCLOVIR,Varicella herpes VARICELLA:,149-160-177,160-167-177-189-200-213-229-238,herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster: acyclovir,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862804,9/16/2015 01:39:45,1739130635,9/16/2015 01:39:15,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,177,189,,,186,198,VARICELLA,ACYCLOVIR,Varicella herpes zoster VARICELLA:,149-160-167-177,189,ACYCLOVIR,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862804,9/16/2015 02:09:49,1739154099,9/16/2015 02:08:31,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,177,189,,,186,198,VARICELLA,ACYCLOVIR,Varicella herpes zoster VARICELLA: acyclovir famciclovir valacyclovir,160-167-177-189-200-213-149,160-167-177-189-200-213-229-149,Varicella herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster:,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862804,9/16/2015 02:23:05,1739165687,9/16/2015 02:22:57,false,instagc,1.0,20043586,USA,NY,Gansevoort,67.248.253.125,177,189,,,186,198,VARICELLA,ACYCLOVIR,Varicella herpes zoster VARICELLA: acyclovir famciclovir valacyclovir,149-160-167-177-189-200-213,160-167-177-189-200-213-229,herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster:,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862804,9/16/2015 02:37:50,1739178857,9/16/2015 02:37:01,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,177,189,,,186,198,VARICELLA,ACYCLOVIR,Varicella herpes zoster VARICELLA:,149-160-167-177,189,ACYCLOVIR,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,177,189,177,189,186,198,-1,RO-may_prevent,820290,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,Varicella,acyclovir
788862805,9/15/2015 22:04:26,1739050875,9/15/2015 22:04:10,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0-10,DIGITALIS compounds,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862805,9/15/2015 22:19:41,1739056051,9/15/2015 22:19:15,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0-10,DIGITALIS compounds,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862805,9/15/2015 22:30:13,1739059466,9/15/2015 22:28:46,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0,DIGITALIS,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862805,9/15/2015 22:30:48,1739059660,9/15/2015 22:30:11,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0-10,DIGITALIS compounds,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862805,9/15/2015 22:35:54,1739061449,9/15/2015 22:35:41,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0-10,DIGITALIS compounds,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862805,9/15/2015 22:51:11,1739066161,9/15/2015 22:50:42,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0-49-60-66,DIGITALIS congestive heart failure,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862805,9/15/2015 22:56:46,1739068407,9/15/2015 22:56:36,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0-10,DIGITALIS compounds,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862805,9/15/2015 23:05:39,1739071233,9/15/2015 23:05:28,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0,DIGITALIS,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862805,9/15/2015 23:10:43,1739073451,9/15/2015 23:10:17,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0-10,DIGITALIS compounds,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862805,9/15/2015 23:16:56,1739075040,9/15/2015 23:16:32,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,49,0,,,73,9,CONGESTIVE HEART FAILURE,DIGITALIS,CONGESTIVE HEART FAILURE,49-60-66,0-10,DIGITALIS compounds,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase.",49 60 66,0,49,0,73,9,-1,RO-may_prevent,820260,"Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+)-ATPase",congestive heart failure,Digitalis
788862806,9/16/2015 00:00:00,1739087424,9/15/2015 23:59:47,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,HANSEN'S DISEASE,29-38,13,THALIDOMIDE,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862806,9/16/2015 01:29:35,1739120485,9/16/2015 01:29:02,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,thalidomide HANSEN'S DISEASE,13-29-38,13-29-38,THALIDOMIDE Hansen's disease,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862806,9/16/2015 01:35:28,1739124301,9/16/2015 01:35:09,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,"HANSEN'S DISEASE side effect,",29-38-46-51,0-4-13-25-29-38,FDA approves THALIDOMIDE for Hansen's disease,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862806,9/16/2015 01:41:26,1739131832,9/16/2015 01:41:11,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,HANSEN'S DISEASE,29-38,13,THALIDOMIDE,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862806,9/16/2015 02:13:27,1739156924,9/16/2015 02:12:36,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,HANSEN'S DISEASE,29-38,13,THALIDOMIDE,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862806,9/16/2015 03:12:27,1739210782,9/16/2015 03:12:15,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,"approves thalidomide for HANSEN'S DISEASE side effect, imposes unprecedented restrictions distribution.",4-13-25-29-38-46-51-59-67-81-97,0-4-13-25-29-38-46-59,FDA approves THALIDOMIDE for Hansen's disease side imposes,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862806,9/16/2015 03:21:48,1739219332,9/16/2015 03:20:58,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,"approves thalidomide for HANSEN'S DISEASE side effect,",4-13-25-29-38-46-51,0-4-13-25-29-38-46-51,"FDA approves THALIDOMIDE for Hansen's disease side effect,","FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862806,9/16/2015 03:24:30,1739222064,9/16/2015 03:24:19,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,HANSEN'S DISEASE,29-38,13,THALIDOMIDE,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862806,9/16/2015 03:31:20,1739228276,9/16/2015 03:29:59,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,"HANSEN'S DISEASE side effect,",29-38-46-51,13,THALIDOMIDE,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862806,9/16/2015 03:53:02,1739248894,9/16/2015 03:52:52,false,elite,1.0,33798502,USA,VA,Manassas,207.244.79.135,29,13,,,45,24,HANSEN'S DISEASE,THALIDOMIDE,"approves thalidomide for HANSEN'S DISEASE side effect, imposes unprecedented restrictions",4-13-25-29-38-46-51-59-67-81,0-4-13-25-29-38-81-67,FDA approves THALIDOMIDE for Hansen's disease unprecedented restrictions,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution.",29 38,13,29,13,45,24,-1,RO-may_treat,820088,"FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution",Hansen's disease,thalidomide
788862807,9/15/2015 21:05:48,1739015211,9/15/2015 21:05:11,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,108,157,,,115,168,MALARIA,CHLOROQUINE,MALARIA,108,157-169,CHLOROQUINE resistance.,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862807,9/15/2015 21:12:51,1739021818,9/15/2015 21:12:39,false,prodege,1.0,3587109,CAN,NS,Sydney,142.177.43.123,108,157,,,115,168,MALARIA,CHLOROQUINE,MALARIA,108,157,CHLOROQUINE,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862807,9/15/2015 21:13:03,1739022108,9/15/2015 21:12:20,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,108,157,,,115,168,MALARIA,CHLOROQUINE,MALARIA,108,157-169,CHLOROQUINE resistance.,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862807,9/15/2015 21:15:25,1739024967,9/15/2015 21:14:51,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,108,157,,,115,168,MALARIA,CHLOROQUINE,MALARIA,108,157-169,CHLOROQUINE resistance.,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862807,9/15/2015 21:16:44,1739026110,9/15/2015 21:16:25,false,neodev,1.0,33758777,USA,"","",38.95.108.251,108,157,,,115,168,MALARIA,CHLOROQUINE,MALARIA,108,157,CHLOROQUINE,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862807,9/15/2015 21:20:29,1739028615,9/15/2015 21:20:16,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,108,157,,,115,168,MALARIA,CHLOROQUINE,MALARIA,108,157-169,CHLOROQUINE resistance.,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862807,9/15/2015 21:21:20,1739029076,9/15/2015 21:21:05,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,108,157,,,115,168,MALARIA,CHLOROQUINE,MALARIA,108,157,CHLOROQUINE,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862807,9/15/2015 21:31:47,1739034996,9/15/2015 21:31:09,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,108,157,,,115,168,MALARIA,CHLOROQUINE,pre hospital treatment chloroquine of MALARIA in children in chloroquine resistance.,17-21-30-49-105-108-116-119-128-157-169,49-108-119-141-145-154-157-169-61,chloroquine contributes malaria children the presence of CHLOROQUINE resistance.,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862807,9/15/2015 21:33:41,1739035979,9/15/2015 21:33:30,false,instagc,1.0,26024737,GBR,H2,Preston,78.144.133.234,108,157,,,115,168,MALARIA,CHLOROQUINE,MALARIA,108,157,CHLOROQUINE,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862807,9/15/2015 21:33:58,1739036175,9/15/2015 21:32:07,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,108,157,,,115,168,MALARIA,CHLOROQUINE,MALARIA,108,157-169,CHLOROQUINE resistance.,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance.",108,157,108,157,115,168,-1,RO-may_prevent,820150,"We conclude that pre-hospital treatment ingested chloroquine contributes significantly to the resolution of malaria in children in Ghana, in the presence of chloroquine resistance",malaria,chloroquine
788862808,9/15/2015 21:54:07,1739046493,9/15/2015 21:53:46,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,37,72,,,41,83,IDDM,NON-INSULIN,"(IDDM),",36,72-76,NON INSULIN,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862808,9/15/2015 22:02:57,1739050358,9/15/2015 22:02:41,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,37,72,,,41,83,IDDM,NON-INSULIN,"insulin dependent diabetics (IDDM),",8-16-26-36,72-76-84-94,NON INSULIN dependent diabetics,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862808,9/15/2015 22:15:56,1739054663,9/15/2015 22:14:46,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,37,72,,,41,83,IDDM,NON-INSULIN,"insulin dependent diabetics (IDDM),",8-16-26-36,72-76-84-94-104,NON INSULIN dependent diabetics (NIDDM.,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862808,9/15/2015 22:25:15,1739057807,9/15/2015 22:24:47,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,37,72,,,41,83,IDDM,NON-INSULIN,"insulin dependent diabetics (IDDM),",8-16-36-26,72-76-84-94-104,NON INSULIN dependent diabetics (NIDDM.,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862808,9/15/2015 22:27:35,1739058506,9/15/2015 22:26:46,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,37,72,,,41,83,IDDM,NON-INSULIN,"insulin dependent diabetics (IDDM),",8-16-26-36,65-72-76-84-94,and NON INSULIN dependent diabetics,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862808,9/15/2015 22:34:23,1739060869,9/15/2015 22:33:57,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,37,72,,,41,83,IDDM,NON-INSULIN,insulin dependent diabetics,8-16-26,72-76-84-94,NON INSULIN dependent diabetics,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862808,9/15/2015 22:48:15,1739065313,9/15/2015 22:47:24,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,37,72,,,41,83,IDDM,NON-INSULIN,diabetics,26,72-76-94-84,NON INSULIN dependent diabetics,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862808,9/15/2015 22:51:52,1739066363,9/15/2015 22:51:38,false,clixsense,1,28457001,CAN,ON,North Bay,24.204.202.220,37,72,,,41,83,IDDM,NON-INSULIN,"dependent diabetics (IDDM),",16-26-36,72-76,NON INSULIN,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862808,9/15/2015 22:52:20,1739066652,9/15/2015 22:51:56,false,instagc,1.0,20043586,USA,NY,Gansevoort,67.248.253.125,37,72,,,41,83,IDDM,NON-INSULIN,insulin - dependent diabetics,8-15-16-26,72-76-84-94,NON INSULIN dependent diabetics,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862808,9/15/2015 22:55:45,1739068135,9/15/2015 22:55:30,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,37,72,,,41,83,IDDM,NON-INSULIN,"dependent diabetics (IDDM),",16-26-36,72-76-84-94,NON INSULIN dependent diabetics,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM.",,72 76,37,72,41,83,-1,RO-may_treat,820134,"10 were insulin-dependent diabetics (IDDM), 24 insulin-requiring and 66 non-insulin dependent diabetics (NIDDM",IDDM,non-insulin
788862809,9/16/2015 00:01:05,1739087622,9/16/2015 00:00:49,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,ASTHMA,151,168,ZAFIRLUKAST.,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862809,9/16/2015 01:32:00,1739121980,9/16/2015 01:31:18,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,"Pulmonary infiltrates, eosinophilia, cardiomyopathy corticosteroid ASTHMA zafirlukast.",42-52-65-83-108-151-168,42-52-65-83-108-151-168,"Pulmonary infiltrates, eosinophilia, cardiomyopathy corticosteroid asthma ZAFIRLUKAST.","Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862809,9/16/2015 01:39:53,1739130710,9/16/2015 01:39:45,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,patients with ASTHMA receiving zafirlukast.,137-146-151-158-168,151-158-168,asthma receiving ZAFIRLUKAST.,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862809,9/16/2015 01:42:08,1739132396,9/16/2015 01:41:57,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,ASTHMA,151,168,ZAFIRLUKAST.,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862809,9/16/2015 02:15:39,1739158761,9/16/2015 02:15:09,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,in ASTHMA,134-151,168,ZAFIRLUKAST.,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862809,9/16/2015 03:13:07,1739211463,9/16/2015 03:12:56,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,withdrawal in patients with ASTHMA receiving zafirlukast.,134-137-146-151-158-168-123,123-146-151-158-168-134,withdrawal in with asthma receiving ZAFIRLUKAST.,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862809,9/16/2015 03:23:08,1739220698,9/16/2015 03:22:35,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,in patients with ASTHMA receiving zafirlukast.,134-137-146-151-158-168,151-158-168,asthma receiving ZAFIRLUKAST.,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862809,9/16/2015 03:25:04,1739222633,9/16/2015 03:24:55,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,ASTHMA,151,168,ZAFIRLUKAST.,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862809,9/16/2015 03:32:37,1739229682,9/16/2015 03:32:20,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,ASTHMA,151,168,ZAFIRLUKAST.,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862809,9/16/2015 03:57:09,1739252402,9/16/2015 03:56:57,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,151,168,,,157,179,ASTHMA,ZAFIRLUKAST,ASTHMA,151,168,ZAFIRLUKAST.,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.",151,168,151,168,157,179,-1,RO-may_prevent,820236,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast",asthma,zafirlukast
788862810,9/15/2015 21:25:00,1739031170,9/15/2015 21:24:36,false,neodev,1,33758777,USA,"","",38.95.108.251,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,DEPRESSION,410,426-436,TRICYCLIC ANTIDEPRESSANTS,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862810,9/15/2015 21:25:30,1739031365,9/15/2015 21:25:18,false,instagc,1,20312760,GBR,O1,Dukinfield,2.96.59.31,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,DEPRESSION,410,426-436,TRICYCLIC ANTIDEPRESSANTS,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862810,9/15/2015 21:42:26,1739040673,9/15/2015 21:41:46,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,DEPRESSION,410,426-436,TRICYCLIC ANTIDEPRESSANTS,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862810,9/15/2015 21:43:12,1739041102,9/15/2015 21:42:43,false,clixsense,1,32053717,GBR,"","",51.174.76.80,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,fluvoxamine ◊ DEPRESSION with tricyclic antidepressants anxiolytics benzodiazepines,396-408-410-421-426-436-544-524,426-436-452-457-460-498,TRICYCLIC ANTIDEPRESSANTS such as amitriptyline sertraline,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862810,9/15/2015 21:50:01,1739044587,9/15/2015 21:49:46,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,DEPRESSION,410,426-436,TRICYCLIC ANTIDEPRESSANTS,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862810,9/15/2015 21:53:24,1739046105,9/15/2015 21:52:45,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,DEPRESSION,410,426-436,TRICYCLIC ANTIDEPRESSANTS,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862810,9/15/2015 21:53:57,1739046379,9/15/2015 21:53:15,false,quickrewards,1,8672587,USA,TX,El Paso,70.120.233.80,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,◊ DEPRESSION,408-410,426-436,TRICYCLIC ANTIDEPRESSANTS,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862810,9/15/2015 21:56:28,1739047382,9/15/2015 21:56:00,false,treasuretrooper,1,17956656,AUS,02,Jannali,14.200.59.55,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,fluvoxamine ◊ DEPRESSION with tricyclic antidepressants,396-408-410-426-436-421,408-410-421-426-436-460,◊ Depression with TRICYCLIC ANTIDEPRESSANTS amitriptyline,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862810,9/15/2015 22:00:03,1739049126,9/15/2015 21:59:14,false,clixsense,1,33878524,CAN,BC,Princeton,75.156.83.71,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,◊ DEPRESSION,408-410,408-426-436,◊ TRICYCLIC ANTIDEPRESSANTS,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862810,9/15/2015 22:01:36,1739049864,9/15/2015 22:01:07,false,instagc,1,21551272,GBR,I9,Dereham,89.243.154.52,410,426,,,420,451,DEPRESSION,TRICYCLIC ANTIDEPRESSANTS,DEPRESSION,410,426-436-460-498,TRICYCLIC ANTIDEPRESSANTS amitriptyline sertraline,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",410,426 436,410,426,420,451,-1,RO-may_treat,820025,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ Depression with tricyclic antidepressants such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on",Depression,tricyclic antidepressants
788862811,9/16/2015 01:45:25,1739134880,9/16/2015 01:44:26,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION.,123-130,71,"WARFARIN,","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862811,9/16/2015 02:20:24,1739163250,9/16/2015 02:19:59,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION.,123-130,71,"WARFARIN,","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862811,9/16/2015 03:15:26,1739213502,9/16/2015 03:15:15,false,elite,1,34356654,USA,DE,"",108.59.11.227,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,"aspirin, clopidogrel in patients with ATRIAL FIBRILLATION.",94-106-109-118-123-130-81,51-58-66-71-81-90-94-42,"dual, triple therapy with WARFARIN, aspirin, and clopidogrel","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862811,9/16/2015 03:29:21,1739226576,9/16/2015 03:28:34,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,patients with ATRIAL FIBRILLATION.,109-118-123-130,51-58-66-71-81-90-94,"triple therapy with WARFARIN, aspirin, and clopidogrel","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862811,9/16/2015 04:05:15,1739259609,9/16/2015 04:04:57,false,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION.,123-130,71,"WARFARIN,","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862811,9/16/2015 04:17:55,1739271685,9/16/2015 04:17:40,false,neodev,1,21515166,NLD,11,Nieuwkoop,83.84.200.25,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION.,123-130,71,"WARFARIN,","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862811,9/16/2015 04:37:09,1739291228,9/16/2015 04:36:46,false,clixsense,1,6330572,GBR,"","",87.115.58.29,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION.,123-130,71,"WARFARIN,","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862811,9/16/2015 05:02:53,1739317569,9/16/2015 05:02:02,false,gifthunterclub,1,24043308,GBR,"","",94.102.147.250,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION.,123-130,51-58-66-71-81-90-94-106-109-118-123-130,"triple therapy with WARFARIN, aspirin, and clopidogrel in patients with atrial fibrillation.","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862811,9/16/2015 05:11:30,1739326431,9/16/2015 05:10:59,false,elite,1,31883685,GBR,"","",79.66.244.188,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION.,123-130,71,"WARFARIN,","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862811,9/16/2015 05:46:42,1739364254,9/16/2015 05:46:25,false,neodev,1,34429821,USA,CA,San Jose,50.118.172.120,123,71,,,142,79,ATRIAL FIBRILLATION,WARFARIN,in patients with ATRIAL FIBRILLATION.,106-109-118-123-130,51-58-66-71-81-90-94,"triple therapy with WARFARIN, aspirin, and clopidogrel","2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.",123 130,71,123,71,142,79,-1,RO-may_treat,820041,"2010-09-13  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation",atrial fibrillation,warfarin
788862812,9/15/2015 22:06:06,1739051467,9/15/2015 22:05:51,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,139,121,,,143,130,PAIN,CAPSAICIN,capsaicin induced PAIN,121-131-139,121-131-139,CAPSAICIN induced pain,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862812,9/15/2015 22:21:56,1739056872,9/15/2015 22:21:04,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,139,121,,,143,130,PAIN,CAPSAICIN,capsaicin induced PAIN,121-131-139,121-131-139,CAPSAICIN induced pain,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862812,9/15/2015 22:31:23,1739059877,9/15/2015 22:31:02,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,139,121,,,143,130,PAIN,CAPSAICIN,capsaicin - induced PAIN,121-131-139-130,121-131-139-130,CAPSAICIN - induced pain,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862812,9/15/2015 22:32:57,1739060410,9/15/2015 22:32:05,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,139,121,,,143,130,PAIN,CAPSAICIN,capsaicin induced PAIN,121-131-139,121-131-139,CAPSAICIN induced pain,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862812,9/15/2015 22:36:40,1739061698,9/15/2015 22:36:17,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,139,121,,,143,130,PAIN,CAPSAICIN,capsaicin induced PAIN,121-131-139,121-131-139,CAPSAICIN induced pain,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862812,9/15/2015 22:53:10,1739067133,9/15/2015 22:52:01,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,139,121,,,143,130,PAIN,CAPSAICIN,PAIN,139,121-139,CAPSAICIN pain,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862812,9/15/2015 22:57:14,1739068540,9/15/2015 22:57:01,false,instagc,1,15577915,USA,IL,Trenton,208.70.36.12,139,121,,,143,130,PAIN,CAPSAICIN,capsaicin induced PAIN,121-131-139,121-131-139,CAPSAICIN induced pain,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862812,9/15/2015 23:06:11,1739071365,9/15/2015 23:05:52,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,139,121,,,143,130,PAIN,CAPSAICIN,capsaicin induced PAIN,121-131-139,121,CAPSAICIN,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862812,9/15/2015 23:13:10,1739074135,9/15/2015 23:12:01,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,139,121,,,143,130,PAIN,CAPSAICIN,contralateral to capsaicin induced PAIN tibialis anterior (TA) muscle.,104-118-121-131-139-151-160-169-174,94-100-104-121-131-139-151-160-169-174,ipsi and contralateral CAPSAICIN induced pain tibialis anterior (TA) muscle.,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862812,9/15/2015 23:18:12,1739075435,9/15/2015 23:17:17,false,clixsense,1,11106820,USA,MA,Taunton,173.48.52.95,139,121,,,143,130,PAIN,CAPSAICIN,capsaicin induced PAIN,121-131-139,121-131-139-144,CAPSAICIN induced pain in,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle.,139,121,139,121,143,130,-1,RO-may_prevent,820174,The aim of the present study was to examine the sensitivity to pressure and pinprick at sites ipsi- and contralateral to capsaicin-induced pain in the tibialis anterior (TA) muscle,pain,capsaicin
788862813,9/15/2015 21:18:40,1739027569,9/15/2015 21:18:22,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,VENTRICULAR TACHYCARDIA,48-60,118,DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862813,9/15/2015 21:19:30,1739028020,9/15/2015 21:19:12,false,neodev,1.0,33758777,USA,"","",38.95.108.251,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,VENTRICULAR TACHYCARDIA,48-60,118,DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862813,9/15/2015 21:22:01,1739029437,9/15/2015 21:21:51,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,TdP VENTRICULAR TACHYCARDIA,44-48-60,118,DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862813,9/15/2015 21:22:38,1739029736,9/15/2015 21:21:19,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,TdP VENTRICULAR TACHYCARDIA,44-48-60,118,DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862813,9/15/2015 21:23:21,1739030126,9/15/2015 21:23:07,false,neodev,1,20306047,GBR,"","",80.41.0.252,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,VENTRICULAR TACHYCARDIA,48-60,118,DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862813,9/15/2015 21:35:29,1739037007,9/15/2015 21:34:26,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,TdP VENTRICULAR TACHYCARDIA induced by combined clarithromycin disopyramide.,44-48-60-72-80-83-99-118,83-96-99-114-118-92,combined use of clarithromycin and DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862813,9/15/2015 21:38:08,1739038392,9/15/2015 21:37:53,false,prodege,1,2143114,CAN,BC,Vancouver,24.85.153.181,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,TdP VENTRICULAR TACHYCARDIA,44-48-60,118,DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862813,9/15/2015 21:40:01,1739039423,9/15/2015 21:39:54,false,neodev,1,33701549,NLD,"","",85.203.17.204,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,report old who developed TdP VENTRICULAR TACHYCARDIA induced by combined disopyramide.,20-30-34-44-48-60-72-80-83-118-3,24-60-96-99-114-118-83,woman tachycardia combined of clarithromycin and DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862813,9/15/2015 21:40:14,1739039509,9/15/2015 21:40:04,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,TdP VENTRICULAR TACHYCARDIA,44-48-60,118,DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862813,9/15/2015 21:41:08,1739040010,9/15/2015 21:40:35,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,48,118,,,71,130,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,TdP VENTRICULAR TACHYCARDIA,44-48-60,99-114-118,clarithromycin and DISOPYRAMIDE.,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide.,48 60,118,48,118,71,130,-1,RO-may_prevent,820374,We report a 76-year-old woman who developed TdP ventricular tachycardia induced by combined use of clarithromycin and disopyramide,ventricular tachycardia,disopyramide
788862814,9/15/2015 21:03:51,1739013040,9/15/2015 21:03:09,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA.,151,105,GLUCOSE,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862814,9/15/2015 21:08:48,1739017735,9/15/2015 21:08:23,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA.,151,105,GLUCOSE,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862814,9/15/2015 21:12:15,1739021268,9/15/2015 21:12:00,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA.,151,105,GLUCOSE,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862814,9/15/2015 21:12:36,1739021566,9/15/2015 21:12:15,false,clixsense,1,10032240,USA,FL,Naples,76.101.211.223,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,rapid recovery from HYPOGLYCEMIA.,131-137-146-151,85-90-93-105-113-120-124,role in maintaining GLUCOSE levels but not,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862814,9/15/2015 21:13:54,1739023213,9/15/2015 21:13:15,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA.,151,105-113,GLUCOSE levels,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862814,9/15/2015 21:15:38,1739025156,9/15/2015 21:15:21,false,neodev,1.0,33758777,USA,"","",38.95.108.251,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA.,151,105,GLUCOSE,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862814,9/15/2015 21:17:11,1739026453,9/15/2015 21:17:02,false,elite,1,28548715,USA,VA,Manassas,198.7.59.107,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA.,151,105,GLUCOSE,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862814,9/15/2015 21:19:45,1739028153,9/15/2015 21:19:35,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA.,151,105,GLUCOSE,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862814,9/15/2015 21:20:22,1739028569,9/15/2015 21:20:10,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA.,151,105,GLUCOSE,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862814,9/15/2015 21:29:33,1739033762,9/15/2015 21:28:25,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,151,105,,,163,112,HYPOGLYCEMIA,GLUCOSE,Cortisol growth hormone rapid recovery from HYPOGLYCEMIA.,0-13-20-131-146-151-137,0-85-90-93-105-78,Cortisol play role in maintaining GLUCOSE,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia.,151,105,151,105,163,112,-1,RO-may_treat,820003,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining glucose levels but not in rapid recovery from hypoglycemia,hypoglycemia,glucose
788862815,9/15/2015 21:25:24,1739031341,9/15/2015 21:25:02,false,neodev,1.0,33758777,USA,"","",38.95.108.251,67,29,,,74,40,MALARIA,CHLOROQUINE,MALARIA,67,29,CHLOROQUINE,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862815,9/15/2015 21:25:44,1739031455,9/15/2015 21:25:31,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,67,29,,,74,40,MALARIA,CHLOROQUINE,symptomatic MALARIA infection,55-67-75,29-41,CHLOROQUINE treatment,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862815,9/15/2015 21:43:32,1739041323,9/15/2015 21:43:13,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,67,29,,,74,40,MALARIA,CHLOROQUINE,placebo chloroquine treatment for symptomatic MALARIA infection,17-29-41-51-55-67-75,17-25-29-41-51-55-67-75,placebo and CHLOROQUINE treatment for symptomatic malaria infection,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862815,9/15/2015 21:47:26,1739043385,9/15/2015 21:46:11,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,67,29,,,74,40,MALARIA,CHLOROQUINE,symptomatic MALARIA infection,55-67-75,29-41,CHLOROQUINE treatment,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862815,9/15/2015 21:50:15,1739044714,9/15/2015 21:50:03,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,67,29,,,74,40,MALARIA,CHLOROQUINE,MALARIA,67,29,CHLOROQUINE,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862815,9/15/2015 21:54:34,1739046661,9/15/2015 21:54:02,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,67,29,,,74,40,MALARIA,CHLOROQUINE,MALARIA infection,67-75,29-41,CHLOROQUINE treatment,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862815,9/15/2015 21:55:15,1739046922,9/15/2015 21:53:26,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,67,29,,,74,40,MALARIA,CHLOROQUINE,symptomatic MALARIA,55-67,29,CHLOROQUINE,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862815,9/15/2015 21:56:51,1739047562,9/15/2015 21:56:28,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,67,29,,,74,40,MALARIA,CHLOROQUINE,symptomatic MALARIA infection,55-67-75,17-29-41-55-67-75,placebo CHLOROQUINE treatment symptomatic malaria infection,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862815,9/15/2015 22:00:52,1739049516,9/15/2015 22:00:04,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,67,29,,,74,40,MALARIA,CHLOROQUINE,symptomatic MALARIA infection,55-67-75,29-41,CHLOROQUINE treatment,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862815,9/15/2015 22:01:58,1739050046,9/15/2015 22:01:37,false,instagc,1.0,21551272,GBR,I9,Dereham,89.243.154.52,67,29,,,74,40,MALARIA,CHLOROQUINE,MALARIA,67,29,CHLOROQUINE,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given.",67,29,67,29,74,40,-1,RO-may_prevent,820273,"Group I received placebo and chloroquine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given",malaria,chloroquine
788862816,9/15/2015 21:20:17,1739028517,9/15/2015 21:19:35,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,Mycobacterium TUBERCULOSIS,129-143,58-67-80,rifampin (RIFAMPICIN) (RIF),"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862816,9/15/2015 21:20:53,1739028825,9/15/2015 21:20:35,false,neodev,1.0,33758777,USA,"","",38.95.108.251,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,143,67,(RIFAMPICIN),"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862816,9/15/2015 21:22:58,1739029966,9/15/2015 21:22:39,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,"Mycobacterium TUBERCULOSIS infected mice,",129-143-156-165,67-58,rifampin (RIFAMPICIN),"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862816,9/15/2015 21:24:24,1739030815,9/15/2015 21:24:03,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,143,67,(RIFAMPICIN),"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862816,9/15/2015 21:29:42,1739033843,9/15/2015 21:28:56,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,Mycobacterium TUBERCULOSIS,129-143,67-80-85,(RIFAMPICIN) (RIF) -,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862816,9/15/2015 21:37:14,1739037940,9/15/2015 21:36:38,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,Mycobacterium TUBERCULOSIS extensive pharmacokinetic,129-143-171-181,58-67-80-86-99-105-143-156,rifampin (RIFAMPICIN) (RIF) pyrazinamide (PZA) combination tuberculosis infected,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862816,9/15/2015 21:38:52,1739038852,9/15/2015 21:38:47,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,"observed in Mycobacterium TUBERCULOSIS infected mice, extensive",117-126-129-143-156-165-171,54-58-67-86,and rifampin (RIFAMPICIN) pyrazinamide,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862816,9/15/2015 21:41:14,1739040070,9/15/2015 21:41:00,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,Mycobacterium TUBERCULOSIS infected,129-143-156,58-67-86,rifampin (RIFAMPICIN) pyrazinamide,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862816,9/15/2015 21:44:11,1739041684,9/15/2015 21:43:17,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,"Mycobacterium TUBERCULOSIS infected mice,",129-143-156-165,58-67,rifampin (RIFAMPICIN),"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862816,9/15/2015 21:47:00,1739043228,9/15/2015 21:46:46,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,143,68,,,155,78,TUBERCULOSIS,RIFAMPICIN,TUBERCULOSIS,143,,,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination.",143,,143,68,155,78,-1,RO-may_prevent,820262,"To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF-PZA combination",tuberculosis,rifampicin
788862817,9/16/2015 02:21:37,1739164307,9/16/2015 02:21:11,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,95,57,,,99,66,PAIN,CAPSAICIN,cardiac nociceptive PAIN,75-83-95,57-67-75-83,CAPSAICIN induced cardiac nociceptive,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862817,9/16/2015 03:15:53,1739213957,9/16/2015 03:15:41,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,95,57,,,99,66,PAIN,CAPSAICIN,influence capsaicin induced cardiac nociceptive PAIN pulses to the,57-67-75-83-95-100-107-110-47,38-43-47-57-67-75-83-100-130-95,does not influence CAPSAICIN induced cardiac nociceptive pain pulses system.,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862817,9/16/2015 03:31:39,1739228574,9/16/2015 03:30:23,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,95,57,,,99,66,PAIN,CAPSAICIN,induced cardiac nociceptive PAIN pulses the,67-75-83-95-100-110,38-43-47-57-67-75-83,does not influence CAPSAICIN induced cardiac nociceptive,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862817,9/16/2015 04:06:47,1739261044,9/16/2015 04:05:58,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,95,57,,,99,66,PAIN,CAPSAICIN,induced cardiac nociceptive PAIN pulses,67-75-83-95-100,57-67-75-83-95-100,CAPSAICIN induced cardiac nociceptive pain pulses,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862817,9/16/2015 04:20:02,1739273798,9/16/2015 04:19:06,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,95,57,,,99,66,PAIN,CAPSAICIN,cardiac nociceptive PAIN pulses,75-83-95-100,57-66-67-75-83-95-100,CAPSAICIN - induced cardiac nociceptive pain pulses,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862817,9/16/2015 04:38:32,1739292632,9/16/2015 04:37:42,false,clixsense,1.0,6330572,GBR,"","",87.115.58.29,95,57,,,99,66,PAIN,CAPSAICIN,capsaicin induced cardiac nociceptive PAIN,57-75-83-95-67,57,CAPSAICIN,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862817,9/16/2015 05:05:14,1739320028,9/16/2015 05:04:12,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,95,57,,,99,66,PAIN,CAPSAICIN,induced cardiac nociceptive PAIN pulses to the central nervous system.,67-75-83-95-100-107-110-114-122-130,38-43-47-57-67-75-83-95-100-107-110-114-122-130,does not influence CAPSAICIN induced cardiac nociceptive pain pulses to the central nervous system.,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862817,9/16/2015 05:12:07,1739327098,9/16/2015 05:11:48,false,elite,1.0,31883685,GBR,"","",79.66.244.188,95,57,,,99,66,PAIN,CAPSAICIN,cardiac nociceptive PAIN pulses,75-83-95-100,57-67-75-83-95,CAPSAICIN induced cardiac nociceptive pain,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862817,9/16/2015 05:48:12,1739365814,9/16/2015 05:47:34,false,clixsense,1,27969116,NLD,"","",91.213.37.165,95,57,,,99,66,PAIN,CAPSAICIN,influence capsaicin induced cardiac nociceptive PAIN pulses to the,47-67-75-83-95-100-107-110-57,47-57-67-75-83-95-100,influence CAPSAICIN induced cardiac nociceptive pain pulses,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862817,9/16/2015 05:54:58,1739373344,9/16/2015 05:53:25,false,points4rewards,1,28703583,USA,"","",184.53.32.197,95,57,,,99,66,PAIN,CAPSAICIN,neurostimulation does not influence capsaicin induced PAIN,21-38-43-47-57-95-67,57-95-100-107-110-114-122-130,CAPSAICIN pain pulses to the central nervous system.,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system.,95,57,95,57,99,66,-1,RO-may_prevent,820304,It is concluded that neurostimulation does not influence capsaicin-induced cardiac nociceptive pain pulses to the central nervous system,pain,capsaicin
788862818,9/15/2015 21:22:11,1739029547,9/15/2015 21:21:55,false,neodev,1.0,33758777,USA,"","",38.95.108.251,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,5,63,INSULIN,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862818,9/15/2015 21:23:48,1739030419,9/15/2015 21:23:38,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,5,63,INSULIN,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862818,9/15/2015 21:35:35,1739037068,9/15/2015 21:34:12,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,5,63,INSULIN,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862818,9/15/2015 21:39:22,1739039121,9/15/2015 21:39:03,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,"HYPERGLYCEMIA In diabetic patients, dosage insulin oral hypoglycemics",5-20-23-32-42-63-74-79,42-49-60-63-71-74-79,dosage adjustment of INSULIN or oral hypoglycemics,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862818,9/15/2015 21:42:13,1739040563,9/15/2015 21:41:58,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,5,63,INSULIN,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862818,9/15/2015 21:47:48,1739043600,9/15/2015 21:47:12,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,"HYPERGLYCEMIA In diabetic patients,",5-20-23-32,63,INSULIN,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862818,9/15/2015 21:48:06,1739043721,9/15/2015 21:47:54,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,5,63,INSULIN,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862818,9/15/2015 21:48:11,1739043758,9/15/2015 21:47:56,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,5,63,INSULIN,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862818,9/15/2015 21:48:38,1739044012,9/15/2015 21:48:25,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,5,63,INSULIN,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862818,9/15/2015 21:49:01,1739044210,9/15/2015 21:48:21,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,5,63,,,18,70,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,5,63,INSULIN,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident.",5,63,5,63,18,70,-1,RO-may_treat,820021,"109  Hyperglycemia  In diabetic patients, dosage adjustment of insulin or oral hypoglycemics may be required; hyperglycemia may occur and latent diabetes mellitus may become evident",Hyperglycemia,insulin
788862819,9/15/2015 21:21:15,1739029008,9/15/2015 21:20:55,false,neodev,1.0,33758777,USA,"","",38.95.108.251,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,TYPE 2 DIABETES,205-210-212,134,ROSIGLITAZONE,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862819,9/15/2015 21:23:11,1739030046,9/15/2015 21:22:58,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,TYPE 2 DIABETES,205-210-212,134,ROSIGLITAZONE,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862819,9/15/2015 21:24:38,1739030947,9/15/2015 21:24:25,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,TYPE 2 DIABETES,205-210-212,134,ROSIGLITAZONE,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862819,9/15/2015 21:31:26,1739034863,9/15/2015 21:29:50,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,TYPE 2 DIABETES,205-210-212,134,ROSIGLITAZONE,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862819,9/15/2015 21:37:57,1739038309,9/15/2015 21:37:15,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,cardiovascular endpoints TYPE 2 DIABETES,163-205-210-212-178,134-148-163-151,ROSIGLITAZONE to investigate cardiovascular,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862819,9/15/2015 21:41:31,1739040179,9/15/2015 21:41:16,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,TYPE 2 DIABETES,205-210-212,134,ROSIGLITAZONE,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862819,9/15/2015 21:45:47,1739042502,9/15/2015 21:44:12,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,TYPE 2 DIABETES,205-210-212,134,ROSIGLITAZONE,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862819,9/15/2015 21:47:15,1739043335,9/15/2015 21:47:01,false,clixsense,1.0,26492726,GBR,H3,Leeds,90.214.17.126,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,TYPE 2 DIABETES,205-210-212,134,ROSIGLITAZONE,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862819,9/15/2015 21:47:26,1739043391,9/15/2015 21:47:11,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,TYPE 2 DIABETES,205-210-212,134,ROSIGLITAZONE,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862819,9/15/2015 21:47:43,1739043524,9/15/2015 21:47:21,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,205,134,,,220,147,TYPE 2 DIABETES,ROSIGLITAZONE,TYPE 2 DIABETES,205-210-212,134,ROSIGLITAZONE,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter.",205 210 212,134,205,134,220,147,-1,RO-may_treat,820045,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long-term, controlled clinical trial of rosiglitazone to investigate cardiovascular endpoints in patients with type 2 diabetes ( GlaxoSmithKline letter",type 2 diabetes,rosiglitazone
788862820,9/15/2015 21:05:06,1739014474,9/15/2015 21:04:31,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA,74,52-67,"ANTIARRHYTHMIC DRUGS,","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862820,9/15/2015 21:12:15,1739021293,9/15/2015 21:09:55,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA aggravation,74-85,52-67,"ANTIARRHYTHMIC DRUGS,","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862820,9/15/2015 21:12:39,1739021604,9/15/2015 21:12:27,false,prodege,1.0,3587109,CAN,NS,Sydney,142.177.43.123,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA in,74-106,52-67,"ANTIARRHYTHMIC DRUGS,","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862820,9/15/2015 21:14:50,1739024392,9/15/2015 21:14:29,false,prodege,1.0,34271751,CAN,ON,Toronto,99.225.188.40,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA aggravation,74-85,52-67,"ANTIARRHYTHMIC DRUGS,","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862820,9/15/2015 21:16:24,1739025808,9/15/2015 21:16:00,false,neodev,1.0,33758777,USA,"","",38.95.108.251,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA,74,52-67,"ANTIARRHYTHMIC DRUGS,","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862820,9/15/2015 21:20:15,1739028499,9/15/2015 21:19:58,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA aggravation,74-85,52-67,"ANTIARRHYTHMIC DRUGS,","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862820,9/15/2015 21:21:05,1739028931,9/15/2015 21:20:53,false,neodev,1.0,20306047,GBR,"","",80.41.0.252,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA,74,52-67,"ANTIARRHYTHMIC DRUGS,","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862820,9/15/2015 21:31:08,1739034683,9/15/2015 21:30:14,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA aggravation occurred in (9%.,74-85-97-106-119,52-67-74-85-97-119,"ANTIARRHYTHMIC DRUGS, arrhythmia aggravation occurred (9%.","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862820,9/15/2015 21:32:06,1739035189,9/15/2015 21:30:14,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA in,74-106,52-67,"ANTIARRHYTHMIC DRUGS,","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862820,9/15/2015 21:34:51,1739036657,9/15/2015 21:34:39,false,instagc,1,26024737,GBR,H2,Preston,78.144.133.234,74,52,,,84,72,ARRHYTHMIA,ANTIARRHYTHMIC DRUGS,ARRHYTHMIA,74,52-67,"ANTIARRHYTHMIC DRUGS,","In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%.",74,52 67,74,52,84,72,-1,RO-may_prevent,820323,"In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%",arrhythmia,antiarrhythmic drugs
788862821,9/15/2015 22:07:00,1739051757,9/15/2015 22:06:38,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,multidrug resistant TUBERCULOSIS,66-76-86,51,ISONIAZID,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862821,9/15/2015 22:25:10,1739057799,9/15/2015 22:24:38,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,multidrug resistant TUBERCULOSIS,66-76-86,51,ISONIAZID,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862821,9/15/2015 22:32:51,1739060390,9/15/2015 22:32:33,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,multidrug - resistant TUBERCULOSIS,66-75-86-76,51,ISONIAZID,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862821,9/15/2015 22:36:58,1739061803,9/15/2015 22:36:16,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,multidrug resistant TUBERCULOSIS,66-76-86,51,ISONIAZID,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862821,9/15/2015 22:38:39,1739062433,9/15/2015 22:37:42,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,multidrug resistant TUBERCULOSIS,66-76-86,51,ISONIAZID,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862821,9/15/2015 22:54:55,1739067902,9/15/2015 22:54:27,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS,86,51-86,ISONIAZID tuberculosis,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862821,9/15/2015 22:58:12,1739068806,9/15/2015 22:57:51,false,instagc,1.0,15577915,USA,IL,Trenton,208.70.36.12,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,multidrug resistant TUBERCULOSIS,66-86-76,51,ISONIAZID,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862821,9/15/2015 23:06:54,1739071751,9/15/2015 23:06:36,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,multidrug resistant TUBERCULOSIS,66-76-86,51-76,ISONIAZID resistant,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862821,9/15/2015 23:16:15,1739074872,9/15/2015 23:15:18,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,"isoniazid multidrug resistant TUBERCULOSIS tuberculosis, tuberculosis drug resistant tuberculosis.",51-66-76-86-180-250-298-303-313,28-51-66-76-86-180-250-298-303-313,"England ISONIAZID multidrug resistant tuberculosis tuberculosis, tuberculosis drug resistant tuberculosis.","We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862821,9/15/2015 23:19:26,1739075797,9/15/2015 23:19:06,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,86,51,,,98,60,TUBERCULOSIS,ISONIAZID,TUBERCULOSIS,86,51,ISONIAZID,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis.",86,51,86,51,98,60,-1,RO-may_prevent,820345,"We compared all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (1993-1994 and 1998-2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug-resistant tuberculosis",tuberculosis,isoniazid
788862822,9/15/2015 23:57:43,1739086927,9/15/2015 23:56:48,false,clixsense,1.0,31304413,CAN,BC,Kelowna,66.183.36.177,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,(endocrine HYPOGONADISM.,266-277,218,TESTOSTERONE,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862822,9/15/2015 23:58:12,1739087000,9/15/2015 23:57:45,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,(endocrine HYPOGONADISM.,266-277,218,TESTOSTERONE,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862822,9/16/2015 00:32:20,1739094754,9/16/2015 00:32:06,false,instagc,1.0,31771119,USA,NY,Victor,72.230.179.20,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,HYPOGONADISM.,277,200-218-190,"(exocrine hypogonadism), TESTOSTERONE","Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862822,9/16/2015 00:52:20,1739099989,9/16/2015 00:50:45,false,neodev,1.0,32114597,USA,"","",73.151.173.249,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,"Gonadal hormone elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), Testosterone below and / or range (endocrine HYPOGONADISM.",0-8-125-134-139-144-148-153-157-170-177-184-190-200-218-231-237-240-241-260-266-277,0-8-74-134-144-148-157-190-200-215-218-231-237-241-244-277-266,"Gonadal hormone hormones FSH, LH, SHBG testosterone (exocrine hypogonadism), 3: TESTOSTERONE below and or LH (endocrine hypogonadism.","Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862822,9/16/2015 01:21:58,1739115923,9/16/2015 01:20:51,false,clixsense,1.0,20587495,CAN,NB,Saint John,142.162.106.74,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,"Gonadal hormone levels gonadal hormones Isolated elevated FSH, LH, SHBG testosterone (exocrine hypogonadism), Testosterone LH (endocrine HYPOGONADISM.",0-8-16-66-74-116-125-134-144-148-157-190-200-218-244-266-277,0-8-66-74-125-134-144-148-157-190-200-215-218-244-266-277,"Gonadal hormone gonadal hormones elevated FSH, LH, SHBG testosterone (exocrine hypogonadism), 3: TESTOSTERONE LH (endocrine hypogonadism.","Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862822,9/16/2015 01:31:31,1739121580,9/16/2015 01:31:14,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,normal range (endocrine HYPOGONADISM.,253-260-266-277,190-200-215-218-231-237-241,"(exocrine hypogonadism), 3: TESTOSTERONE below and or","Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862822,9/16/2015 01:39:14,1739130094,9/16/2015 01:39:00,false,prodege,1.0,10959404,USA,CA,Studio City,108.217.110.104,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,(endocrine HYPOGONADISM.,266-277,218,TESTOSTERONE,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862822,9/16/2015 02:08:27,1739152965,9/16/2015 02:08:02,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,(endocrine HYPOGONADISM.,266-277,218,TESTOSTERONE,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862822,9/16/2015 02:22:57,1739165512,9/16/2015 02:22:35,false,instagc,1.0,20043586,USA,NY,Gansevoort,67.248.253.125,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,(endocrine HYPOGONADISM.,266-277,218,TESTOSTERONE,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862822,9/16/2015 02:37:00,1739178042,9/16/2015 02:36:08,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,277,218,,,289,230,HYPOGONADISM,TESTOSTERONE,HYPOGONADISM.,277,218,TESTOSTERONE,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism.",277,218,277,218,289,230,-1,RO-may_treat,820143,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism",hypogonadism,Testosterone
788862823,9/15/2015 21:53:45,1739046284,9/15/2015 21:53:33,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,FUNGAL INFECTIONS,14-21,84-97,AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862823,9/15/2015 22:02:40,1739050252,9/15/2015 22:02:00,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,Systemic FUNGAL INFECTIONS,5-14-21,84-97,AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862823,9/15/2015 22:14:45,1739054261,9/15/2015 22:13:15,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,Systemic FUNGAL INFECTIONS b,5-14-21-33,84-97,AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862823,9/15/2015 22:24:46,1739057664,9/15/2015 22:23:47,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,FUNGAL INFECTIONS,14-21,84-97,AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862823,9/15/2015 22:26:46,1739058261,9/15/2015 22:25:37,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,FUNGAL INFECTIONS b,14-21-33,84-97,AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862823,9/15/2015 22:33:55,1739060677,9/15/2015 22:33:42,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,Systemic FUNGAL INFECTIONS,5-14-21,84-97,AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862823,9/15/2015 22:40:37,1739063090,9/15/2015 22:40:27,false,instagc,1.0,23287154,USA,CA,San Jose,50.184.60.102,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,Systemic FUNGAL INFECTIONS,5-14-21,84-97,AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862823,9/15/2015 22:43:09,1739063712,9/15/2015 22:42:44,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,FUNGAL INFECTIONS,14-21,84-97,AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862823,9/15/2015 22:47:24,1739065083,9/15/2015 22:46:08,false,fusioncash,1.0,31742806,USA,OH,Kent,66.61.82.242,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,FUNGAL INFECTIONS,14-21,14-84-97-21,fungal infections AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862823,9/15/2015 22:50:15,1739065916,9/15/2015 22:48:27,false,neodev,1.0,17426565,CAN,BC,Burnaby,70.79.9.44,14,84,,,31,98,FUNGAL INFECTIONS,AMPHOTERICIN B,Systemic FUNGAL INFECTIONS b,5-14-21-33,84-97,AMPHOTERICIN B.,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B.,14 21,84 97,14,84,31,98,-1,RO-may_prevent,820171,b ?  Systemic fungal infections  b   unless needed to control drug reactions due to amphotericin B,fungal infections,amphotericin B
788862824,9/15/2015 21:24:34,1739030925,9/15/2015 21:24:12,false,neodev,1.0,33758777,USA,"","",38.95.108.251,74,15,,,80,27,PLAQUE,NON-FLUORIDE,PLAQUE,74,15-19,NON FLUORIDE,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862824,9/15/2015 21:25:16,1739031296,9/15/2015 21:25:03,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,74,15,,,80,27,PLAQUE,NON-FLUORIDE,PLAQUE,74,15-19,NON FLUORIDE,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862824,9/15/2015 21:41:41,1739040248,9/15/2015 21:41:12,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,74,15,,,80,27,PLAQUE,NON-FLUORIDE,PLAQUE,74,15-19-28,NON FLUORIDE agents,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862824,9/15/2015 21:42:42,1739040880,9/15/2015 21:42:08,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,74,15,,,80,27,PLAQUE,NON-FLUORIDE,"acid in PLAQUE either antimicrobially, biochemically, anticaries systems.",66-71-74-82-89-106-224-235,15-19-66-71-74,NON FLUORIDE acid in plaque,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862824,9/15/2015 21:49:45,1739044491,9/15/2015 21:49:31,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,74,15,,,80,27,PLAQUE,NON-FLUORIDE,PLAQUE,74,15-19,NON FLUORIDE,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862824,9/15/2015 21:52:45,1739045848,9/15/2015 21:51:38,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,74,15,,,80,27,PLAQUE,NON-FLUORIDE,PLAQUE,74,15-19,NON FLUORIDE,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862824,9/15/2015 21:53:14,1739046022,9/15/2015 21:52:41,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,74,15,,,80,27,PLAQUE,NON-FLUORIDE,PLAQUE,74,15-19-28,NON FLUORIDE agents,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862824,9/15/2015 21:55:59,1739047224,9/15/2015 21:55:45,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,74,15,,,80,27,PLAQUE,NON-FLUORIDE,PLAQUE,74,15-19-28,NON FLUORIDE agents,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862824,9/15/2015 21:59:12,1739048764,9/15/2015 21:58:17,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,74,15,,,80,27,PLAQUE,NON-FLUORIDE,PLAQUE,74,15-19-28,NON FLUORIDE agents,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862824,9/15/2015 22:01:05,1739049624,9/15/2015 22:00:14,false,instagc,1.0,21551272,GBR,I9,Dereham,89.243.154.52,74,15,,,80,27,PLAQUE,NON-FLUORIDE,PLAQUE,74,15-19-28,NON FLUORIDE agents,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",74,15 19,74,15,80,27,-1,RO-may_prevent,820369,"In the future, non-fluoride agents which modify the production of acid in plaque--either antimicrobially, biochemically, or directly--appear to have the most promise for use in topical products and may prove to be effective anticaries systems",plaque,non-fluoride
788862825,9/15/2015 21:25:46,1739031457,9/15/2015 21:25:25,false,neodev,1.0,33758777,USA,"","",38.95.108.251,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,DUODENAL ULCER,60-69,0,SUCRALFATE,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862825,9/15/2015 21:25:58,1739031605,9/15/2015 21:25:45,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,DUODENAL ULCER,60-69,0,SUCRALFATE,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862825,9/15/2015 21:44:00,1739041589,9/15/2015 21:43:33,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,"the treatment of DUODENAL ULCER multicenter, randomized,",43-47-57-60-69-83-96,0-11-15-47-60-69-83-96,"SUCRALFATE and ranitidine treatment duodenal ulcer multicenter, randomized,","Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862825,9/15/2015 21:47:48,1739043604,9/15/2015 21:47:32,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,DUODENAL ULCER,60-69,0,SUCRALFATE,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862825,9/15/2015 21:50:29,1739044870,9/15/2015 21:50:16,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,DUODENAL ULCER,60-69,0,SUCRALFATE,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862825,9/15/2015 21:55:43,1739047079,9/15/2015 21:55:16,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,DUODENAL ULCER,60-69,0,SUCRALFATE,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862825,9/15/2015 21:56:46,1739047527,9/15/2015 21:55:31,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,DUODENAL ULCER,60-69,0,SUCRALFATE,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862825,9/15/2015 21:57:07,1739047691,9/15/2015 21:56:52,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,DUODENAL ULCER,60-69,0-15,SUCRALFATE ranitidine,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862825,9/15/2015 22:01:17,1739049715,9/15/2015 22:00:53,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,DUODENAL ULCER,60-69,0,SUCRALFATE,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862825,9/15/2015 22:02:11,1739050140,9/15/2015 22:01:59,false,instagc,1.0,21551272,GBR,I9,Dereham,89.243.154.52,60,0,,,74,10,DUODENAL ULCER,SUCRALFATE,DUODENAL ULCER,60-69,0-15,SUCRALFATE ranitidine,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study.",60 69,0,60,0,74,10,-1,RO-may_prevent,820226,"Sucralfate and ranitidine were compared in the treatment of duodenal ulcer in this multicenter, randomized, double-blind study",duodenal ulcer,Sucralfate
788862826,9/15/2015 21:51:31,1739045302,9/15/2015 21:51:13,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,148,165,THYROXINE,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
788862826,9/15/2015 21:58:27,1739048370,9/15/2015 21:58:03,false,treasuretrooper,1.0,17956656,AUS,02,Jannali,14.200.59.55,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM + thyroxine administration groups,148-163-165-175-190,148-163-165-175-190,hypothyroidism + THYROXINE administration groups,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
788862826,9/15/2015 21:58:47,1739048545,9/15/2015 21:57:27,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM thyroxine,148-165,148-163-165,hypothyroidism + THYROXINE,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
788862826,9/15/2015 21:59:04,1739048657,9/15/2015 21:58:35,false,quickrewards,1.0,8672587,USA,TX,El Paso,70.120.233.80,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,148,165,THYROXINE,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
788862826,9/15/2015 22:04:46,1739050989,9/15/2015 22:02:53,false,clixsense,1.0,33878524,CAN,BC,Princeton,75.156.83.71,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,148,165,THYROXINE,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
788862826,9/15/2015 22:15:34,1739054516,9/15/2015 22:14:48,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,148,165,THYROXINE,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
788862826,9/15/2015 22:16:03,1739054703,9/15/2015 22:15:18,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,148,165,THYROXINE,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
788862826,9/15/2015 22:30:04,1739059414,9/15/2015 22:29:51,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM thyroxine administration,148-165-175,165,THYROXINE,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
788862826,9/15/2015 22:34:41,1739060967,9/15/2015 22:34:33,false,neodev,1,31984900,CAN,AB,Edmonton,208.123.223.144,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,the control and HYPOTHYROIDISM thyroxine administration groups,132-136-144-148-165-175-190,144-148-163-165-175-190-197,and hypothyroidism + THYROXINE administration groups and,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
788862826,9/15/2015 22:37:50,1739062127,9/15/2015 22:36:57,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,148,165,,,162,174,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM + thyroxine administration groups,148-165-175-190-163,144-148-163-165-175-190,and hypothyroidism + THYROXINE administration groups,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p.,148,165,148,165,162,174,-1,RO-may_prevent,820218,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and hypothyroidism + thyroxine administration groups and the levels in hypothyroidism + thyroxine administration group were higher than those in the control and hypothyroidism groups (p,hypothyroidism,thyroxine
